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Abstract 
Since the 1980’s, HIV has plagued the population on a global scale, with millions of newly infected 
individuals reported every year. However, with the introduction of combination therapy, which can 
significantly suppress viremia to almost undetectable levels in the infected populace, the disease can be 
managed to a point where the infected population can live almost normal lives. Unfortunately, although 
able to improve quality of life and prevent the onset of AIDS, combination therapy is not curative as issues 
related to drug resistance and adherence can lead to the re-emergence of high viremia, AIDS and, 
inevitably, death. Consequently, there remains a need for the continued development of new and 
superior ARVs that are effective against wild-type and resistant strains of HIV and are well tolerated for 
chronic use. 
In an effort to address this need, our group has focused on the design and synthesis of new NNRTIs.  In 
the clinic, NNRTIs are an important part of first-line regimens employed in the treatment of HIV. In 
particular, our group focused on the synthesis of a series of small benzimidazolone-containing NNRTIs 
which were initially designed to address lability issues exhibited by a series of potent indole-based NNRTIs. 
These first-generation benzimidazolones were readily synthesized over five steps and, following 
evaluation in an HIV whole cell assay, were found to be potent inhibitors of HIV RT, but were susceptible 
to clinically relevant resistant strains such as K103N and Y181C. 
As a result, we synthesized a series of second-generation benzimidazolone NNRTIs which were designed 
to overcome, specifically, the Y181C resistant strain. Starting from 2-amino-3-nitrophenol, the 
benzimidazolone precursor for these compounds was synthesized over six steps. This precursor was then 
coupled to various aryl or heteroaryl halides by way of an Ullmann reaction or SNAr. Of this small library, 
one compound in particular was found to be potent (with low nanomolar activity), not only against wild-
type, but also against Y181C, Y188C and the double mutant K103N/Y181C. Furthermore, this compound, 
3-chloro-5-((3-ethyl-2-oxo-1-((2-trimethylsilyl)ethoxy)methyl)-2,3-dihydro-1H-benzo[d]imidazol-4-
yl)oxy)benzonitrile, exhibited only low levels of susceptibility against the most problematic K103N 
resistant strain. 
We envisaged that by introducing additional electrostatic interactions between our potent lead 
compound and the NNIBP we would succeed in optimizing the efficacy of our compound against wild-type 
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and resistant strains of HIV. In order to achieve these additional interactions we adopted two different 
approaches. 
The first approach focused on targeting a lysine residue located at the top of a narrow hydrophobic 
chimney towards the back of the NNIBP. To this end, we installed a cyanovinyl substituent onto our lead 
compound which, based on docking studies, would protrude into the chimney and form a hydrogen bond 
with the targeted lysine. Installation of the cyanovinyl substituent was achieved using the well-established 
Heck coupling reaction. Although this compound, (E)-3-(2-cyanovinyl)-5-((3-ethyl-2-oxo-2,3-dihydro-1H-
benzo[d]imidazol-4-yl)oxy)benzonitrile, was also a potent inhibitor of HIV RT, it was unfortunately not 
significantly more potent than our existing lead compound.    
The second approach employed a molecular hybridization technique to form a combination of our lead 
compound and efavirenz, in order to achieve additional hydrogen bonding to the backbone of Lys101. 
This new hybrid compound, 3-chloro-5-((4,4-dimethyl-2-oxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-5-
yl)oxy)benzonitrile, was successfully synthesized over seven steps and found to be slightly more potent 
than our lead compound with an improved selectivity index.  
  
  





Sedert die 1980’s het MIV in ‘n globale pandemie geraak waar miljoene mense jaarliks gediagnoseer word. 
Die gebruik van kombinasie terapie het gelei tot grootskaalse onderdrukking van viremie in so ‘n mate dat 
dit gevolglik onopspoorbaar is, en dus sorg dat mense met HIV amper ‘n normale lewe kan lei. Alhoewel 
die behandeling van mense met HIV hulle lewens gehalte verbeter het en die aanvang van VIGS verhoed, 
is hedendaagse behandeling nie genesend nie, en as gevolg van dwelm-bestandhied moontlik kan lei to 
die herverskyning van ‘n hoë viralelading, VIGS en dan dood. As gevolg van hierdie dilemma, is daar tans 
‘n groot nood vir navorsing en onwikkeling vir nuwe ARV medisyne wat effektief is teen wilde-tipe en 
dwelm-bestande MIV stamme, tesame met minimale newe effekte wat ‘n resultaat is van daaglikse 
gebruik.  
Om die tekort aan nuwe en effektiewe antiretrovirale medisyne aan te spreek, het ons groep gefokus op 
om nuwe nie-nukleosied-omgekeerde transkriptase-inhibeerders (NNRTI’s) te ontwerp en te sintetiseer, 
sedert NNRTI’s beskou word as ‘n belangrike gedeelte vir die behandeling van MIV. Ons groep het onder 
andere gefokus op die sintesise van ‘n klein reeks molekules wat ‘n bensimidasoloon kern bevat. Die reeks 
was aanvanklik gesintetiseer om probleme rakend die chemiese stabiliteit van ‘n voorheen 
gesintetiseerde reeks indool NNRTI’s, ook deur ons groep ontwikkel, aan te spreek. Die eerste generasie 
reeks bensimidasoloon molekules was maklik geskep oor vyf stappe, en heel sel toetse teenoor MIV 
omgekeerde transkriptase het getoon dat hulle kragtige inhibeerders van die ensiem was, maar was ook 
onder andere vatbaar vir relevante MIV stamme soos K103N en Y181C.  
As gevolg daarvan het ons ‘n tweede generasie reeks bensimidasoloon NNRTI’s ontwerp om hierdie 
tekortkoming teenoor K103N en spesifiek die Y181C weerstandige stam te verbeter. Deur te begin met 2-
amino-3-nitro fenol was die bensimidasoloon voorloper gesintetiseer in ses stappe. Die voorloper was dan 
gekoppel met menigte aromatiese en heteroaromatiese haliede deur middel van of die Ullmann-koppel 
reaksie of SNAr. Een molekule uit hierdie reeks, 3-chloro-5-((3-ethyl-2-oxo-1-((2-
trimethylsilyl)ethoxy)methyl)-2,3-dihydro-1H-benzo[d]imidazol-4-yl)oxy)benzonitrile, was aktief gewees 
met lae nanomolaar aktiwiteit teenoor die wilde-tipe MIV maar ook teenoor Y181C, Y188C en die dubbel 
mutant K103N/Y181C, met net ‘n klein hoeveelheid weerstand teenoor die problematiese K103N MIV 
stam.  
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Deur addisionele elektrostatiese interaksies by te voeg tussen ons aktiefste molekule en die NNIBP, het 
ons probeer bevestig of ons die aktiwitiet teenoor die wilde tipe MIV stam sal kan verbeter. Om hierdie 
idee van addisionele interaksies te laat realiseer het ons twee verskillende metodes benader. In die eerste 
metode het ons daarop gefokus om ‘n lisien residu te teiken wat in die boonste gedeelte van die smal 
hidrofobiese skoorsteen in die aktiewe setel van die NNIBP geleë is. Ons het ‘n nitriel-viniel groep 
geïnstalleer op ons mees aktiefste molekule wat, deur middle van dokstudies, getoon het dat die nitriel-
viniel groep moontlik sal inbeweeg in die skoorsteen gedeelte en ‘n waterstof-binding vorm met die lisien 
residu. Inkorporering van die nitriel-viniel substituent was gedoen deur die uitvoering van ‘n Heck-koppel 
reaksie. Alhoewel die nitriel-viniel molecule, (E)-3-(2-cyanovinyl)-5-((3-ethyl-2-oxo-2,3-dihydro-1H-
benzo[d]imidazol-4-yl)oxy)benzonitrile, goeie aktiwiteit getoon het teenoor MIV omgekeerde 
transkriptase, was dit nie moontlik om die oorspronlike aktiewe molekuul se aktiwiteit drasties te verbeter 
nie.  
Die tweede benadering het ‘n molekulêre hibridisasie tegniek ingesluit waar ons ons aktiewe molekuul en 
efavirenz gebaster het sodat daar moontlik ‘n addisionele waterstof-binding gemaak kan word met ‘n 
Lys101 residu in die aktiewe setel. Hierdie hibried molekuul, 3-chloro-5-((4,4-dimethyl-2-oxo-1,4-dihydro-
2H-benzo[d][1,3]oxazin-5-yl)oxy)benzonitrile, was suksesvol gesintetiseer oor sewe stappe, en was meer 
aktief as die oorspronglike aktiewe molekuul, maar het ook ‘n verbeterde selektiwiteits indeks getoon in 
vergelyking met die oorspronklike aktiewe molekuul. 
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3’-P   – 3’-processing 
3TC   – lamivudine 
6HB  – six-helix bundle formation 
ABC  – abacavir 
AIDS  – acquired immunodeficiency virus 
ART  – antiretroviral therapy 
ARVs – antiretrovirals 
AZT   – azidothymidine 
BPI  – boosted protease inhibitor 
BW   – Burroughs Wellcome Co. 
CA   – capsid 
CC50  – half maximal cytotoxic concentration 
CCD   – catalytic core domain 
CDI  – carbonyldiimidazole 
CDK9   – cyclin dependent kinase 9 
CTD   – C-terminal binding domain 
cycT1  – cyclin T1 
CYP450  – cytochrome P450 
d4T   – stavudine 
ddC   – zalcitabine 
Ddl   – didanosine 
dsDNA   – double-stranded DNA 
Env   – viral envelope protein 
ESCRT   – endosomal sorting complex required for transport 
EWG  – electron-withdrawing group 
FLV   – Friend Leukemia Virus 
FTC   – emtricitabine 
FTIR  – fourier-transform infrared spectroscopy 
GPCRs   – G-protein-coupled receptors 
HAART   – highly-active antiretroviral therapy 
HaSV  – Harvey Sarcoma Virus 
hDNA   – host DNA 
HEPT  – 1-(2-hydroxyethoxymethyl)-6-(phenylthiol)thymine 
HIV  – human immunodeficiency virus 
HRMS  – high resolution mass spectroscopy 
HTLV-1   – human T-cell leukemia virus 1 
IC50  – half maximal inhibitory concentration 
IN   – integrase 
INSTIs   – integrase strand transfer inhibitors 
LDA – lithium diisopropyl amide 
LTR  – long-terminal-repeat 
MA   – matrix protein 
Met-tRNA  – methionyl-tRNA 
n-BuLi  – n-butyl lithium 
NC   – nucleocapsid 
NMR  – nuclear magnetic resonance spectroscopy 
NMT   – N-myristoltransferase 
NNIBP   – non-nucleoside inhibitor binding pocket 
NNRTIs   – non-nucleoside reverse transcriptase inhibitors 
NRTIs   – nucleoside reverse transcriptase inhibitors 
NTD   – N-terminal binding domain 
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pbs   – primer binding site 
Pd(OAc)2  – palladium diacetate 
Pd(PPh3)2  – tetrakis(triphenylphosphine)palladium(0) 
Pd/C  – palladium on carbon 
PIC   – preintegration complex 
Pol II   – RNA polymerase II 
PPh3  – triphenyl phosphine 
PR   – protease 
Pr55Gag   – Gag precursor polyprotein 
pre-mRNA  – precursor mRNA 
P-TEFb   – positive transcription elongation factor 
RNase H  – ribonuclease H 
RRE   – Rev response element 
RT   – reverse transcriptase 
RTC   – reverse transcription complex 
SAR  – structure activity relationship 
SEM  – 2-(trimethylsilyl)ethoxy methyl 
SIVcpz   – Chimpanzee associated Simian Immunodeficiency Virus 
SIVgor   – Gorilla associated Simian Immunodeficiency Virus 
SNAr  – aromatic nucleophilic substitution reaction 
ssDNA   – single-stranded DNA 
ssRNA   – single-stranded RNA 
ST   – strand-transfer 
STR   – single tablet regimen 
TAR  – transactivation response element 
Tat   – transcriptional transactivator protein 
TBAF – tetrabutylammonium fluoride 
TCDI  – thiocarbonyldiimidazole 
TDF   – tenofovir disoproxil fumarate 
TIBO  – 4,5,6,7- tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepine-2(1H)one 
TLC  – thin layer chromatography 
TMS  – trimethylsilyl 
vDNA  – viral DNA 
Vpr   – viral protein R 
WHO   – World Health Organization 
  
Amino Acids:  
Asn (N)  – asparagine 
Asp (D)  – aspartic acid 
Cys (C)   – cysteine 
Glu (E)  – glutamic acid 
Lys (K)  – lysine  
Phe (F)    – phenylalanine 
Trp (W)   – tryptophan 
Tyr (Y)   – tyrosine 
Val (V)   – valine 
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Chapter 1: A Brief Introduction to HIV and Current Therapeutic Strategies 
 
1.1. The Discovery of HIV-1 as the Cause of AIDS 
On the 3rd of January 1983, in the lab of Francoise Sinoussi, a new retrovirus was identified in a T-
lymphocyte culture obtained from a man with a lymphadenopathy in the neck.1 This new retrovirus,  
which we now know to be human immunodeficiency virus (HIV) and the causative agent of acquired 
immune-deficiency virus (AIDS), would become the most significant epidemic to plague the population on 
a global scale. 
The discovery of HIV as the cause of AIDS was a serendipitous one at a time when it was believed that 
human retroviruses did not exist and that severe epidemic diseases were restricted to the “Third World”.2 
As a result it was thought that other factors such as chemicals, fungi and autoimmune responses to 
leukocytes were responsible for the onset of AIDS. Despite this unfavourable backdrop, a few scientists 
remained persistent in their efforts to identify retroviruses in human cancers, particularly in breast cancer 
and leukemia.3 In 1979 in the laboratory of Robert Gallo, human T-cell leukaemia virus 1 (HTLV-1), the 
first human retrovirus was discovered and isolated. Not long after that Luc Montagnier identified 
lymphotropic retroviruses in human T-cell cultures.1-2 These discoveries were significant in establishing 
that human retroviruses did exist and encouraged speculation that a retrovirus could be the causative 
agent of AIDS. Gallo hypothesized that this retrovirus would be a close relative of HTLV-1 due to 
observations that HTLV-1 and AIDS manifested in a similar manner.4 Patients with AIDS and those infected 
with HTLV-1 both presented with decreased levels of CD4+ T-cells and it was known that both diseases 
could be transmitted through blood, sexual activity and mother-to-child transmission. However, it was 
later discovered that HIV was not a close relative to HTLV-1, but a completely new retrovirus altogether.2 
What followed in the years 1983 to 1987 was considered a “period of intense discovery” by Jonathon 
Mann of the World Health Organization (WHO).5 Within two years of the discovery of HIV as the causative 
agent of AIDS the HIV genome was fully cloned and sequenced, the heterogeneity of the HIV genome 
described, the first blood test was made available and treatment in the form of AZT was introduced.5-6  
The rapidity with which research progressed led to the hope and expectation that the problem of AIDS 
would be swiftly resolved. In fact, in 1984 the then US Secretary of Health and Human Services, Margaret 
M. Heckler, predicted that a vaccine and consequently a cure would become available in the next two 
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years.6 However, the defences of HIV to avoid the immune response would render the development of a 
viable vaccine close to impossible. 
 
1.2. The State of HIV-1 Today 
Despite high expectations, 34 years after its discovery HIV still affects millions of people on a global scale. 
The latest statistics reported by UNAIDS and the WHO in 2017 estimated that 36.7 million people 
worldwide were living with HIV in 2016 and approximately 1.8 million of those reported were newly 
infected.7 Sadly, of the millions of infected individuals, approximately 6% are children under the age of 15 
years.7 Most of these children became infected due to mother-to-child transmission in utero, during 
delivery or through breastfeeding.8 For the rest of the population HIV can be transmitted through 
accidental contact with infected blood due to contaminated needles, blood transfusions or sexual 
intercourse. Individuals considered to be at high risk of infection include individuals who practise 
promiscuous and risky homo or heterosexual behaviour and intravenous drug users.8 In low to middle 
income countries young women under the age of 24 are also associated with increased risk of infection, 
a consequence of gender-based violence, inequity and a lack of awareness of the disease.8-9 
The most severely affected areas are developing countries which include most of Africa, South America, 
Southeast Asia and India.7 Sub-Saharan Africa alone hosts almost 70% of the globe’s infected population 
and of the Sub-Saharan African countries, South Africa has the highest reported incidence of HIV-positive 
individuals.8  
Even though HIV-1 still poses a significant public health challenge, the acquisition of HIV is no longer a 
death sentence and most of the infected population can live a relatively normal life. This can largely be 
attributed to the introduction of antiretroviral (ARV) therapeutics (To be discussed in more detail in 
section 1.5.). Today, ARVs are administered the moment a diagnosis of HIV is made regardless of age and 
CD4+ count.10 Although not a cure for HIV-1, the introduction of ARVs has improved quality of life and 
decreased the mortality rate by controlling viral loads in the infected population. In 2016 the number of 
AIDS related deaths was reported to be 1.0 million, a 48% decrease from the number of deaths reported 
in 2005.7 According to the 2016 UNAIDS global AIDS update approximately 17 million people infected with 
HIV are taking ARVs, a significant improvement on the 7.5 million reported in 2010.11 Although a notable 
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achievement for the “90-90-90”* initiative against HIV, these statistics suggest that the remaining 54% of 
the infected population are not receiving treatment.12 A shortfall that could be a consequence of the fact 
that a large number of HIV-positive individuals are not aware of their HIV status.11 
In high-prevalence regions such as Sub-Saharan Africa, ARV coverage is less than optimal as a majority of 
the population are situated in resource-poor rural areas with limited access to adequate health care 
facilities and qualified medical staff.10 Not only does this prevent infected individuals from seeking ARV 
treatment, it also affects the adherence of those already receiving ARV treatment.13 Furthermore, 
deficiencies in service delivery resulting in pharmacy drug stock-outs represents another major issue for 
drug adherence.14 This poses a serious problem for maintaining the suppression of viral levels in infected 
individuals as poor adherence would unavoidably lead to the onset of drug resistance, disease progression 
to AIDS and ultimately death. 
Complex social, structural and economic factors need to also be recognized as impediments to the global 
initiative against HIV.11 Accounts of HIV-related stigma and discrimination against HIV-positive individuals 
completely undermine preventative measures.15-16 HIV-related stigma often leads to the refusal of 
infected individuals to seek out treatment, divulge their status to prospective partners for fear of rejection 
or to adhere to recommended treatment regimens.17  
 
1.3. HIV Origins and Heterogeneity 
The origin of HIV-1 can be traced back to a lentivirus known as simian immunodeficiency virus (SIV) 
isolated from the common chimpanzee (Pan troglodytes troglodytes, SIVcpz) found only in the Central 
African regions of southern Cameroon, Gabon and the Republic of Congo.18-20 Not only did SIVcpz share a 
close genetic relationship to HIV-1 but in some cases manifested in the same manner with decreased CD4 
levels and increased risk of death.21 The exact means by which the primate precursor to HIV was 
transmitted to humans has not yet been determined. However, researchers have hypothesized that 
transmission of the virus to humans occurred due to accidental exposure to blood or bodily fluids of 
                                                          
* The 90-90-90 initiative is a UNAIDS initiative to end the AIDS epidemic. The aim of this initiative is to 
ensure that by 2020 90% of individuals living with HIV should know their HIV status, 90% of all individuals 
diagnosed with HIV will receive antiretroviral therapy and that 90% of those individuals on antiretroviral 
therapy will experience viral suppression.  
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infected chimpanzees through hunting, the preparation of bushmeat or from bites or scratches obtained 
from captive chimpanzees.21  
The evolution of SIVcpz, the primate precursor of HIV, has resulted in four divergent lineages of HIV-1 
termed group M (major), O (outlier), N (nonmajor) and P. Studies have determined that groups M, and N 
arose as a result of two independent cross-species transmission events between chimpanzees and 
humans in the early twentieth century.22 Interestingly, group P was found to originate from SIVgor, a 
lentivirus discovered in the Western lowland gorilla of Cameroon in 2006.23-24 Just recently, in 2015, the 
question as to whether group O originated from SIVcpz or SIVgor was resolved as researchers isolated a 
new SIVgor strain closely related to the group O virus.25 SIVgor shares a close phylogenetic relationship 
with SIVcpz, suggesting that a cross-species transmission event was likely to have occurred between 
chimpanzees and gorillas.21 
Group M is the predominant and pandemic form of HIV-1 affecting millions of people on a global scale. 
Group M was also the first HIV-1 lineage to be discovered and can be further divided into nine subtypes 
(A to K), as well as over 40 varying recombinant forms resulting from the recombination of subtypes in 
dually infected individuals.21 Subtype C is largely found in Southern Africa, Asia and India while subtype B 
is predominant in Europe and the United States.26  
Unlike group M which affects the population on a global scale, non-M group (O, N and P) associated 
infections have been mostly limited to individuals living in or associated with Cameroon. Group O, 
identified in 1989, affects less than 1% of the population located in Cameroon, Gabon and neighbouring 
countries.27 Occurrence of group N, identified in 1998, is even rarer with only 13 cases reported in 
Cameroon.22, 28-30 Only 2 cases of individuals infected with group P have been reported.31 The first case 
was discovered in a Cameroonian woman in France in 2009.22, 24 All HIV lineages are capable of causing a 
decrease of CD4+ T cells but the transmissibility of non-M groups is much lower than for group M.  It has 
been speculated that the slower spread of non-M groups could be attributed to poorer human adaptation. 
In 1986 a new variant of HIV was discovered in Western Africa and has remained largely confined to the 
area. This variant, now known as HIV-2, has origins that could also be traced back to SIV. However, unlike 
HIV-1 where the disease was traced back to SIV in chimpanzees, HIV-2 is suspected to originate from the 
sooty mangabey (SIVsmm).32-33 Most individuals with HIV-2 do not progress to AIDS as the pathogenicity 
of HIV-2 is lower than HIV-1.34 As a result, HIV-2 expresses lower levels of viremia than HIV-1.34-35 
Furthermore, the transmission rate of HIV-2 is inferior to HIV-1 and mother-to-child transmission for HIV-
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2 is almost non-existent. It is therefore unsurprising that the prevalence of HIV-2 today is largely 
declining.36 
 
1.4. HIV-1 Replication Cycle and Mode of Infection 
As mentioned in section 1.2, HIV is acquired through contact with infected blood or bodily fluids either by 
blood transfusion, sexual transmission or mother-to-child transmission. The most significant 
manifestation of HIV infection is the depletion of CD4 + T cells in the gastrointestinal tract, peripheral 
blood, lymph nodes and other lymphatic tissues, while the levels of viremia increase due to rapid viral 
replication.37-38 
The HIV replication cycle comprises of several critical steps, many of which have been considered as viable 
targets for therapeutic intervention as shown in Figure 1. 
 
Figure 1 An overview of the HIV replication cycle indicating several steps currently targeted for therapeutic intervention. Taken 
from Barré-Sinoussi et al.39 
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1.4.1. Viral fusion and entry 
The first step of the HIV replication cycle is viral fusion and entry (Figure 1). The primary cell surface 
receptor for HIV is the CD4 receptor, an integral plasma membrane glycoprotein expressed in CD4+ T cells, 
as well as dendritic and macrophage derived cells.40 Adsorption of the virus to the host cell occurs due to 
the high affinity that CD4 has for the viral envelope protein (Env).  Env is a heavily glycosylated trimer 
comprising of heterodimeric subunits gp120, a docking glycoprotein responsible for receptor binding and 
gp41, a transmembrane protein responsible for anchoring gp120 to the viral membrane and catalysing 
membrane fusion.41 The binding of CD4 to gp120 elicits a conformational change in gp120 bringing the 
outer membranes of virus and host into close proximity in preparation for membrane fusion (Figure 2). 
However, the binding of CD4 alone is not sufficient for merging viral and host cell membranes and 
additional binding to a chemokine coreceptor (CCR5 or CXCR4) is required.42 
CCR5 and CXCR4 are members of a family of G-protein-coupled receptors (GPCRs) that are expressed 
predominantly on T cells, monocytes, macrophages and dendritic cells.43 HIV-1 strains that utilize CCR5, 
known as the R5 virus, are predominant in the early stages of the disease and are more readily transmitted 
than strains that use CXCR4, known as the X4 virus.44 X4 viruses are often associated with rapid disease 
progression and only emerge years later after infection.45 In some instances dual tropism occurs where 
HIV recruits both chemokine receptors. This is referred to as the R5X4 virus.44 
The binding of gp120 with a coreceptor triggers a structural rearrangement in gp41. This results in the 
exposure and insertion of gp41 into the host cell membrane, tethering the viral membrane to the host.41 
The region of gp41 that inserts into the host membrane is a highly hydrophobic region known as the fusion 
peptide.46 The ectodomain of gp41, the domain of gp41 extending into extracellular space, consists of an 
N-terminal and C-terminal helical region which upon tethering are brought in close proximity resulting in 
the formation of a six-helix bundle (6HB) as demonstrated in Figure 2. The 6HB is responsible for the 
formation, stabilization and enlargement of the fusion pore which itself permits the delivery of the viral 
nucleocapsid or core into the host cell cytoplasm.47 
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Figure 2 Overview of HIV fusion and entry. Viral envelope protein (Env) consists of subunits gp41 (red) and gp120 (blue). Gp120 
is responsible for receptor and coreceptor binding while gp41 is responsible for tethering the viral membrane to the host cell 
membrane. Tethering results in the formation of a six-helix bundle and ultimately the fusion pore, permitting entry of the viral 
nucleocapsid into the host cell. Image adapted from Wilen et al.41 
 
1.4.2. Release of viral RNA and reverse transcription 
Once the viral core has been delivered into the cytoplasm of the host cell a process known as ‘uncoating’ 
occurs whereby the protective conical capsid surrounding the HIV RNA genome and viral proteome is 
removed.48 Once the capsid has been removed the viral genome and most of the viral proteins remain 
associated forming a complex referred to as the reverse transcription complex (RTC).38 Viral proteins 
observed to be associated with RTC include reverse transcriptase (RT), integrase (IN), matrix protein (MA), 
nucleocapsid (NC) and accessory viral protein R (Vpr).38 
During or following the ‘uncoating’ process the viral single-stranded RNA (ssRNA) is converted into double-
stranded DNA (dsDNA) by the viral enzyme RT.48-49 RT exists as an asymmetric heterodimer comprising of 
two subunits p66 (66 kDa) and p51 (51 kDa) which share a largely similar protein sequence but adopt 
different tertiary structures.38 The p66 subunit comprises of a ribonuclease H (RNase H) domain, 
responsible for the degradation of the viral RNA, and four pol subdomains. Three of the four pol 
subdomains are referred to as the palm, fingers and thumb subdomains since structurally, p66 resembles 
a right hand. The fourth pol subdomain is referred to as the connection domain, connecting the ‘hand’ to 
the RNase H domain.50 
The first step of reverse transcription is the formation of the RNA/DNA hybrid at the polymerase active 
site located in the palm subdomain.38 A molecule of tRNA bound to the primer binding site (pbs) acts as a 
primer to initiate the synthesis of the complementary DNA strand from the viral ssRNA in order to 
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generate the hybrid. The RNA portion of the hybrid is then degraded by RNase H.38 Various biological steps 
follow from this point which ultimately result in the propagation of the ‘free’ single-stranded DNA (ssDNA) 
molecule and the synthesis and propagation of a complementary strand of DNA to generate a molecule 
of viral dsDNA (vDNA).38 The newly synthesized vDNA remains associated with RTC, now referred to as 
the preintegration complex (PIC).38  
 
1.4.3. Integration of viral DNA into the host genome 
The following crucial step in the HIV replication cycle involves the integration of the newly generated 
vDNA into the host cell chromosome. This step is catalysed by IN, a 32 kDa protein comprising of three 
structural domains which include the N-terminal domain (NTD) containing a zinc-binding motif, a catalytic 
core domain (CCD) containing the enzymatic catalytic site and a C-terminal nonspecific DNA binding 
domain (CTD).51 
Integration occurs in two parts. The first part involves the priming of vDNA for integration. This process 
known as 3’-processing (3’-P) is also catalysed by IN but takes place in the cytoplasm of the host cell.51 As 
mentioned previously IN is one of the enzymes associated with PIC. 3’-P involves the endonucleolytic 
cleavage of two nucleotides (GT) from the tetranucleotide CAGT situated at the 3’-end of the vDNA. The 
CA dinucleotide that is subsequently exposed is highly conserved among retroviruses.51 
Following 3’-P, PIC is transported to the nucleus where IN catalyses the insertion of vDNA into the host 
chromosome. This step known as strand-transfer (ST) occurs through divalent metal-mediated 
phosphodiester transesterification between the exposed 3’-OH groups of the CA dinucleotide and 
phosphodiester bonds on complementary strands of the host DNA (hDNA).51 In this instance IN distorts 
the phosphodiester bonds on the backbone of the hDNA making it vulnerable to nucleophilic attack by 
the vDNA 3’-OH in an SN2-like mechanism to form a new phosphodiester bond (Figure 3).52-53 The metal 
ions involved in this step are typically two magnesium ions which coordinate to the IN catalytic triad 
comprising of residues Asp116 (D116), Asp64 (D64) and Glu152 (E152).54 These metal ions aid in the 
stabilization of the DNA-enzyme complex and facilitate the transesterification reaction by activating the 
incoming nucleophile, stabilizing the pentacoordinate transition state and activating the 3’-oxoanion 
leaving group (Figure 3).55 
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Figure 3: The second part of the integration process involves strand transfer of the vDNA (red) to a complementary strand of 
the hDNA (blue). This occurs through metal-mediated phosphodiester transesterification between the 3’-OH group of the vDNA 
and phosphodiester bonds of hDNA. 
Once ST has occurred host cell DNA polymerases fill in the resulting gaps between viral and host DNA.51 
The integrated vDNA, now considered a provirus, behaves as a cellular gene functioning as a template for 
the transcription of new viral mRNA that is able to encode for all the necessary viral proteins to promote 
viral replication.38  
 
1.4.4. Viral transcription and translation 
Transcription of the provirus is a multistage and complex process employing both viral and cellular factors. 
This process is initiated and regulated at the long-terminal-repeat (LTR) region at the 5’ end of the DNA 
provirus by promoter and enhancer elements, short segments of DNA that are able to bind to proteins to 
stimulate gene expression.56 Promoter elements recruit RNA polymerase II (pol II) which initiates synthesis 
of viral mRNAs.57 Enhancer elements associate with the transcriptional transactivator protein Tat which 
drastically increases the rate and efficiency of gene expression.58 In order to transactivate gene expression 
Tat first forms a complex with a positive transcription elongation factor b (P-TEFb), a large cellular protein 
complex composed of proteins cyclin T1 (cycT1) and cyclin-dependent kinase 9 (CDK9).38 The Tat/P-TEFb 
complex then binds with the transactivation response element (TAR) located at the 5’-end of nascent RNA 
resulting in the hyperphosphorylation of pol II and ultimately efficient elongation and synthesis of viral 
mRNA.58 
Transcription results in the synthesis of unspliced and partially spliced mRNA in addition to the fully spliced 
or mature mRNA.38 Normally unspliced and partially spliced mRNA, also known as precursor mRNA (pre-
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mRNA) are degraded within the nucleus. However in the case of HIV-1, pre-mRNA are essential for 
encoding important viral proteins such as gag and gagpol polyprotein precursors, Env and other important 
accessory proteins.59 To overcome this issue of degradation HIV-1 expresses the Rev protein which 
facilitates the export of the pre-mRNA from the nucleus to the cytoplasm of the host cell.57 This is achieved 
by the recognition of an RNA element found only in pre-mRNA referred to as the Rev response element 
(RRE). Rev binds to the RRE forming a complex which enables it to utilize cellular nuclear export machinery 
transporting the pre-mRNA from the nucleus.38, 59 
Once in the cytoplasm mRNA and pre-mRNA are translated to various viral proteins. This process is utterly 
dependent on the host cell to provide the translational machinery including ribosomes, tRNA, amino acids 
and all other factors relating to translational initiation, elongation and termination.60 Depending on the 
mRNA each translational process is different but can be loosely divided into four stages. 
The first step involves the recruitment of the 43S pre-initiation complex to the mRNA. 43S comprises of 
the small host cell ribosomal subunit (40S), a number of initiation factors and a molecule of methionyl-
tRNA (Met-tRNA).61 43S scans the mRNA until it locates the initiation codon (AUG) on the mRNA through 
complementarity with the anticodon on Met-tRNA.60 Following this step the large ribosomal unit (60S) is 
employed to 43S resulting in the formation of the 80S ribosome complex. 80S is then able to decode the 
mRNA and subsequently recruit the amino acids necessary to elongate and synthesize the viral protein.61 
Elongation factors introduce the required amino acids which are bound to molecules of peptidyl-tRNA, 
RNA-containing adapter molecules responsible for linking and matching amino acids to complementary 
codons on the viral mRNA and ultimately transferring the amino acids to the growing polypeptide chain.61 
Penultimately, the 80S complex reaches the termination codon which can be UGA, UAA or UAG and 
termination of the translational process commences. Termination is achieved through the hydrolysis of 
the ester bond binding the nascent polypeptide to tRNA.62 The final step is termed ribosome recycling 
whereby the ribosome is dissociated from the mRNA and tRNA in preparation for the next round of 
translation.63 
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1.4.5. Viral assembly, budding and maturation 
The final stages of the HIV-1 replication process involve assembly, budding and maturation of HIV-1, all of 
which takes place at the host cell plasma membrane (Figure 4). 
 
Figure 4 An illustration of the final stages of the HIV-1 replication process. Image was taken from Freed.64 
The Gag precursor polyprotein (Pr55Gag) is an essential component of the assembly process as it is 
responsible for targeting and binding the plasma membrane, encapsulating viral RNA and budding or 
pinching-off the immature virion from the host cell membrane.38 The major Gag domains involved in these 
processes include the N-terminal MA domain, the central capsid (CA) domain, the basic NC domain and 
the C-terminal p6 domain.65 
The MA domain targets and binds the host cell plasma membrane.66 Post-translationally MA is 
myristoylated by N-myristoltransferase (NMT) which is essential for viral assembly as the myristic acid 
moiety, when exposed, interacts with phospholipids on the inner lipid bilayer of the plasma membrane 
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forming a lipid anchor to stabilize membrane binding in preparation for immature virion formation.67-68 
Additional interactions between a highly basic region of MA adjacent to the myristoylation site and anionic 
phospholipids on the lipid bilayer further promote membrane binding.68 Viral Env glycoproteins also 
gather at the plasma membrane simultaneously to Gag and the MA domain is responsible for the 
incorporation of the Env glycoproteins into the forming virion.64 
Upon reaching the plasma membrane, in addition to interactions between Gag and the lipid membrane, 
Gag-Gag and Gag-RNA interactions are required to initiate the assembly of the immature virions.66 The 
former is mediated by the CA domain while the latter is mediated by the NC domain.38  
It has been well established that HIV-1 virions carry two copies of the full RNA genome which dimerize in 
the cytoplasm prior to their encapsidation in the forming virion.69 NC identifies a packaging signal located 
on the 5’-ends of the dimerized viral RNA known as the ψ-element. This packaging signal has a high affinity 
for NC and is recognized by two zinc finger motifs located in the NC domain.70 The binding of NC to the 
RNA dimer is thought to aid in nucleating viral assembly. However, as mentioned previously the 
multimerization process, the formation of Gag-Gag interactions, is largely mediated by the CA domain.38  
Pr55Gag then assembles into spherical immature particles with the membrane bound Gag molecules and 
the GagPol precursor projecting towards the interior of the forming virion while part of the cellular 
membrane makes up the viral membrane (Figure 4).71 The subsequent budding of the newly formed 
immature particles is promoted by the p6 domain of Pr55Gag which recruits the cellular endosomal sorting 
complex required for transport (ESCRT) machinery, a series of cellular protein complexes and accessory 
proteins required for membrane scission.64 
Finally, as budding of the immature virion is initiated, protease (PR) is activated and cleaves the Gag and 
GagPol polyprotein precursors into their mature constituent proteins.38 These proteins include the MA, 
CA, NC and p6 proteins from Gag and RT, IN and PR from GagPol, although the mechanism by which PR is 
activated is not completely understood.65 PR is a dimeric aspartic acid protease and cleaves the Gag and 
GagPol polyprotein precursors in an ordered step-wise manner by recognizing specific sites along the 
peptide chains.65 Interestingly, studies suggest that PR does not recognize specific amino acid sequences 
but rather recognizes the overall shape of the cleavage site.72 
After cleavage by PR the mature proteins rearrange within the virion. The most significant rearrangement 
involves the arrangement of CA into a conical shell surrounding the RNA-NC complex (Figure 4).38 This  
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overall process, known as maturation, converts the immature virion into a mature virus able to infect the 
next host cell.64 
During the acute or primary phase of infection, the levels of viremia are at their peak with approximately 
106 – 107 virion copies per mL of plasma.8 Acutely infected individuals are therefore more likely to transmit 
the virus to others.73  Initially, upon infection, HIV is held in the mucosal tissues but before long the virus 
is able to cross the mucosal barrier and spread through the bloodstream to various lymphoid organs such 
as the gut-associated lymphoid tissue, thymus, spleen and lymph nodes.74 During this stage of infection 
the levels of CD4+ T cells, the major target for HIV infection, drastically decrease by 20 – 40% in the 
bloodstream.75  
Following acute infection, a period known as clinical latency occurs. During this stage the host immune 
response gains some control over the viral levels in the bloodstream. By employing CD8+ T cells and 
antibodies the immune system is able to significantly decrease the levels of HIV in the blood allowing for 
the levels of CD4+ T cells to be restored almost back to normal.75 This is known as the latent stage of 
infection because despite the immune response, HIV continues to replicate without detection in the 
lymphoid organs.75 Normally upon infection, CD4+ T cells die quickly due to the immune response or 
cytopathic effects of HIV however, some infected cells are able to survive long enough to revert to a 
resting or latent state.76 These latently infected cells have the HIV provirus integrated into their genome 
but are transcriptionally dormant and therefore do not express viral RNA and proteins. These cells can 
periodically reactivate to replenish the viral load in the bloodstream, albeit at low levels.77 
Over time, left untreated, HIV again causes a slow decline in levels of CD4+ T cells, a process which can 
take up to 10 years.  The resultant deterioration of an infected individual’s immune system with CD4+ T 
cell levels less than 200 copies per mL3 of blood eventually results in the onset of opportunistic infections, 
such as tuberculosis.75 At this point HIV-infection has progressed to AIDS. Individuals with AIDS can survive 
for a time ranging from 3 months to over 2 years before death.73 
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1.5. Changing the outcome of HIV-infection: An overview of the different classes of HIV-1 
ARVs 
The very first ARV for HIV-1 was discovered in 1984 by Burroughs Wellcome Co. (BW). During a random 
screening of compounds, they found that azidothymidine (AZT) (Figure 5), later known as zidovudine, 
showed significant activity against murine retroviruses Friend Leukemia virus (FLV) and Harvey Sarcoma 
virus (HaSV). A few months later AZT was screened against HIV with the same positive outcome.78-79  
 
Figure 5 AZT (zidovudine) the first ARV licensed by the FDA. 
AZT was first synthesized in 1964 as part of an effort to synthesize novel therapeutic agents able to combat 
the proliferation of cancer cells. When tested against leukemic cells in mice, AZT had no effect and was 
forgotten until it resurfaced in 1984.78  
The FDA approved AZT (Retrovir®) for use in 1987, only 3 years after its identification as a potent anti-HIV 
therapeutic. At this time it was believed that AZT would be the ‘wonder-drug’ to completely eradicate 
AIDS.75 Unfortunately, the success of AZT was short-lived due to issues pertaining to toxicity and the 
emergence of drug-resistance.8, 80 The failure of AZT to eradicate the AIDS pandemic initiated a global 
effort to identify other more effective ARVs for HIV-1. 
It was not until the mid-1990’s, with the introduction of combination therapy, that the long-term outlook 
for infected individuals began to improve.81 The introduction of combination therapy, also known as 
highly-active antiretroviral therapy (HAART) or triple therapy, made significant strides in reducing the 
morbidity and mortality of the infected global population.82 Although not a cure for HIV, combination 
therapy has succeeded in transforming a ‘death sentence’ into a chronic but manageable disease. The 
motivation behind the development of HAART was to encumber the onset of drug resistance associated 
with monotherapeutic regimens. The poor proof-reading ability of HIV RT, combined with the high 
replication rate of HIV results in a high mutation rate of 3.4 X 10-5 mutations per base pair per replication 
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cycle resulting in significant variations in the HIV genome.80 In the case of ARVs, the mutated genome 
codes for viral proteins that maintain their function despite the presence of the inhibitor.82  
To overcome resistance HAART needs to drastically improve viral suppression.8 This is achieved through 
the use of two or more ARVs from different classes targeting different stages of the HIV-1 life cycle. 
Currently HAART regimens are made up of two nucleoside reverse transcriptase inhibitors (NRTIs) and 
either a non-nucleoside reverse transcriptase inhibitor (NNRTI), integrase strand transfer inhibitor (INSTI) 
or a boosted protease inhibitor (BPI).83  
 
1.5.1. Nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs and NtRTIs) 
The major component of HAART and the earliest class of ARVs are NRTIs. Like AZT these compounds are 
mimics of naturally occurring nucleosides but lack the 3’-hydroxyl group at the 2’-deoxyribosyl sugar 
moiety.81 In the case of AZT, the 3’-hydroxyl moiety is replaced with a 3’-azido moiety (Figure 5). NRTIs 
competitively target the catalytic site of RT where they bind to and terminate the propagating vDNA chain. 
As NRTIs lack the 3’-hydroxyl group, 3’,5’-phosphodiester bonds with incoming nucleotides cannot be 
formed.81  
NRTIs are administered as prodrugs which means that in their dispensed forms they are inactive.84 
Therefore, in order for these NRTIs to be incorporated into the propagating chain they need to be 
metabolically converted into an active form.85 This entails three consecutive phosphorylations by cellular 
kinases of the NRTI to the monophosphate, diphosphate and finally the active triphosphate form (Figure 
6).86  
 
Figure 6 NRTIs have to be metabolically converted into the active triphosphate form. This activation process is carried out in 
three consecutive phosphorylation steps by cellular kinases. 
Currently there are seven NRTIs approved by the FDA. In addition to AZT (Figure 5) these include 
didanosine (ddI, Videx®), zalcitabine (ddC, Hivid®), stavudine (d4T, Zerit®), abacavir (ABC, Ziagen®), 
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emtricitabine (FTC, Emtriva®) and lamivudine (3TC, Epivir®) (Figure 7). Of all the currently approved NRTIs, 
emtricitabine and lamivudine have the lowest propensity for causing mitochondrial toxicity in patients 
and exhibit the highest barrier to resistance.87-88  
In some instances NRTIs are administered with the monophosphate already installed to overcome the 
activation barrier often encountered with the first phosphorylation step, and are referred to as nucleotide 
reverse transcriptase inhibitors (NtRTIs).86 Currently two NtRTIs have been approved by the FDA for the 
treatment of HIV-1; tenofovir disoproxil fumarate (TDF, Viread®) and tenofovir alafenamide fumarate 
(TAF) (Figure 7). However, TAF has only been approved as a coformulation with FTC and an NNRTI or INSTI 
(Descovy®, Genvoya® and Odefsey®). Both tenofovir prodrugs contain lipophilic groups to mask the two 
negative charges on the phosphonate moiety, which otherwise would limit cellular permeability and 
prohibit oral administration.89 Cleavage of these groups by various cellular hydrolases reveals the 
monophosphate which is subsequently converted into the active triphosphate.89-90 
Based on WHO recommendations TDF in combination with emtricitabine or lamivudine  is currently used 
for first-line treatment of infected individuals or for pre-exposure prophylaxis.83, 88 However, TAF exhibits 
a lower propensity for renal and bone toxicity and delivers higher levels of tenofovir at lower doses than 
TDF and is therefore expected to replace TDF in future regimens.8 
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Figure 7 In addition to AZT 6 other NRTIs and 2 NtRTIs have been approved by the FDA for the treatment of HIV-1. All NRTIs lack 
the 3'-OH moiety required for DNA chian propagation. NtRTIs require only two phosphorylation steps to become active 
inhibitors of vDNA chain propagation. 
 
1.5.2. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) 
Like NRTIs, NNRTIs target RT, but at a small hydrophobic allosteric pocket known as the non-nucleoside 
inhibitor binding pocket (NNIBP) situated approximately 10 Å from the catalytic site.91 Under normal 
circumstances, in the apo-enzyme this NNIBP does not exist but opens only during the binding of an 
NNRTI.50 Upon binding to the NNIBP, NNRTIs cause conformational changes to the enzyme as a result of 
torsional rotations of particular amino acids in the NNIBP.92 This conformational change distorts the 
catalytic site and hinders propagation of the vDNA chain.91-92 Unlike NRTIs, NNRTIs do not require 
metabolic activation to inhibit enzyme activity.75 NNRTIs are small, non-competitive, hydrophobic 
molecules that are able to cross the blood-brain barrier (BBB) and exhibit high levels of structural and 
chemical diversity.93 
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It was only in the late 1980’s that two series of compounds were discovered to inhibit RT at the NNIBP. 
These first NNRTIs belonged to a series of 1-(2-hydroxyethoxymethyl)-6-(phenylthiol)thymine (HEPT)  and 
4,5,6,7-tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepine-2(1H)one (TIBO) derivatives.94-95 HEPT 
derivatives were initially designed as NRTIs but it was discovered that these compounds inhibited RT 
through a completely different mechanism to other NRTIs.94 Despite the structural differences between 
the HEPT and TIBO derivatives, both series of compounds adopted a butterfly-like conformation in the 
NNIBP.96 The clinical candidates of both series, emivirine (HEPT) and tivirapine (TIBO), were found to be 
potent inhibitors of RT but were never developed for clinical use (Figure 8).96  
 
Figure 8 The very first NNRTI candidates were emivirine, a HEPT derivative and tivirapine, a TIBO derivative. Although both 
were potent inhibitors of RT neither made it past clinical trials. 
Although the HEPT and TIBO compounds were never marketed, their development paved the way for the 
discovery of other more successful NNRTIs. The first NNRTI to be approved for clinical use in 1996 was 
nevirapine (Viramune®) (Figure 9) which like HEPT and TIBO adopted the rigid butterfly-like conformation 
in the NNIBP.97 A year later another NNRTI, delavirdine (Rescriptor®), was also licensed by the FDA (Figure 
9).81 Nevirapine and delavirdine are today classified as first-generation NNRTIs. This classification is based 
on the observation that despite both NNRTIs’ ability to reduce viral levels in infected individuals, they 
suffer from a low genetic barrier to resistance.98 This means that after prolonged exposure to treatment 
single amino acid mutations will confer resistance and significantly reduce the potency of these NNRTIs.98  
 
Figure 9 First-generation NNRTIs shown here are potent inhibitors of RT but suffer from a low genetic barrier to resistance. 
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Mutations that confer resistance to NNRTIs are situated in the immediate vicinity of the NNIBP and 
therefore, directly affect the binding of an NNRTI.75 The most common clinically relevant mutations are 
K103N and Y181C. Other mutations include Y188C/L, V106A/M, G180A/S and A98G.99 There are two 
methods by which these mutations can confer resistance to NNRTIs. The first is by decreasing the affinity 
of any NNRTI for the NNIBP by reducing Van der Waals interactions, π-π stacking interactions or changing 
the hydrogen bonding capabilities of the NNIBP.100 The susceptibility of nevirapine to the Y181C mutation 
is an example of this. The affinity of nevirapine for the NNIBP relies heavily on π-π stacking interactions 
between the 4-methylpyridine present in nevirapine and Tyr181.101 The Y181C mutation replaces the 
aromatic tyrosine residue with an aliphatic cysteine residue and as a result nevirapine loses that π-π 
stacking interaction and consequently suffers reduced efficacy.102 The second method is by creating a 
steric conflict between any NNRTI and the NNIBP.100 Interestingly, the prominent K103N mutation does 
not confer resistance by either of these methods. Instead, studies suggest that the K103N mutation 
stabilizes the closed form of the NNIBP by forming a hydrogen bond between the amide of the mutated 
N103 residue and the hydroxyl group of Y188.103 
By understanding the mechanisms by which mutations confer resistance, successful strides were made in 
developing NNRTIs with improved resistance profiles. Efavirenz (Sustiva® or Stocrin®) was licensed only 
two years after nevirapine but is able to maintain activity in the presence of the Y181C mutation that 
renders nevirapine ineffective (Figure 10)81, 102 This can be attributed to the presence of a cyclopropyl 
moiety present in efavirenz in place of the 4-methylpyridine found in nevirapine, which does not rely on 
π-π interactions with Tyr181.102 Despite the improved resistance profile of efavirenz against the Y181C 
mutation, the overall genetic barrier to resistance is low.104  Consequently, significant cross-resistance 
between efavirenz and nevirapine ensures that these two NNRTIs cannot be administered sequentially 
after virologic failure.104 Nevertheless, efavirenz is currently the preferred NNRTI used in first-line 
treatment regimens for adults and adolescents.83  
Etravirine (Intelence®) and rilpivirine (Edurant®) are the latest NNRTIs to be approved by the FDA and are 
considered to be second-generation NNRTIs (Figure 10). These NNRTIs fall into a new class of 
diarylpyrimidine (DAPY) NNRTIs that possess an element of structural flexibility not demonstrated by the 
first-generation NNRTIs, nevirapine and efavirenz.105-106 This characteristic is believed to explain the 
superior resistance profile associated with these NNRTIs as conformational flexibility enables these 
compounds to cope with mutation associated structural changes in the NNIBP.106 Despite their higher 
Stellenbosch University  https://scholar.sun.ac.za
Chapter 1: A Brief Introduction to HIV and Current Therapeutic Strategies 
20 
 
barrier to resistance, etravirine and rilpivirine are only introduced as a salvage therapy after other NNRTIs 
have failed.8 
 
Figure 10  A depiction of efavirenz and second-generation NNRTs etravirine and rilpivirine. Second-generation NNRTIs are 
characterised by a higher genetic barrier to resistance. 
Doravirine (Figure 11) is a next generation NNRTI currently in phase III clinical trials.107 Doravirine  has 
been shown to exhibit comparable efficacy to efavirenz, but with superior tolerability and a lower 
propensity for efavirenz associated side effects of the central nervous system (CNS).108 Studies have also 
demonstrated that doravirine exhibits an even higher barrier to resistance than all currently licensed 
NNRTIs.108-109  
 
Figure 11 Doravirine, a new generation NNRTI with a superior resistance profile to currently licensed NNRTIs. 
 
1.5.3. Protease Inhibitors (PIs) 
Until recently PIs together with NRTIs and NNRTIs were recommended for use as a first-line treatment 
option for infected individuals. Today, however, the WHO recommends the use of PIs for second-line 
treatment regimens or as a salvage therapy.83 Currently there are ten PIs licensed by the FDA and, all but 
one, are characterized by the presence of a hydroxyethylene core (Figure 12) as opposed to the normal 
peptidyl linkage found in polyprotein precursors.93 This structural feature characterizes PIs as non-scissile 
peptidomimetic substrate analogues for HIV protease as the hydroxyethylene moiety cannot be 
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hydrolytically cleaved by the enzyme.93 This results in the blockage of the enzyme active site preventing 
cleavage of GagPol polyprotein precursors and subsequent maturation of the HIV virion.86 The first PI, 
saquinavir (Invirase®), was approved by the FDA in 1995. Over the next two years three more PIs were 
licensed by the FDA: ritonavir (Norvir®) and indinavir (Crixivan®) in 1996 and nelfinavir (Viracept®) in 1997 
(Figure 12).81 These PIs are identified as first-generation PIs as they suffered from poor bioavailability, a 
low genetic barrier to resistance and toxicity issues.110  
Notably it was discovered that ritonavir, in addition to protease inhibition, was able to inhibit metabolic 
pathways of cytochrome P450 (CYP450) and could therefore be utilized as a booster for other PIs.110-111 
By co-administering ritonavir with another PI the bioavailability and potency of that PI would improve.110 
Unfortunately, in the case of first-generation inhibitors, this method only worked well with saquinavir. 
Ritonavir co-administered with indinavir led to greater nephrotoxicity or, with nelfinavir, had no notable 
effect on bioavailabilty.110, 112  
 
Figure 12 A depiction of the first-generation PIs with the characteristic hydroxyethylene core in blue. 
Due to the limited success of first-generation PIs, second-generation PIs with improved pharmacokinetic 
and resistance profiles were developed. The first of these was amprenavir (Lexiva®) (Figure 13). Like the 
earlier PIs, amprenavir possessed the characteristic hydroxyethylene core however, unlike earlier PIs, 
amprenavir exhibited a unique resistance profile which resulted in a higher barrier to resistance with little 
cross-resistance to other PIs.113 Unfortunately, the use of amprenavir was associated with low plasma 
levels and consequently a high pill burden of eight tablets, twice daily.110 Fosamprenavir, a prodrug of 
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amprenavir, was developed to reduce the high pill burden linked with the administration of amprenavir.113 
The success of this endeavour led to the replacement of amprenavir with fosamprenavir. Following the 
approval of amprenavir and fosamprenavir, the FDA approved another four second-generation PIs, 
namely lopinavir (Kaletra®), atazanavir (Reyataz®), tipranavir (Aptivus®) and darunavir (Prezista®) (Figure 
13). Lopinavir in combination with ritonavir is currently the preferred PI combination used in second-line 
treatment regimens.83 The PI tipranavir falls into a new class of non-peptidomimetic inhibitors which differ 
structurally from other PIs. In the place of the common hydroxyethylene core, tipranavir is characterised 
by a dihydropyrone core (Figure 13). This structural diversity enables this class of PIs to maintain efficacy 
against various drug-resistant strains of HIV.114 Unfortunately, harsh side-effects became associated with 
the administration of tipranavir.115  
 
Figure 13 A depiction of the five FDA approved second-generation PIs. These PIs are characterized by a higher genetic barrier to 
resistance. Once again, the hydroxyethylene core is shown in blue with the exception of tiprananvir with its dihydropyrone core 
shown in red. 
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1.5.4. Integrase Strand Transfer Inhibitors (INSTIs) 
The latest class of ARVs to be approved and recommended for first-line treatment in HAART are INSTIs. 
The discovery of INSTIs was made by pharmaceutical companies Merck and Shionogi in 2000. Through in 
vitro assays researchers from both companies discovered that aryl diketo acids (DKA) and derivatives 
thereof were effective inhibitors of IN.116-117 Furthermore, as the name implies, these inhibitors specifically 
target the second step of the integration process, the strand transfer step (Refer to section 1.4.3).118 
Examples of these include the pyrrole-containing compound L-731,988 (Merck) and indole-based 
compound 5-CITEP (Shionogi) shown below (Figure 14). 
 
Figure 14 Merck and Shinonogi discovered that aryl diketo acids and related derivatives were effective inhibitors of HIV 
integrase. 
INSTIs bind to the catalytic site of IN only in the presence of vDNA. It has been hypothesized that the 
presence of the vDNA stabilizes the formation of the active site hydrophobic binding pocket, which only 
exists following 3’-P, allowing for INSTI binding.118-119 All effective INSTIs possess two important structural 
features: The first is the characteristic DKA moiety (in some cases monoketo acids are employed) which is 
particularly important to the mode of action of INTSIs as it chelates the divalent magnesium ions present 
at the catalytic triad in the active site. The second structural feature is a hydrophobic aromatic group able 
to form interactions with the binding pocket, as well as the penultimate deoxycytidine nucleobase located 
at the 3’-end of the vDNA (Figure 15).119 
The first two INSTIs to be made commercially available for the treatment of HIV-1 encompass both these 
features. Raltegravir (Isenstress®) and elvitegravir (Vitekta®) were approved  by the FDA in 2007 and 2014 
respectively (Figure 15).81, 120 Both raltegravir and elvitegravir were found to be potent inhibitors of IN, 
effectively reducing viral levels in treatment naïve and experienced individuals.51 Unfortunately, despite 
their efficiency both INSTIs suffer from a moderate barrier to resistance as well as significant cross-
resistance.121-123 Single-point mutations that cause high levels of resistance to these first-generation INSTIs 
are not in the immediate vicinity of the INSTIs, but are believed to prompt conformational changes in the 
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catalytic site which decreases the affinity of the INSTIs for IN.51 In addition to a moderate genetic barrier 
to resistance, elvitegravir is readily metabolized by liver enzymes and therefore, like many PIs, has to be 
administered with a booster.108, 124 Cobicistat, a structural analogue of ritonavir lacking significant antiviral 
activity, is the recommended pharmacological booster for elvitegravir.124 
 
Figure 15 First-generation INSTIs raltegravir and elvitegravir possess two structural features important for binding to the active 
site of IN. The DKA moiety (green) to chelate to divalent magnesium ions and an aromatic ring (red) capable of forming 
interactions with residues in the pocket and the deoxycytidine nucleobase of the bound vDNA. 
Following the observed trend with the ARVs discussed so far, a need for the development of second-
generation INSTIs was required to deal with the resistance issues associated with raltegravir and 
elvitegravir. To this end the INSTI dolutegravir (Tivicay®) was developed and recently approved by the FDA 
(Figure 16).125 Dolutegravir is a potent INSTI with a high genetic barrier to resistance, maintaining efficacy 
in the presence of mutations that confer resistance to raltegravir and elvitegravir.51 Studies have 
suggested that dolutegravir adapts its conformation with the structural changes that occur within the 
mutated active site.126 Due to a good pharmacokinetic profile with little to no evidence of any serious side 
effects, dolutegravir is also part of the preferred first line regimen with 3TC and TDF as an alternative to 
regimens containing efavirenz. 83, 127 
 
Figure 16 Dolutegravir is a second-generation INSTI with a high genetic barrier to resistance and is currently used as an 
alternative to efavirenz in first line treatment regimens. 
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1.5.5. Other classes of ARVs: Fusion and Entry Inhibitors 
Maraviroc (Selzentry®) was the first ARV developed to target viral entry into the host cell (Figure 17). 
Maraviroc targets the chemokine receptor CCR5 preventing cellular fusion between the HIV viral envelope 
and the host cell plasma membrane. In binding to CCR5, maraviroc induces a conformational change in 
the chemokine receptor that prevents interactions with gp120.81 Initially it was considered unusual to 
target CCR5 (a host receptor) due to the risks associated with the intervention of host cellular function 
especially at chronic doses.128 However, studies have shown that CCR5 is a superfluous receptor and that 
chronic inhibition of this receptor does not alter the normal function of a host’s immune system.129 This 
observation is based on research around 1% of north European Caucasians who are resistant to HIV-1 
infection as they lack the CCR5 receptor. Despite the lack of CCR5 these individuals suffered no health 
adversities.130 A major drawback to maraviroc is that administration is limited to individuals who possess 
the CCR5 coreceptor, as maraviroc does not bind to and therefore has no activity against CXCR4, an issue 
affecting carriers of the R5/X4 virus as well.131 As a result infected individuals have to be tested prior to 
taking maraviroc to establish whether the virus is R5 or X4 tropic.130 Maraviroc is currently not on the list 
of recommended ARVs for HAART. 
 
Figure 17 Maraviroc was the first ARV developed to target viral entry.  
Enfuvirtide (Fuzeon®, Figure 18) is a complex 36 amino acid helical peptide developed by Roche and 
approved by the FDA in 2003 to inhibit viral fusion.132-133 Enfuvirtide is derived from the C-terminal helical 
region of the gp41 ectodomain (Refer to section 1.4.1) and is therefore a competitive inhibitor for the 
complementary N-terminal helical region of the gp41 ectodomain.134-135 By binding to gp41, enfuvirtide 
prevents the formation of the 6HB fusion pore which would allow for delivery of the viral genome into 
the host cell.136 Although a potent inhibitor of viral fusion, enfuvirtide has limited oral bioavailability and 
a half-life of only 3.5 to 4.5 hours.135 As a result, administration of enfuvirtide is carried out intravenously 
twice daily, a regimen which can be challenging for chronic use.85 Consequently, enfuvirtide is only 
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administered as a salvage therapy to treatment experienced patients with no remaining therapeutic 
options.137  
 
Figure 18 The first fusion inhibitor enfuvirtide is a synthetic peptide derived from gp41. 
Interestingly an alternative to enfuvirtide has been in development for use in China. This alternative fusion 
inhibitor, albuvirtide is a 3-maleimimidopropionic acid peptide inhibitor.138 Albuvirtide is related to 
enfuvirtide but has a superior half-life of approximately 11 days and requires once-weekly intravenous 
administration.139 This is a consequence of albuvirtide’s ability to conjugate to serum albumin, the most 
abundant protein found in human plasma.140  
Fostemsavir (Figure 19) is the latest investigational ARV being developed as an entry inhibitor, more 
specifically an attachment inhibitor. Currently in Phase III clinical trials for treatment-experienced 
patients, fostemsavir acts by binding to gp120 preventing the conformational change that allows for 
binding to the host CD4 cell, although the exact mechanism is still under investigation.141 Fostemsavir has 
been developed as a phosphonooxymethyl prodrug of the original azaindole compound to overcome 
adsorption issues of low solubility.142 
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Figure 19 Fostemsavir is the latest entry inhibitor in clinical trials. In comparison to other licensed inhibitors, fostemsavir 
prevents viral entry by binding directly to gp120. 
 
1.6. Conclusion 
Over the past 30 years 25 ARVs targeting different stages of the HIV replication cycle have been licensed 
by the FDA. In addition, many new generation inhibitors that improve upon the profiles of currently 
licensed therapeutics, or are pursuing new targets altogether, are currently under investigation. These 
advances in combating HIV have drastically changed the outlook for sufferers of the disease. The 
introduction of combination therapy has successfully suppressed viremia in infected individuals to almost 
undetectable levels, improving quality of life and preventing the onset of AIDS. However, the use of 
combination therapy is not curative as difficulties related to drug resistance and adherence can lead to 
the re-occurrence of high plasma viral levels, AIDS and ultimately death. Until a cure for HIV is found there 
still exists a necessity for continued clinical development of novel superior ARVs that are efficacious 
against wild-type and mutated targets and that are inexpensive and well tolerated for chronic use. 
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Chapter 2: Optimization of a lead compound - a scaffold-hopping approach. 
 
2.1. The discovery of a series of indole-based NNRTIs as potent inhibitors of RT 
At the end of Chapter 1 it was concluded that despite the substantial number of anti-HIV agents on the 
market or in clinical development, the onset of resistance ensures that there remains a perpetual need 
for the development of new agents that can overcome this issue and effectively control the viral levels in 
the infected population.  
In an effort to address this need our group has focused on the design and development of novel and 
potent NNRTIs with emphasis on the use of indoles as the core scaffold. Indoles are considered a 
“privileged scaffold”† in drug discovery and the development of indole-based NNRTIs as potent inhibitors 
of HIV RT has been well established in the literature.143-146  
In 2014 our research group reported the development of a series of novel 3-alkyloxyindole derivatives (1 
– 3, Figure 20) that exhibited low nanomolar activity against wild-type HIV.147 Of this series, compound 3 
was significantly more potent across a number of clinically relevant resistant strains. More importantly 
compound 3 was found to maintain potency in the presence of the most problematic and wide-spread 
K103N mutation.147 The activity of these compounds can be attributed to a number of key structural 
features that enhance their affinity for the NNIBP. Using compound 3 as an example, Figure 20 shows a 
schematic representation of the proposed binding mode of these indole analogues within the NNIBP. The 
3,5-dimethylphenyl moiety located at the 3-position of the indole achieves π-π stacking interactions with 
Tyr181, while the methoxy moiety, located on the carbon linker joining the aryl ring to the indole core, 
occupies a small hydrophobic pocket in the vicinity of Val179. The indole NH and the ester carbonyl 
occupying position 2 on the indole core facilitate hydrogen bonding interactions with the backbone of 
Lys101. Prior structure-activity-relationship (SAR) studies have established the importance of these 
structural features towards the activity of these analogues. It was observed that the absence of any of 
these features would result in a significant loss in activity.147-148  
                                                          
† A term coined by Evans and co-workers in 1988 to describe modifiable molecular structures capable of providing 
novel ligands as agonists and antagonists for various receptors.4  
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Figure 20. (left) Novel 3-alkyloxyindole derivatives were developed that exhibited low nanomolar activity against wild-type HIV 
RT. (right) A schematic representation of the binding mode of compound 3 in the NNIBP. 
Despite the promising activity profile of these indole analogues against wild type HIV and K103N it was 
discovered that these compounds, when exposed to an acidic environment, were prone to degradation 
through hydrolysis of the alkoxy moiety.149 Although this observation could be exploited in the synthesis 
of these compounds it did not bode well for the stability of these indole analogues in vivo. Using 
compound 1 as an example, Scheme 1 depicts the proposed method by which acid-mediated hydrolysis 
occurs. In the presence of acid, the methoxy group is activated through protonation (4). The indole then 
facilitates the elimination of the activated methoxy group resulting in the formation of a reactive 
electrophilic intermediate 5 which is subsequently attacked by water to afford the (1H-indol-3-
yl)methanol derivative 6. The conversion of 1 to 6 was highly unfavourable as 6 was found to be a 
significantly poorer inhibitor of HIV RT when evaluated in a phenotypic assay.149 Consequently, the 
acknowledgement of the alkoxy moiety as the indole analogue’s ‘Achille’s heel’ would hinder the 
possibility of advancing these compounds towards clinical development. 
 
Scheme 1 A depiction of the manner in which indole analogues, such as compound 1, are hydrolysed in the presence of acid to 
afford the hydroxyindole 6, a poor inhibitor of HIV RT.  
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2.2. The exploration of a suitable bioisosteric replacement to improve upon the stability 
of a lead compound 
In order to address this issue of acid lability a suitable bioisosteric replacement for the problematic 
alkyloxy moiety had to be discovered. It was crucial that the chosen bioisostere would occupy the Val179 
pocket in a manner similar to the original alkyloxy moiety so as not to alter the binding orientation of the 
compound in the NNIBP. To this end three bioisosteric replacements, expected to be less susceptible to 
acid-promoted hydrolysis, were identified (Figure 21). These bioisosteres included a methyl sulfide group 
(7), a poorer Lewis base and therefore less likely to undergo acid-promoted hydrolysis, an ethyl group (8), 
lacking a protonatable heteroatom altogether and an N-ethylaniline moiety (9) for which acid promoted 
elimination would not be possible. Molecular modelling of compounds 7 – 9 suggested that all identified 
bioisosteres would be well accommodated in the NNIBP and that all the important interactions between 
ligand and NNIBP described for the indole analogues in Figure 20 would be maintained. 
 
Figure 21 Three possible bioisosteric replacements for the problematic alkyloxy moiety were identified. 
The synthesis and evaluation of compounds 7 and 9 was published in 2016.149 As with the original lead 
compound 1, compound 7 and a few derivatives thereof exhibited low nanomolar activity against wild-
type HIV (Figure 21). Stability testing of analogues of compounds 1 and 7 involved suspension of these 
analogues in solutions of concentrated sulfuric acid in ethanol and the periodic monitoring of degradation 
by HPLC. This study revealed that, unlike the methoxy indole compound which within 2 hours had been 
fully degraded, the corresponding methyl sulfide compound had remained unaffected after 72 hours.149 
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From this we could conclude that the methyl sulfide analogues were not only potent inhibitors of RT, but 
were stable under acidic conditions. 
Unfortunately, compound 9 did not fare well as a replacement candidate, exhibiting poor activity against 
HIV and further study of this analogue was not pursued.149 
Compound 8 was recently evaluated in a whole cell assay and was also found to exhibit low nanomolar 
activity against wild-type HIV. Although the stability of these compounds has not yet been evaluated we 
envisaged that derivatives of compound 8 would be unlikely to experience degradation through hydrolysis 
in acidic media due to the complete lack of a protonatable heteroatom.  
Through the identification of indole analogues 7 and 8 our group had successfully optimized the stability 
of lead compound 1 while maintaining excellent activity against HIV. Nevertheless, these analogues were 
still not suitable for drug candidacy. We had recognized another lability issue in the form of the ester on 
the indole scaffold. We understood that, in vivo, the indole ester would likely be hydrolysed to the 
corresponding carboxylate by various cellular esterases which are ubiquitous in the human body.150 This 
presented a serious problem as, in earlier studies, it had been established that the carboxylate was 
approximately 300 times less potent than its ester counterpart.148 
Unfortunately, removing the ester entirely was not a suitable remedy to this issue. It had already been 
established that the presence of the ester was paramount to the activity of the indole series of 
compounds. In a previous study the synthesis and evaluation of the methoxy indole analogue with and 
without the ester present was reported (Figure 22).147 It was observed that by removing the ester 
completely, the methoxy indole compound 10 suffered a greater than 100-fold loss in potency.  
 
Figure 22 
The contribution of the ester towards the activity of the indole compounds is thought to be two-fold. 
Firstly, the ester improves the affinity of the compound for the NNIBP by introducing additional 
electrostatic interactions with the backbone of Lys101 (Figure 20). Secondly, it was proposed that the 
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presence of the ester could be responsible for improving the hydrogen bonding capability of the adjacent 
indole NH. The presence of an electron withdrawing group such as the ester would pull electron density 
from the indole ring system, increasing the polarization of the indole N-H bond and thereby increasing its 
efficacy as a hydrogen bond donor.   
 
2.3. A scaffold-hopping approach to overcome the metabolic instability of the labile 
indole ester 
Although there exist a number of suitable bioisosteric replacements for the ester we decided to take a 
novel approach and address this issue by exchanging the indole scaffold altogether with a suitable 
replacement which we would identify through a scaffold hopping approach. The concept of ‘scaffold 
hopping’ was introduced by Schneider et al. in 1999 and has become increasingly popular in lead 
optimization.151 This method, by definition, is a means to replace a known scaffold with one that is 
isofunctional but has altered certain properties that may have previously hindered drug development.151-
152  
Using this approach, and with the aid of molecular modelling, we identified the benzimidazolone 
heterocycle as a suitable bioisosteric replacement for the ethyl indole-2-carboxylate scaffold (Figure 23). 
Molecular modelling studies were undertaken using Schrӧdinger software, with extra-precision Glide as 
the main docking tool in order to compare the binding mode of the benzimidazolone scaffold against the 
indole series.153 Schematic representations of indole compound 1 and corresponding benzimidazolone 
compound 11 bound to the NNIBP reveal that compound 11 maintains a similar binding orientation to the 
indole analogues by retaining interactions with Tyr181 and the backbone of Lys101 and by occupying the 
Val179 pocket (Figure 23). Although with this new scaffold the hydrogen bond acceptor in the form of the 
ester carbonyl was lost, it was hoped that the presence of the carbonyl directly adjacent to the 
benzimidazolone NH would be able to sufficiently strengthen the hydrogen bonding capability of the urea, 
thereby compensating for the loss of the second hydrogen bond. 
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Figure 23 (top) schematic representations comparing the binding mode of compounds 1 and 11 in the NNIBP. (bottom) overlay 
of compounds 1 (white) and 11 (orange) in the NNIBP. Docking studies were conducted using the receptor PDB ID 2RF2. 
Interestingly, a survey of the literature revealed that we were not the first to consider the 
benzimidazolone heterocycle as a potential NNRTI scaffold. In 2005 another group had designed and 
synthesized a series of similar compounds based on a 3D pharmacophore model built from efavirenz.154-
156 These benzimidazolone analogues exhibited moderate to excellent activity against HIV. Sulfonamide 
compound 12 in particular was the most potent of the series and displayed moderate activity against 
problematic mutant strains such as K103N (Figure 24).155-156  
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These results provided confirmation that our choice of scaffold was not unfounded. Furthermore, in light 
of the fact that these benzimidazolone analogues exhibited excellent potency against HIV RT we were 
optimistic that the same exceptional results for our own benzimidazolone compounds would be obtained. 
 
2.4. The strategy towards the synthesis of target compound 11 
Having identified our target compound 11 we could embark upon its synthesis. We decided to base our 
synthetic strategy on the synthesis described for compound 12 due to the similarity with our target 
compound.156 The reported synthetic strategy was fairly straightforward and comprised of three separate 
steps shown below in Scheme 2.  
 
Scheme 2: Synthetic strategy of target compound 11 based on the synthetic procedure described by Barecca et al.156 
The first step would involve the N-functionalization of 5-chloro-2-nitroaniline 13 with an appropriate aryl 
halide, which in our case would be (1-iodopropyl)benzene 14, to yield the functionalized precursor 15. 
Subsequent steps would involve the reduction of the nitro group to the diamine 16 and cyclization in the 
presence of CDI to yield the target compound 11 (Scheme 2).  
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As part of our strategy to synthesize 11, the alkylating agent (1-iodopropyl)benzene 14, which was not 
commercially available, had to be synthesized. Through retrosynthetic analysis it was anticipated that 
compound 14 could be synthesized from the corresponding alcohol 17 through a simple substitution 
reaction with an appropriate iodine source (Scheme 3). In turn, it was envisaged that the 2˚ alcohol 17 
could be readily obtained through a Grignard reaction between commercially available ethyl iodide 18 
and benzaldehyde 19 (Scheme 3). It is important to note that at this stage stereoselectivity was not 
important. As with the original series of indole compounds we acknowledged that the target compound 
11 would be obtained as the racemate to establish a proof-of-concept and overall, to avoid synthetic 
complexity. 
 
Scheme 3 A retrosynthetic approach to the synthesis of compound 14 
 
2.4.1. Synthesis of (±)-1-phenylpropan-1-ol (17)  
 
Scheme 4 
For the Grignard reaction to form the precursor 17 we resolved to synthesize the Grignard reagent in situ 
despite the ready availability of solutions of ethylmagnesium bromide. This was achieved by the addition 
of ethyl iodide 18 to magnesium turnings in diethyl ether (Scheme 4). Notable consumption of the 
magnesium indicated that oxidative insertion of the magnesium to form the Grignard reagent had 
occurred. Subsequent addition of 19, allowed for the nucleophilic addition of the Grignard reagent onto 
the aldehyde and an acid quench resulted in the formation of 17 in an 84% yield after purification. 
At first glance, the presence of aromatic and aliphatic signals in the 1H and 13C NMR spectra gave a clear 
indication that the formation of 17 had occurred successfully. This observation was further justified by 
the complete lack of a singlet belonging to the aldehyde in the 1H NMR spectrum and the appearance of 
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a broad singlet at 2.43 ppm which coincided with the presence of the hydroxyl group on 17. As this was a 
known compound it was possible to compare the chemical shifts obtained experimentally with those 
reported in the literature and it was found that all spectroscopic data compared favourably.157 
 
2.4.2. Synthesis of (±)-(1-iodopropyl)benzene (14) 
 
Scheme 5 
With compound 17 in hand we could attempt the conversion of the alcohol to the corresponding iodine 
14. A survey of the literature revealed a large variety of methods to achieve this conversion. One 
publication in particular described the selective iodination of allylic and benzylic alcohols using KI in the 
presence of the Lewis acid BF3·Et2O as a mild and efficient method for the preparation of alkyl iodides.158 
Encouraged by the high yields reported in this publication, we resolved to employ this method for the 
conversion of 17 to the corresponding iodo-compound 14. In our hands this Lewis acid assisted 
substitution of a benzylic hydroxyl group for an iodine produced 14 in a moderate yield of 67% (Scheme 
5).  
The notable absence of the OH signal in the 1H NMR spectrum was the first indication that the conversion 
of 17 into 14 had occurred. In the 13C NMR spectrum an upfield shift from 75.97 ppm to 36.74 ppm was 
observed for the sp2 carbon directly attached to the iodine providing further evidence that the conversion 
had taken place. As with compound 17, 14 was also a known compound and therefore the experimentally 
obtained chemical shifts could be compared to the chemical shifts reported in the literature. Again, all 
spectroscopic data was found to be in accordance with that in the literature.159 
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2.4.3. Synthesis of (±)-5-chloro-2-nitro-N-(1-phenylpropyl)aniline (15) 
 
Scheme 6 
Having successfully synthesized the precursor 14 we could proceed with the synthesis of target compound 
11 using the strategy described in Scheme 2. The first step in this strategy was the N-functionalization of 
5-chloro-2-nitroaniline 13. This was readily achieved through the treatment of 13 with 14 in the presence 
of NaH in THF. The N-substituted aniline 15 was obtained in 88% yield (Scheme 6). 
In the 1H NMR spectrum all signals previously associated with compound 14 were observed in the 
spectrum for 15 in addition to four new signals. Of these new signals a broad doublet at 8.57 ppm was the 
most noteworthy. This signal which integrated for one proton corresponded to the amine and the 
multiplicity observed could be attributed to coupling of the amine to the adjacent benzylic proton. In the 
13C NMR spectrum 3 aliphatic and 10 aromatic signals were observed coinciding with the expected number 
of signals for compound 15. 
 
2.4.4. Synthesis of (±)-5-chloro-N1-(1-phenylpropyl)benzene-1,2-diamine (16)  
For the reduction of the nitro group on 15 we decided to employ an alternative strategy to the classical 
catalytic hydrogenation method using Pd/C in the presence of hydrogen. This decision was based on the 
concern that under these conditions reductive dehalogenation of the chloride present on 15 could occur. 
While scrutinizing the literature we happened upon a publication which described the use of iron powder 
or stannous chloride under ultrasonic irradiation as an efficient method of reducing aryl nitro groups.160 
Not only did this method boast mild reaction conditions, short reaction times and high yields but it was 
also found to be selective for aryl nitro groups in the presence of various sensitive functional groups such 
as aryl halides, ketones and nitriles.160 The use of ultrasonic irradiation is often associated with high 
reaction rates relative to reactions carried out under thermal conditions, an advantage most notable in 
reactions involving metals. This comes as a result of ultrasound cavitation and activation through the 
continuous cleaning of the metal surface to limit surface impurities such as oxides, hydroxides and 
carbonates which inhibit contact between reagents and the metal surface.161  
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Of the two reducing agents employed in this publication, iron powder in the presence of glacial acetic acid 
was reported to be superior to stannous chloride. With this in mind, iron powder was added to 15 in a 
2:2:1 solution of glacial acetic acid, ethanol and water and the reaction was exposed to ultrasonic 
irradiation for 2 hours (Scheme 7). Interestingly, within this time the originally bright red reaction mixture 
had turned clear. As nitro-containing aryl compounds are often brightly coloured this became a clear 
visual indication that the nitro group had been reduced to the amine, an observation confirmed by TLC. 
After purification we were able to obtain the diamine 16 in a yield of 78%. 
Inspection of the 1H NMR spectrum of 16 revealed a broad singlet located at 5.08 ppm which integrated 
for 3 protons. Although the only real notable observation, it attested to the successful reduction of the 
nitro moiety to the amine. Unfortunately, due to degradation issues we were unable to characterize this 
compound using HRMS. 
 




With the diamine 16 in hand we could attempt the final stage in this synthetic procedure which involved 
the cyclization of 16 to the target compound 11. For the synthetic procedure reported in the literature 
the final cyclization step was achieved through the use of phosgene.156 We envisaged that the same 
reaction could be achieved by employing carbonyldiimidazole (CDI), a less toxic alternative. Through the 
use of CDI we were able to synthesize our target compound 11 in a yield of 73%. 
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The most distinguishing feature of the 1H NMR spectrum was the presence of a highly deshielded broad 
singlet at 10.54 ppm. This singlet we could confidently assign to the benzimidazolone NH. All other 
expected proton signals were accounted for. A signal at 156.52 ppm was the only distinguishing feature 
in the 13C NMR spectrum and attested to the presence of the benzimidazolone carbonyl group. 
 
2.5. Synthesis of (±)-6-chloro-1-(1-phenylpropyl)-1,3-dihydro-2H-benzo[d]imidazole-2-
thione (20), a sulfur-containing analogue of target compound 11 
In addition to compound 11, we decided that it would be worthwhile to synthesize the sulfur-containing 
analogue 20 (Scheme 9). Although sulfur is less electronegative than oxygen, it has a greater ability to 
accommodate and stabilize a negative charge due to its larger size, resulting in a much more polarized Sδ-
=Cδ+ bond.162-163 As a result, thioureas are more acidic than their urea counterparts and are, therefore, 
considered to be better hydrogen bond donors.164 Despite its larger size, molecular modelling indicated 
that the sulfur analogue 20 would be well-accommodated in the NNIBP. Based on this information we 
would expect compound 20 to exhibit improved activity over the urea analogue 11. 
 
Scheme 9 
As the ring-closing step is the final stage in the synthetic strategy, the synthesis of compound 20 would 
not deviate much from the synthesis described for compound 11. In fact, the only deviation would be the 
use of thiocarbonyldiimidazole (TCDI) for the final cyclization step in place of CDI. As planned, the reaction 
of diamine 16 with TCDI afforded the sulfur compound 20 in a 91% yield.  
As with compound 11, a highly deshielded singlet was observed in the 1H NMR spectrum. This singlet 
corresponding to the NH of compound 20 was located more downfield at 11.73 ppm, which gave credence 
to the fact that the thiourea is more acidic than its urea counterpart. The same trend was observed for 
the 13C NMR spectrum with the thiocarbonyl signal being observed at 170.30 ppm. 
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2.6. Biological evaluation of compounds 11 and 20 
Having arrived at our target compounds 11 and 20, they could be evaluated for activity against HIV. To 
this end, the compounds were shipped to Johannesburg to be evaluated by our collaborator Dr Adriaan 
E. Basson at the HIV Pathogenesis Research Unit at WITS University. Here IC50 values were determined 
using an in vitro single-cycle, nonreplicating phenotypic assay and CC50 values were determined in a 
tetrazolium-based colorimetric assay. Both assays utilized HEK293T cell lines.165-167 
Evaluation of these compounds revealed that 11 was a potent inhibitor of HIV with an IC50 value of 22 nM 
(Figure 25). This signified that compound 11 exhibited the same potency as the original lead indole 
compounds 1 – 3, despite the lack of an additional hydrogen bond to the backbone of Lys101. This 
observation gave credence to our hypothesis that having an electron-withdrawing group directly adjacent 
to the hydrogen bond donor would compensate for the lack of the hydrogen bond acceptor in the form 
of the ester. Furthermore, not only was 11 potent against HIV, it also addressed the two lability issues 
exhibited by our indole analogues, namely the issue of acid stability and that of ester hydrolysis. 
Compound 20, on the other hand, was found to be ten times less potent than compound 11. This 
observation initially came as a surprise as we would have expected better, if not the same activity as for 
11. In an attempt to rationalize the poorer activity observed for 20, we hypothesized that, perhaps, the 
introduction of the sulfur increases the lipophilicity of the compound which can negatively influence 
membrane penetration and solubility.168 On the other hand, despite the results obtained by molecular 




Due to the potency of compound 11 it was decided to further evaluate the compound’s efficacy against 
the most problematic resistant strains in the clinic, namely K103N and Y181C. 
Disappointingly, against K103N and Y181C compound 11 suffered a significant loss in activity. In the case 
of Y181C, this loss in activity could be attributed to the fact that benzimidazolone compound 11 relies 
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heavily on π-π stacking interactions between the aryl moiety situated at the N1 position and Tyr181 
(Figure 23). The mutation of the aromatic tyrosine to the aliphatic cysteine residue results in a complete 
loss of this interaction and as a result, the binding affinity of these compounds for the NNIBP is reduced. 
The loss in activity against K103N was a little more difficult to rationalize as the manner in which this 
mutation confers resistance is still not fully understood. 
 
2.7. Concluding Remarks – Can the loss in activity against resistant strains be overcome? 
In conclusion, guided by molecular modelling we were able to significantly improve the acid stability and 
esterase lability of the lead indole compounds 1 – 3 by exchanging the indole scaffold for the 
benzimidazolone heterocycle. At the same time, we were able to maintain low nanomolar activity against 
wild-type HIV. Unfortunately, just like the indole series, lead compound 11 was susceptible to the Y181C 
resistant strain of HIV.  
As a means to combat this issue we would need to eliminate any reliance on π-π stacking with Tyr181 
altogether. To this end we envisaged designing a library of second-generation benzimidazolone 
compounds that would not rely on interactions with Tyr181 for their affinity to the NNIBP.  
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Chapter 3: The Design and Synthesis of a Series of Second-generation 
Benzimidazolone Compounds 
 
3.1. Targeting Tyr181 and Trp229 as a strategy to overcome susceptibility to the Y181C 
resistance mutation 
The strategy of reducing a therapeutic agent’s reliance on interactions with a mutable amino acid residue 
in order to overcome resistance has found considerable success in the case of the licensed NNRTI 
efavirenz. In Chapter 1, we discussed and compared the susceptibility of first-generation NNRTIs 
nevirapine and efavirenz to the Y181C resistant strain. Efavirenz, unlike nevirapine, does not depend on 
π-stacking interactions with Tyr181 and as a result is able to maintain activity in the presence of the Y181C 
resistant strain of HIV.169 
In an attempt to overcome the susceptibility of lead benzimidazolone compound 11 to the Y181C resistant 
strain we decided to employ a similar strategy. However, instead of removing the aryl functionality 
completely, which we knew from the indole analogues would result in a significant loss in potency, we 
envisaged transposing the aryl group from the 1-position to the 7-position on the benzimidazolone 
scaffold. According to molecular modelling, this shift would result in the occurrence of π-π interactions 
between the aryl ring and the conserved residue Trp299, as well as Tyr188, and the loss of π-π interactions 
with the mutable residue, Tyr181 (Figure 26).  
 
Figure 26 In an attempt to overcome susceptibility to the Y181C resistant strain we envisaged transposing the aryl group from 
position 1 to position 7 on the benzimidazolone scaffold. 
This strategy presents a major advantage in light of the fact that Trp229 is a highly conserved residue in 
the NNIBP of RT.170 Trp229 forms part of the primer grip region of the enzyme, and is thus responsible for 
maintaining the structural integrity of the primer terminus which enables propagation of the nascent DNA 
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chain at the active site.171 It is therefore not surprising that site-directed mutagenesis at Trp229 severely 
compromises the viability of the enzyme.170 As a result, it has been proposed that in designing NNRTIs 
that target immutable amino acid residues such as Trp229, the problematic susceptibility to resistant 
strains of HIV could be overcome.172 In fact, the strategy of targeting Trp229 has already found 
considerable success in a number of other potent NNRTIs such as capravirine, lersivirine and doravirine 
(Figure 27).173-175  
 
Figure 27 Capravirine, lersivirine and doravirine are known potent NNRTIs that bind to the NNIBP by forming π-π interactions 
with conserved residue Trp229 and Tyr188. 
Docking studies, using extra-precision Glide, were employed to determine the binding mode of these 
second-generation benzimidazolone compounds within the NNIBP. Encouragingly, these studies revealed 
that despite the transposition of the aryl ring on the benzimidazolone scaffold we would be able to 
maintain a similar binding orientation to our lead compound 11. This signified that, in addition to π-π 
interactions with Trp229 and Tyr188, these compounds would be able to retain the important hydrogen 
bonding interaction with the backbone of Lys101 (Figure 28). Furthermore, by maintaining the presence 
of an alkyl group at position 1 on the benzimidazolone scaffold we would still be able to occupy the small 
hydrophobic pocket in the vicinity of Val179. 
It is also worth mentioning that by transposing the aryl ring from the 1 to 7-positon on the 
benzimidazolone scaffold, Tyr181 is able to adopt the energetically favoured “down” orientation as found 
in the apo form of the enzyme.176-177 In the case of all licensed NNRTIs and our first-generation compound 
11, Tyr181 is forced to adopt an “up” orientation upon binding to the NNIBP (Figure 28).178 
With the aid of molecular modelling we eventually decided upon compounds 21 and 22 as suitable proof-
of-concept compounds for the second-generation benzimidazolone series (Figure 28). Compound 21, 
which possesses the unsubstituted phenyl ring, came about as an obvious extension of lead compound 
11.  The decision to synthesize compound 22, on the other hand, which possesses the two methyl 
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substituents at meta-positions on the “upper” aryl ring, was based on observations made concerning the 
m-xylene-containing indole compound 3 discussed in Chapter 2. It was found that the presence of the 
methyl substituents on the aryl ring significantly improved the activity profile of 3 against the K103N 
resistant strain.147  
 
Figure 28 (top) By relying on π-π interactions with Tyr181 compound 11 is susceptible to the Y181C mutation (left). The strategy 
to overcome this involves transposing the aryl group to form π-π interactions with Tyr188 and conserved residue Trp229 (right). 
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(bottom) An overlay of compounds 11 (green) and 22 (orange) demonstrates how the orientation of Tyr181 moves from the 
"up" to the "down" position. Images were created using PDB files 2RF2 and 2JLE in Discovery Studio. 
A similar observation was made for an earlier HEPT NNRTI, emivirine mentioned in Chapter 1. An analogue 
of emivirine, GCA-186 featuring two methyl substituents on the “upper” aryl ring in the vicinity of amino 
acid residue Trp229, was found to be a potent inhibitor of RT with an improved activity profile against the 
Y181C and K103N resistant strains (Figure 29).179  
 
Figure 29 By introducing methyl groups on the "upper" ring of emivirine the activity profile against mutant strains Y181C and 
K103N was significantly improved. 
It is important to note that docking studies indicated that the methyl groups on our benzimidazolone 
scaffold would be well-accommodated within the NNIBP and would not alter the binding orientation of 
22.  
For ease of synthesis we decided to introduce an oxygen linker atom at the 7-positon on the 
benzimidazolone scaffold, as this would enable us to employ classical coupling techniques to install the 
“upper” aryl group at this position. From Figure 27 it can be seen that the use of an oxygen linker is not 
without precedence. Moreover, we decided to functionalize position 1 on the benzimidazolone scaffold 
with an ethyl chain. Due to the fact that the ethyl groups of compounds 21 and 22 occupy the same region 
as the ethyl group on 11, we were concerned that the installation of larger groups would not be tolerated 
(Figure 28).  
Finally, in an attempt to reduce synthetic complexity, we decided not to introduce the chloride at position 
6 on proof-of-concept compounds 21 and 22. Although the loss of a halogen at this position might be 
expected to affect the efficacy of these compounds, the similarity of the docking scores obtained for 
compounds with (-13.141 kcal/mol) and without (-13.120 kcal/mol) the chloride present at this position 
implied that this would not be case.  
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3.2. Synthesis of proof-of-concept compounds 21 and 22 
With a plausible strategy to overcome resistance to Y181C in mind we could embark upon the synthesis 
of our proof-of-concept compounds 21 and 22. It was envisaged that target compounds 21 and 22 could 
be readily accessed by starting from commercially available 2-nitro-3-aminophenol 23 (Scheme 10). A 
coupling reaction between 23 and aryl iodides, iodobenezene 24 and 5-iodo-m-xylene 25 would yield the 
biaryl ether precursors 26 and 27. From this point, the subsequent steps in the synthesis of compounds 
21 and 22 would follow a similar route to that which was used to synthesize first-generation compound 
11 described in Chapter 2. These steps would involve the N-alkylation of the biaryl ether precursor with 
ethyl iodide to obtain the functionalized biaryl ethers 28 and 29, reduction of the nitro group to yield 30 




3.2.1. Synthesis of biaryl ether precursors 26 and 27 by way of an Ullmann ether coupling 
reaction 
For the coupling between 23 and aryl iodides 24 and 25, it was imperative that coupling conditions were 
chosen that would allow for the chemoselective arylation of the phenol without competitive coupling to 
the aniline. Such conditions were described in a publication by Maiti and Buchwald.180 Herein they 
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reported the discovery of a copper catalyst derived from CuI and picolinic acid which, in the presence of 
K3PO4 and DMSO, could selectively catalyze the arylation of phenols in the presence of amines. It appeared 
that the chemoselectivity reported was based on the large differences in pKa between phenols (pKa ≈ 18) 
and anilines (pKa ≈ 31) in DMSO.181  
For the synthesis of biaryl ether 27, a mixture of 23 and 25 in DMSO was treated with picolinic acid and 
K3PO4. The DMSO was then thoroughly degassed under vacuum for approximately 15 minutes to ensure 
a completely oxygen-free atmosphere prior to the introduction of the copper catalyst, CuI. Following the 
addition of CuI, the reaction was heated to 90 ˚C and left for 18 hours (Scheme 11). 
 
Scheme 11 
After this time TLC revealed that all of 23 had been consumed and only one product had formed and 
following purification by column chromatography we were able to isolate this product in 89% yield. 
At first glance, in the 1H and 13C NMR spectra of this product all signals expected for the biaryl ether 
compound 27 were accounted for. However, in the 1H NMR spectrum two broad singlets at 5.67 and 7.33 
ppm, each integrating for one proton, were observed as opposed to just one broad singlet integrating for 
two protons which would be expected for the aniline. In order to absolutely confirm the chemoselectivity 
of the reaction we obtained FTIR data for the product. Analysis of the FTIR spectrum revealed a broad 
signal at 3429 cm-1, a characteristic absorption typically associated with an alcohol or phenol OH stretch. 
Unfortunately, these observations indicated that the coupling had occurred exclusively on to the aniline 
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3.3. A new synthetic strategy to overcome the problem of chemoselectivity 
Having run into chemoselectivity issues with our current synthetic strategy, we decided to introduce the 
aryl group only at the end of the synthesis, following the formation of the benzimidazolone core (Scheme 
13). Installing the aryl ring at the end of the synthesis would necessitate the introduction of a suitable 
protecting group for the phenol 23, thereby increasing the number of steps in the synthesis. However, 
this new route would allow for divergence of the synthesis to occur at the final step in that a range of 
variously substituted aryl groups could be introduced at the end of the synthesis. 
The first step in the revised synthetic strategy would involve the introduction of a benzyl protecting group 
onto the phenol 23, which could be readily installed and removed under mild reaction conditions (Scheme 
13). The subsequent steps in the revised strategy would follow the route described in Scheme 10, which 
would involve the N- alkylation of the amine 33, reduction of the nitro compound 34 and a ring-closing of 
the diamine 35 with CDI to afford the precursor 36. Due to the chemoselectivity issues faced previously, 
we decided that the introduction of a suitable protecting group onto the benzimidazolone scaffold 36 
prior to debenzylation would also be a necessity. Although Boc protecting groups are often utilized for the 
protection of amines, we did not believe that a Boc group would survive the subsequent coupling 
conditions due to the utilization of K3PO4 and high temperatures (In the synthesis of indole analogues 1 – 
3, described in Chapter 2, we were able to readily remove the Boc protecting group with K3PO4 at 70 ˚ C).149 
As a result we had to find an alternative protecting group that would survive the Ullmann coupling 
conditions. To this end we came upon the 2-(trimethylsilyl)ethoxy methyl (SEM) protecting group as an 
appropriate alternative due to its stability under a variety of reaction conditions.182 SEM protection of 36 
would afford 37 which could subsequently undergo a debenzylation reaction to yield precursor 38. 
Penultimately, the Ullmann ether coupling reaction with aryl iodides 24 and 25 would afford the desired 
precursors 39 and 40. From the literature we were able to ascertain that the SEM protecting group could 
then be readily removed by introducing a fluoride source by way of BF3.OEt or TBAF to afford the proof-
of-concept compounds 21 and 22.182-186 
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Scheme 13  
 
3.3.1. Synthesis of 2-(benzyloxy)-6-nitroaniline (33) 
 
Scheme 14 
The first reaction in the altered synthetic route between 23 and benzyl bromide in the presence of 
potassium carbonate proceeded readily to afford 33 (Scheme 14). Interestingly, we found that if the 
benzyl bromide was added at room temperature or even at 0 ˚C we would form some of the doubly 
benzylated product (O- and N-benzylated) which, due to the similarity in Rf value, would be challenging to 
separate from the desired product 33. However, by running the reaction at a lower temperature of -10 ˚C 
(acetone/ice) the amount of doubly benzylated product was almost negligible, enabling the isolation of 
33 in a yield of 95%.  
The identification of a singlet at 5.12 ppm integrating for 2 protons and a multiplet at 7.40 ppm integrating 
for 5 protons gave a clear indication that the benzyl group had been installed onto 23 successfully. A broad 
singlet at 6.46 ppm integrating for 2 protons suggested that the primary amine was unaffected and that 
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only the phenol had been benzylated. This was confirmed by the absence of a phenolic stretch in the 
corresponding FTIR spectrum. 
 
3.3.2. Synthesis of 2-(benzyloxy)-N-ethyl-6-nitroaniline (34) 
 
Scheme 15 
The subsequent N-alkylation of compound 33 which involved the use of ethyl iodide and sodium hydride 
in THF provided the alkylated product 34 in a disappointingly low yield of 42% (Scheme 15). Inexplicably, 
when we attempted to improve the yield by increasing the amount of reagent added, the yield was found 
to decrease further. Monitoring the reaction by TLC revealed the formation of a significantly more polar 
by-product which become more prominent upon the addition of more reagent. Fortunately, it was 
possible to isolate and characterize this unknown by-product. Study of the 1H NMR spectrum revealed the 
presence of a triplet and quartet which was indicative that alkylation did occur. However, these aliphatic 
signals were accompanied by the presence of a singlet at 2.59 ppm which integrated for 3 protons. 
Furthermore, in the 1H NMR spectrum, although there was a notable absence of any proton signal 
belonging to the aniline, all signals belonging to the benzyl and aromatic portion of the compound were 
still present. In the 13C NMR spectrum two additional signals not expected for the alkylated product 34 
were observed. Finally, HRMS of the unknown product provided a mass of 283.1441 amu, which was 10 
units higher than the mass obtained for the alkylated product 34.  
At first, this characterization data compiled for the unknown compound was confusing. However, while 
attempting to make sense of it all, we came upon a paper by Gardiner and Loyns who described the one-
pot synthesis of a series of O-alkylated-N-hydroxybenzimidazoles (Scheme 16).187 Their discovery of this 
one-pot synthesis towards these heterocycles appeared to have been a serendipitous one. In an attempt 
to alkylate 6-methyl-2-nitroaniline 41 with propyl iodide in the presence of sodium hydride, they found 
that the O-alkylated-N-hydroxybenzimidazole 43 was being formed as a major product. The desired N-
alkylated product 42, on the other hand, they were never able to isolate in greater than 5% yield. 
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The almost exclusive formation of 43 came as a surprise as prior to this discovery, base-mediated 
cyclization of N-substituted 2-nitroaniline derivatives were limited to N-alkyl groups that possessed a 
relatively acidic or benzylic proton α to the nitrogen. Furthermore, in situ O-alkylation under these 
circumstances did not occur.188-190 Although the mechanism for the cyclization of N-substituted 2-
nitroanilines without an acidic or benzylic α-proton is not fully understood, it has been generally accepted 
that the formation of the O-alkylated-N-hydroxybenzimidazole product occurs as a three-step process 
which involves N-alkylation, cyclization and O-alkylation. Nevertheless, in a related publication Gardiner 
et al. proposed two possible mechanisms for the formation of these heterocycles (Scheme 17 and Scheme 
18).191 These proposed mechanisms take into account the fact that no N-dialkylated products and no 
unalkylated 1-hydroxybenzimidazoles were ever obtained.  
Mechanism A proposes that, following N-alkylation to afford 42, the N-anion 42A tautomerizes to the α-
carboanion 42B which promptly cascades through to benzimidazole-N-oxide 44. Rapid alkylation with 
excess alkyl halide (propyl iodide in the case of 43) then affords the O-alkylated-N-hydrobenzimidazole 
product (Scheme 17).191 
 
Scheme 17 
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For the alternative mechanism B, it was postulated that an intramolecular deprotonation by the nitro 
oxygen occurs by way of the mesomeric form 42C of 42A. Cyclization onto the resulting imine 42D 
regenerates the aminoanion 45, which then undergoes a dehydration and subsequent tautomerization to 
afford 44. As with mechanism A, 44 is then alkylated in situ to afford 43 (Scheme 18).191 
 
Scheme 18 
Having established precedence for the formation of the O-alkylated-N-hydroxybenzimidazole heterocycle, 
we revisited the characterization data obtained for our unknown by-product and came to the realization 
that we had also formed the O-alkylated-N-hydroxybenzimidazole 46 (Scheme 19).  
 
Scheme 19 
We knew that in order to avoid the formation of 46 only one equivalent of ethyl iodide and one equivalent 
of NaH could be added to the reaction mixture. Although this provided us with 34 in a low yield, never 
greater than 45%, we were always able to recover the starting material 33. In an attempt to improve upon 
the yield of the alkylation reaction we decided to introduce a much better electrophile in the form of 
diethyl sulfate (DES) (Table 1). By carrying out the alkylation reaction with DES in presence of NaH we 
were able to improve the yield of 34 to a moderate 64%. Encouraged by this result, we were tempted to 
try and improve this yield further by changing the solvent from THF to DMF. DMF, unlike THF, poorly 
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solvates anionic species thereby enhancing nucleophilic reactivity.192 To our delight, the alkylation 
reaction with DES and with DMF as the solvent afforded the product 34 in a much improved yield of 81%. 
 
Table 1 
In the 1H NMR spectrum of 34 the presence of a multiplet and triplet at 3.57 and 1.18 ppm, integrating 
for two and three protons respectively, attested to the presence of the ethyl group. This observation was 
supported by the presence of two additional aliphatic signals in the corresponding 13C NMR spectrum. 
Furthermore, a broad singlet observed at 7.54 ppm, which integrated for only one proton, was indicative 
that N-alkylation had occurred only once. 
 
3.3.3. Synthesis of 3-(benzyloxy)-N2-ethylbenzene-1,2-diamine (35) 
Having successfully optimized the N-alkylation reaction we could endeavour to perform the subsequent 
nitro reduction step to afford 35. In Chapter 2 we described the use of iron powder in the presence of 
glacial acetic acid with ultrasonic irradiation as an alternative means to reduce a nitro group in the 
presence of sensitive functional groups. As classical dehydration methods using palladium on activated 
carbon would result in the removal of the benzyl protecting group, we decided to employ these alternative 
conditions for the nitro reduction of 34. Under these conditions we were able to obtain the reduced 
product 35 in high yields up to 79% (Conditions A, Scheme 20). However, when we attempted to scale-up 
this reaction we found that yields decreased significantly. In fact, we were only able to obtain product 35 
in yields up to 40%. 
In a publication by Gamble et al., the use of a large excess of stannous chloride dihydrate with ultrasonic 
irradiation was reported as an effective alternative to the iron powder/acetic acid route (Conditions B, 
Scheme 20).160  We decided to attempt the reduction under these conditions in the hope that this would 
provide an improvement on the yields obtained on a larger scale. Fortunately, when we utilized these 
conditions we were able to obtain the reduced product 35 in high yields regardless of the scale of the 
Stellenbosch University  https://scholar.sun.ac.za
Chapter 3: The Design and Synthesis of a Series of Second-generation Benzimidazolone Compounds 
54 
 
reaction. Furthermore, while conditions A required approximately 2 hours for the reaction to reach 
completion (as determined by the obvious colour change described in Chapter 2 and TLC), under 
conditions B the reaction reached completion within 15 minutes. 
 
Scheme 20 
It is worth noting that the diamine 35 had a tendency to degrade, a process which appeared to be 
accelerated following purification by column chromatography. As a result, we decided to utilize 35 crude 
in the subsequent ring-closing step with CDI. 
The most distinguishing feature in the 1H NMR spectrum of 35 was a broad singlet located at 5.41 ppm 
which integrated for three protons. This could be attributed to the presence of the three exchangeable 
protons of the phenylenediamine 35. This observation was further corroborated by the HRMS obtained 
for 35 which gave a mass of 243.1504 amu, coinciding with the calculated mass of 243.1497 amu. 
 
3.3.4. Synthesis of 7-(benzyloxy)-1-ethyl-1,3-dihydro-2H-benzo[d]imidazol-2-one (36) 
 
Scheme 21 
The subsequent ring-closing reaction between phenylenediamine 35 and CDI in THF was carried out at 
room temperature for 18 hours to afford the cyclized product 36 in a moderate yield of 66% (Scheme 21). 
Unfortunately, purification by column chromatography proved to be problematic as the product tended 
to stick to the column resulting in significant band broadening and consequently, tailing on the column. 
This often led to inconsistent yields or the acquisition of impure product.  
By surveying the literature it was found that, in some instances, through the use of acetonitrile the 
benzimidazolone product would precipitate out of solution which removed the need for further 
purification by column chromatography.193-194 We decided to attempt this in the hope that our compounds 
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would also precipitate from solution. Fortunately, while both 35 and CDI were soluble in acetonitrile, the 
resulting benzimidazolone product 36 was not. As a result, we were able to obtain 36 in relatively high 
yields by filtration (Scheme 22). Moreover, the product obtained was pure enough that no further 
purification was necessary. 
 
Scheme 22 
In the 1H NMR spectrum of 36 the presence of a singlet at 10.38 ppm, which integrated for one proton, 
attested to the presence of the urea NH proton. Additionally, the absence of the broad singlet observed 
for the exchangeable protons for 35 confirmed that the cyclization with CDI had occurred. In the 13C NMR 
spectrum all the expected carbon signals for 36 were observed. 
 
3.3.5. Synthesis of 4-(benzyloxy)-3-ethyl-1-(((2-(trimethylsilyl)ethoxy)methyl)-1,3-dihydro-
2H-benzo[d]imidazol-2-one (37) 
Having successfully optimized all the steps in the synthetic sequence leading up to the formation of the 
benzimidazolone precursor 36 we could introduce the SEM-protecting group in preparation for the 
subsequent debenzylation and biaryl ether coupling reactions.  
 
Scheme 23 
To this end, 2-(trimethylsilyl)ethoxymethyl chloride (SEM-Cl) was added to a solution of 36 and NaH in 
DMF at 0 ˚C (Scheme 23). After 18 hours the reaction was quenched and purified by column 
chromatography to afford 37 in a very good yield of 82%. 
In the 1H NMR spectrum of 37, the absence of the characteristic urea NH signal at 10.38 ppm observed 
for 36 provided a clear indication that a group had been installed onto the benzimidazolone scaffold. This 
observation was accompanied by the presence of four additional aliphatic signals belonging to the SEM 
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group. These included a singlet at 5.30 ppm integrating for two protons belonging to the methylene, two 
multiplets at 3.61 and 0.93 ppm each integrating for two protons belonging to the ethyl portion and a 
large singlet at -0.03 ppm integrating for nine protons attributed to the trimethylsilyl group. The 
corresponding additional aliphatic signals were observed in the 13C NMR spectrum. 
 
3.3.6. Synthesis of 3-ethyl-4-hydroxy-1-((2-(trimethylsilyl)ethoxy)methyl)-1,3-dihydro-2H-
benzo[d]imidazol-2-one (38) 
With compound 37 in hand we could attempt to remove the benzyl protecting group in preparation for 
the subsequent Ullmann coupling step. The debenzylation of 37 took place readily with palladium on 
carbon under an atmosphere of hydrogen to afford 38 in 85% yield (Scheme 24). 
 
Scheme 24 
In the 1H and the 13C NMR spectra of 38 the absence of the benzylic methylene signal and five aromatic 
proton signals attested to the fact that the benzyl group had been removed. In addition to a broad singlet 
at 6.99 ppm integrating for one proton in the 1H NMR spectrum which could be attributed to the phenol, 
the success of the debenzylation was further validated by FTIR which exhibited the characteristic phenol 
absorbance stretch at 3144 cm-1. 
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3.3.7. Synthesis of 3-ethyl-4-phenoxy-1-((2-(trimethylsilyl)ethoxy)methyl)-1,3-dihydro-2H-
benzo[d]imidazol-2-one (39) and 4-(3,5-dimethylphenoxy)-3-ethyl-1-((2-
(trimethylsilyl)ethoxy)methyl)-1,3-dihydro-2H-benzo[d]imidazol-2-one (40) by way of 
an Ullmann ether coupling reaction 
With 38 in hand and confident that the unprotected phenol was the only available nucleophile on the 
scaffold we could attempt to carry out the penultimate step in the reaction sequence which involved an 
Ullmann ether coupling reaction between 38 and aryl iodides 24 and 25.  
 
Scheme 25 
For the coupling between 38 and 24 or 25 we decided to employ the same conditions described for the 
attempted synthesis of 27 in section 3.2.1. To this end, 38 and aryl iodide 24 or 25 were treated with 
K3PO4, picolinic acid and CuI at 85 °C. After 18 hours, TLC revealed full consumption of the starting material 
and, following purification by column chromatography, we were able to obtain the desired products 39 
and 40 in moderate yields of 70% and 61% respectively (Scheme 25).  
The absence of the broad phenol signal in the 1H NMR spectra of compounds 39 and 40 and the 
observance of additional aromatic signals in the 1H and 13C NMR spectra gave testimony to the success of 
the Ullmann ether coupling reaction. Furthermore, all signals attributed to the SEM protecting group were 
observed in the 1H and 13C NMR spectra of 39 and 40 indicative that, as expected, the SEM group had 
survived these reaction conditions. 
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3.3.8. SEM-deprotection to obtain target compounds 1-ethyl-7-phenoxy-1,3-dihydro-2H-
benzo[d]imidazol-2-one (21) and 7-(3,5-dimethylphenoxy)-1-ethyl-1,3-dihydro-2H-
benzo[d]imidazol-2-one (22) 
Finally, having successfully obtained the precursors 39 and 40 in satisfactory yields, we could attempt to 
remove the SEM protecting group to afford the final proof-of-concept compounds 21 and 22.  
 
Scheme 26 
A survey of the literature suggested that the use of TBAF was the most popular SEM N-deprotection 
method.195-198 Therefore, for the removal of the SEM group, an excess solution of 1.0M TBAF in THF was 
added to a solution of the precursor 39 in THF and the reaction was heated to 60 ˚ C (Scheme 26). However, 
after approximately 18 hours monitoring the reaction by TLC revealed that the reaction had not reached 
completion. This situation did not appear to change even with the addition of additional equivalents of 
TBAF. Unfortunately, subsequent workup and attempted purification by column chromatography 
afforded the desired compound 21, albeit impure, in an unacceptably low yield of 18%. Due to the poor 
yield obtained we did not possess enough of 21 to attempt a second purification, obtain full 
characterization and evaluate for activity against HIV RT. 
In an attempt to optimize this reaction, we decided to employ boron trifluoride diethyl etherate (BF3OEt2) 
as an alternative means to remove the SEM protecting group.185-186 To this end, BF3OEt2 was added to 39 
in DCM at 0 ˚C (Scheme 27). The reaction was warmed to room temperature and encouragingly, after 30 
minutes TLC revealed that all of 39 had been consumed. As the product formed shared the same Rf value 
as the product obtained from the deprotection reaction with TBAF we were fairly surprised when analysis 
of the 1H NMR spectrum for the resulting product indicated that the desired compound 21 was not the 
product that had been isolated.  
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At first glance the signals associated with the SEM group appeared to be absent from the 1H NMR 
spectrum, yet the expected urea signal normally observed between 10 and 11 ppm was also absent. On 
closer inspection, however, we realized that the signal for the methylene protons at 5.45 ppm of the 
aminomethanol portion of the SEM group was still present. This was also observed in the corresponding 
13C NMR spectrum. This implied that BF3OEt2 had removed only the ethyltrimethylsilyl portion of the SEM 
group and that the resulting product was, in fact, the hemiaminal 47 (Scheme 28).  
 
Scheme 28 
In a publication by Muchowski and Solas the same phenomenon was described for the N-SEM 
deprotection of pyrroles and indoles.199 Herein, they reported that N-SEM deprotection with BF3OEt2 
would lead exclusively to the formation of the hemiaminal product. However, the hemiaminal could be 
readily cleaved through the introduction of base. In the paper by Muchowski and Solas, the hemiaminal 
was cleaved through the introduction of benzyltrimethylammonium hydroxide or Triton B.199 
Nevertheless, a review of the literature revealed that the hemiaminal could just as readily be cleaved with 
more common benchtop reagents such as sodium hydroxide (NaOH).200-201 To this end, NaOH was added 
to the hemiaminal 47 in a solution of THF and water and the reaction was carried out for 18 hours at room 
temperature (Scheme 29).   
It is worth mentioning that in the publication by Muchowski and Solas it was reported that N-SEM 
deprotection by way of BF3OEt2 and base, although a two-step process, was overall found to be superior 
to TBAF with regards to yield and purity.199 This observation was reflected in the deprotection of 39. After 
purification by column chromatography the desired product 21 was afforded in a yield of 44% over 2 steps.  
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In the 1H NMR spectrum of 21, the expected urea proton signal was detected at 11.07 ppm which attested 
to the successful cleavage of the hemiaminal 47. This conclusion was made in conjunction with the notable 
disappearance of the hemiaminal methylene signal in the 1H and 13C NMR spectra. Finally, HRMS which 
provided a mass of 255.1128 amu confirmed that 21 had been successfully synthesized. 
Despite the additional step required to obtain the desired N-deprotected product, the overall yield 
obtained for 21 using BF3OEt2 and NaOH was notably superior to the yield obtained for the single-step 
SEM-deprotection method with TBAF. Therefore, we decided to employ these SEM deprotection 
conditions for the N-deprotection of the dimethyl analogue 40 (Scheme 30). In this instance we decided 
not to isolate and purify the hemiaminal but rather take it crude to the subsequent cleavage step with 




3.4. Evaluation of target compounds 21 and 22 
Having arrived at our proof-of-concept compounds 21 and 22 we could evaluate whether our strategy to 
target Tyr188 and Trp229 by transposing the aryl group from position 1 to 7 on the benzimidazolone 
scaffold was a feasible one.  
Unfortunately, the activity results obtained in the phenotypic HIV assay for compounds 21 and 22 were 
disappointingly poor compared with the results for the lead compound 11.  
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Compound 21, in particular, exhibited very poor activity against HIV with an IC50 value of 4 µM (Figure 30). 
Interestingly, with the introduction of the two methyl groups on the “upper” aryl ring the potency of 
compound 22 was salvaged by almost 13-fold. 
 
Figure 30  
Although still significantly less potent than lead compound 11, the gain in potency due to the introduction 
of the methyl groups on 22 indicated that our aim to target Tyr188 and Trp229 was still viable. In fact, we 
were optimistic that by altering the substituents on the “upper” aryl ring of our second-generation 
compounds we would be able to further salvage their activity. 
This optimism was based on a series of publications by Mowbray et al. which demonstrated that by 
manipulating the substituents on an aryl ring the pharmacokinetic properties, and consequently the 
efficacy of a compound, could be altered.202-204  The best example of this was reported for pyrazole NNRTIs 
48 and 49 for which the 3,5-dimethyl aryl group of compound 48 was replaced by a 3-chloro-5-benzonitrile 
ring to afford 49 resulting in a 15-fold improvement in potency against wild-type HIV RT (Figure 31).  
 
Figure 31 
As a proof-of-concept we decided to employ the same substitution pattern exhibited by pyrazole 
compound 49 on our own benzimidazolone compounds in the hope that we would observe a similar 
improvement in potency (Figure 32).  
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3.5. Altering the substituents on the “upper” aryl ring in an attempt to improve potency 
For compound 50 we envisaged being able to employ a similar synthetic strategy to what was used in the 
synthesis of compounds 21 and 22 (Scheme 13). Unfortunately for the coupling step, as we were unable 
to obtain the 3-chloro-5-cyano-substituted aryl iodide or bromide, we could not utilize the Ullmann 
coupling conditions described for the synthesis of 39 and 40. However, we were able to obtain 3-chloro-
5-fluorobenzonitrile 51 and therefore, envisaged that the coupling reaction could be achieved by way of 
an aromatic nucleophilic substitution (SNAr) reaction between compounds 38 and 51  (Scheme 31).  
 
Scheme 31 
The nucleophilic displacement of fluorine on an aromatic ring is made possible by the strong electron-
withdrawing inductive effect which polarizes the CArδ+ – Fδ- bond on the aryl ring and increases the 
susceptibility of the δ+ CAr atom to nucleophilic attack.205-206 Typically, this reaction is facilitated by the 
presence of an electron-withdrawing group (EWG), such as a nitro group, situated ortho or para to the 
fluoride on the aryl ring.207-208 However, on our system the EWG, the nitrile, is situated meta to the fluoride 
and, therefore, cannot facilitate the SNAr reaction to the same extent. Despite this, in the literature there 
exist a number of examples where SNAr reactions are carried out with similar aryl fluorides with the 
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electron-withdrawing group situated meta as opposed to ortho or para to the fluoride.209-210 These 
reactions are typically carried out in the presence of K2CO3 or Cs2CO3 in DMF or NMP at high temperatures.  
 




For the synthesis of 52, Cs2CO3 was added to 38 and 51 in DMF and the reaction was heated to 100 ˚C 
(Scheme 32). The reaction was closely monitored by TLC and after two hours it was observed that all of 
the starting material 38 had been consumed. Subsequent quenching and purification by column 
chromatography provided 52 in a 74% yield. 
As with compounds 39 and 40, the most notable feature in the 1H NMR spectrum of 52 was the absence 
of the proton signal attributed to the phenol of 38. In addition, three additional proton signals in the 
aromatic region of the 1H NMR spectrum and seven additional signals in the aromatic region of the 13C 
NMR spectrum of 52 attested to the successful coupling of 51 and 38. 
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With 52 in hand, we could carry out the subsequent N-SEM deprotection using the two-step method 
described for compounds 21 and 22. To this end, 52 was treated with BF3OEt2. After 3 hours TLC revealed 
that all of 52 had been consumed and the reaction was subsequently stopped by quenching with NaHCO3. 
The resulting hemiaminal was then treated with NaOH to afford the desired product 50 in a moderate 
yield of 50% over two steps (Scheme 33). 
A singlet observed at 10.04 ppm in the 1H NMR spectrum of 50 could be attributed to the urea NH which 
gave testimony to the success of the N-SEM deprotection. This was supported by HRMS which gave a mass 
of 314.0711 amu, which correlated well with the theoretical mass of 314.0696 amu. 
 
3.6. Evaluation of compound 50 
Having successfully synthesized compound 50 we could evaluate the effectiveness of our strategy to 
introduce alternative substituents onto the “upper” aryl ring in an attempt to improve the potency of our 
second-generation benzimidazolone compounds. 
 
Figure 33 
To our delight, evaluation of 50 in a phenotypic assay revealed that by altering the substituents we were 
able to significantly improve the potency of our second-generation benzimidazolone compounds from 
300 nM to 26 nM (Figure 33)! We hypothesized that the significant improvement in potency could 
somehow be attributed to the idea that the introduction of an EWG such as the nitrile optimizes the edge-
to-face π- interactions with Trp229.211 Nevertheless, although we had succeeded in obtaining another lead 
compound with low nanomolar activity we still had to verify the feasibility of our strategy to target Trp229 
and Tyr188 in an attempt to overcome resistance to the Y181C resistant strain. To this end, compound 50 
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Remarkably, from these results it was clear that compound 50 was able to maintain complete potency 
against the Y181C resistant strain. This result was particularly significant when compared to the currently 
licensed first-generation NNRTI nevirapine, which is highly susceptible to the Y181C resistant strain (Figure 
35).104 Furthermore, compound 50 was found to maintain potency against the Y188C resistant strain, 
despite the fact that it forms π-π stacking interactions with this amino acid residue when bound to the 
NNIBP (Figure 34). Against the most problematic K103N resistant strain, compound 50 experienced only 
low levels of resistance with a 4-fold loss in potency. This result is considerable when compared to the 
susceptibility of first-generation NNRTIs nevirapine and efavirenz to the K103N mutant. Nevertheless, as 
Figure 35 demonstrates, second-generation NNRTIs etravirine and rilpivirine still exhibit the best 
performance against K103N as they are able to maintain efficacy against this resistant strain.104 
Remarkably, against the K103N/Y181C double mutant which causes high levels of resistance to first-
generation NNRTIs efavirenz and nevirapine, compound 50 was found to perform similarly to second-
generation NNRTIs etravirine and rilpivirine, exhibiting only a 2-fold loss in potency (Figure 35). 
 
Figure 35 A series of charts comparing the fold change (IC50(mutant)/IC50(WT)) observed for all currently licensed NNRTIs and lead 
compound 50 in the presence of the K103N, Y181C and K103N/Y181C resistant strains of HIV RT.  
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3.7. The generation of a small library of second-generation benzimidazolone compounds 
Having successfully designed and synthesized a second-generation benzimidazolone compound with low 
nanomolar activity against wild-type RT and the clinically relevant Y181C and K103N/Y181C resistant 
strains, we could embark upon the synthesis of a small library of second-generation compounds. For this 
library we would endeavour to derivatize the alkyl and aryl substituents at positions 1 and 7 on the 
benzimidazolone scaffold respectively and subsequently explore the effects that these derivations have 
on the potency of the new lead compound 50. 
 
3.7.1. Derivatizations at position 1 on the benzimidazolone scaffold: Testing the limits of the 
Val179 pocket 
At the start of Chapter 2 we mentioned that the occupation of the small hydrophobic pocket in the vicinity 
of Val179 was highly influential towards the activity of a compound against HIV RT.  As a result, we wished 
to explore the effect that exchanging the ethyl for a methyl or propyl substituent at position 1 would have 
on the activity of our lead compound 50 (Figure 36).  
In section 3.1. we expressed the concern that the propyl group would not be well-tolerated in the Val179 
pocket due to a possible clash with surrounding amino acid residues. However, subsequent docking 
studies suggested that the propyl chain would be able to occupy the Val179 pocket despite its length. This 
observation was substantiated by comparing the binding energies calculated for compounds 50, 53 and 
54 (Figure 36). The binding energies calculated for all three compounds were found to be very similar 
which implied that all three compounds would be effective inhibitors of RT regardless of the length of the 
alkyl chain at position 1.  
 
Figure 36 The similarity of the binding energies calculated for compounds 50, 53 and 54 suggested that compounds 53 and 54 
would be as effective in inhibiting HIV RT as lead compound 50. 
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For the synthesis of compounds 53 and 54 we could begin with the N-alkylation of benzyl protected 2-
amino-3-nitrophenol 33, synthesized previously in section 3.6. The N-propylation of 33 with propyl 
bromide and sodium hydride in DMF proceeded readily affording the alkylated product 55 in a moderate 
yield of 68% (Table 2). However, the corresponding methylation of 33 with methyl iodide in DMF afforded 
exclusively the di-alkylated product. Surprisingly, it was only by returning to the use of THF as the solvent 
that we were able to obtain solely the mono-alkylated product 56 in a yield of 97% (Table 2).  
 
Table 2 
The presence of a singlet at 3.15 ppm in the 1H NMR spectrum of 55 which integrated for three protons 
attested to the successful methylation of 33. Furthermore, the presence of a broad singlet at 7.56 ppm 
which integrated for one proton could be attributed to the amine, indicating that the methylation had 
occurred only once. For 56, the presence of a triplet at 3.49 ppm, a multiplet at 1.56 ppm and a triplet at 
0.85 ppm which integrated for two, two and three protons respectively attested to the success of the 
propylation of 33.  
Fortunately, all subsequent steps in the synthesis of compounds 53 and 54, which followed the route 
described for lead compound 50 in section 3.6, were carried out without incident (Scheme 34). Reduction 
of the nitro groups on compounds 55 and 56, followed by a ring-closing reaction with CDI afforded 
benzimidazolones 57 and 58 in yields of 79% and 89% respectively over two steps. High yields were also 
obtained for the N-SEM protection affording 59 and 60 and for the subsequent debenzylation with 
palladium on carbon under an atmosphere of hydrogen affording the compounds 61 and 62. The 
penultimate SNAr reaction between 61 or 62 and 3-chloro-5-fluorobenzonitrile 51 provided the biaryl 
ether compounds 63 and 64 in moderate yields of 64% and 74% respectively. Finally, the two-step N-SEM 
deprotection with BF3OEt2 and NaOH afforded the desired compounds 53 and 54 in yields of 62% and 29% 
respectively over two steps. 
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3.7.2. Derivatizing the “upper” aryl ring 
In addition to varying the alkyl group at position 1, we decided to explore the effect that various aryl and 
heteroaryl groups at position 7 on the benzimidazolone scaffold would have on the efficacy of our 
compounds. To this end, we chose to synthesize compounds 65 to 69 (Figure 37). Although the binding 
energies calculated for these compounds were notably lower than the binding energy obtained for our 
lead compound 50, which implied that they would be less effective, we decided to pursue the synthesis 
of these compounds as a proof-of-concept and as a means to establish the accuracy and dependability of 
our docking studies.  
 
Figure 37 
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The synthesis of compounds 65 – 69 could be readily achieved by the coupling of commercially available 
aryl and heteroaryl halides with the benzimidazolone precursor 38, the synthesis for which was described 
previously in this chapter.  
 
3.7.2.1. Synthesis of 5-((3-ethyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)oxy)isophthalonitrile 
(65) 
For the synthesis of 65, 38 and 70 were heated to 100 °C for 2 hours in the presence of Cs2CO3. Once TLC 
had indicated that the reaction had reached completion, a workup and subsequent purification by column 
chromatography afforded the precursor 71 in a 94% yield (Scheme 35).  
 
Scheme 35 
In the 1H NMR spectrum of 71 the notable absence of the phenolic proton signal, in conjunction with the 
appearance of a doublet integrating for two protons at 7.47 ppm and a triplet integrating for one proton 
at 7.64 ppm attested to the successful coupling of 70 to 38. These additional aromatic signals could be 
attributed to the isophthalonitrile portion of 71. Furthermore, in the 13C NMR spectrum of 71 all expected 
carbon signals were accounted for. 
With 71 in hand we could carry out the subsequent SEM deprotection with BF3OEt2 and NaOH (Scheme 
36). This two-step process afforded the product 65 in a satisfactory yield of 54% over two steps.  
 
Scheme 36 
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The presence of the highly deshielded urea signal at 11.14 ppm in the 1H NMR spectrum of 65 provided 
the most conclusive evidence that the removal of the SEM protecting group and subsequent cleavage of 
the resulting hemiaminal had occurred. This conclusion was further supported by the notable absence of 
the hemiaminal methylene carbon signal in the 13C NMR spectrum of 65. Finally, HRMS analysis provided 
a mass of 305.10302 amu which coincided with the theoretical mass for 65. 
 
3.7.2.2. Synthesis of 1-ethyl-7-(naphthalen-1-yloxy)-1,3-dihydro-2H-benzo[d]imidazol-2-one (66) 
For the Ullmann ether coupling, benzimidazolone precursor 38 and iodonaphthalene were treated with 
K3PO4, picolinic acid and CuI in DMSO which had been thoroughly degassed under a positive pressure of 
argon to ensure an oxygen-free environment. After 18 hours, full consumption of 38 was observed by way 
of TLC. Therefore, following workup and purification we were able to obtain compound 72 in an excellent 
yield of 91% (Scheme 37).  
 
Scheme 37 
In the 1H NMR spectrum of 72 we observed the presence of seven additional aromatic protons signals. 
This observation, in conjunction with the absence of the phenolic proton signal in the 1H NMR spectrum 
and the addition of ten additional carbon signals in the 13C NMR spectrum of 72 offered clear evidence 
that the Ullmann coupling between 38 and iodonaphthalene had transpired. 
For the subsequent SEM deprotection with BF3OEt2 and NaOH, the desired product 66 was obtained 
impure despite attempted purification by column chromatography. However, from a recrystallization 
from EtOH we were able to obtain pure 66, albeit in an inexplicably poor yield of 16% (Scheme 38). 
However, we were fortunate that, despite the yield, we had isolated enough product to proceed with full 
characterization and evaluation in a phenotypic assay. 
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The characteristic urea proton signal observed at 10.31 ppm in the 1H NMR spectrum of 66, in conjunction 
with HRMS analysis which provided the desired mass of 305.1281 amu attested to the successful, albeit 
low yielding, removal of the SEM group to afford the desired product 66. 
 
3.7.2.3. Synthesis of the substituted pyridine-containing analogues 76 - 78 
For the synthesis of pyridine-containing precursors 76 – 78 (Scheme 39) we envisaged employing simple 
SNAr reaction conditions due to the fact that nucleophilic substitution on pyridine rings occurs readily at 
the 2, 4 and 6 positions.212 The SNAr reactions between 38 and pyridine analogues 73 – 75 were carried 
out with K2CO3 in DMF at 90 ˚C (Scheme 39). When all the starting material had been consumed (as 
determined by TLC after 18 hours), purification with column chromatography afforded compounds 76 – 
78 in yields ranging from 62 – 90%. It is worth noting that for the SNAr reaction with the dichloro-pyridine 
analogue 75, although two potential substitution sites exist, a survey of the literature revealed that in 
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For precursors 76 – 78 the absence of the phenolic proton signal in the 1H NMR spectra and the 
observance of the expected number of additional proton and carbon aromatic signals belonging to the 
substituted pyridine portion of compounds 76 – 78 in the 1H and 13C NMR spectra indicated that all SNAr 
couplings between 38 and pyridine analogues 73 – 75 had occurred successfully. 
Finally, the subsequent N-SEM deprotection reaction on compounds 76 – 78 was carried out in the 




In the 1H NMR spectra of compounds 67 – 69, the absence of all signals attributed to the SEM protecting 
group, including the methyl alcohol portion, and the appearance of the characteristic urea proton signal 
attested to the successful removal of the SEM. This was further validated by analysis of the corresponding 
13C NMR spectra and HRMS. 
 
3.7.3. Biological evaluation of our small library of benzimidazolone analogues 
Having successfully generated a small library of second-generation benzimidazolone compounds we could 
evaluate their efficacy in a phenotypic assay. 
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Of this library of compounds, only compounds 53, 54 and 65, which most closely resembled lead 
compound 50, were found to be potent inhibitors of HIV RT (Table 3). For compound 54 this indicated 
that, despite our concerns, the larger propyl chain could be accommodated in the hydrophobic pocket in 
the vicinity of Val179. Compound 53 in particular, performed very similarly to lead compound 50 against 
wild-type HIV RT, but also exhibited a slightly improved selectivity index. As a result, we were interested 
in comparing the activities of 53 and 50 against a panel of resistant strains in the hope that we might 
observe an improvement in the overall resistance profile (Table 4). 
 
Table 4 
Against the most problematic clinical resistant strain K103N, compounds 53 and 50 performed similarly, 
exhibiting only low levels of resistance (<10 fold). However, for the Y181C and Y188C resistant strains 
against which compound 50 was able maintain full potency, compound 53 experienced low to high levels 
of resistance.  Unfortunately, we were unable to obtain activity data against the K103N/Y181C double 
mutant. Nevertheless, due to the susceptibility of 53 to both single-point mutations we would expect a 
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similar susceptibility to the double-mutant. Overall, we concluded that lead compound 50 generally 
performed better against the resistant strains of HIV and, therefore, remained our most promising 
second-generation benzimidazolone compound. 
Interestingly, with the introduction of the naphthalene and pyridine analogues we observed a significant 
drop in potency. More specifically, compounds 66 and 69 exhibited only low micromolar activity while 
compounds 67 and 68 were inactive. The inactivity of compounds 67 and 68 can be explained by taking 
into account the position of the pyridine nitrogen and the fact that the lone pair of electrons on the 
pyridine nitrogen occupy an sp2 orbital which is situated in the plane of the pyridine ring (Figure 38). For 
compounds 67 and 68, this orbital is pointed directly towards Trp229. We postulated that this would result 
in an electronic repulsion between these compounds and Trp229 which would, consequently, remove the 
ability to form the edge-to-face π stacking interactions normally achieved by the “upper” aryl ring of the 
benzimidazolone scaffold without the nitrogen present. This hypothesis is somewhat substantiated by the 
fact that when the pyridine nitrogen is not in the vicinity of Trp229, the activity is to some extent restored, 
as observed for compound 69. 
 
Figure 38 For compounds 67 and 68 the complete lack of activity against HIV RT is thought to be a consequence of the position 
of the pyridine nitrogen which causes an electronic clash with Trp229. 
Although, from this library lead compound 50 remains the most potent compound with the best resistance 
profile, it is worth noting that there appears to be a direct correlation between the binding energies 
calculated and the IC50 values obtained (Table 3). This observation provides testimony to the fact that for 
this series of compounds, molecular modelling could be relied upon for the design of other 
benzimidazolone analogues. 
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3.8. A short SAR study to corroborate the proposed binding mode of lead compound 50 
In order to confirm our proposed binding orientation, we decided to carry out SAR studies for the second-
generation benzimidazolones within the NNIBP which were discussed earlier in this chapter. According to 
molecular modelling, the key binding interactions for these compounds are the hydrogen-bonding with 
the backbone of Lys101 and π-π stacking interactions with Tyr188 and Trp229 (Figure 28). We postulated 
that if compound 50 binds in the manner predicted, then by removing the possibility for these key 
interactions between the ligand and the NNIBP to form, consequently, we would observe a notable 
decrease in the potency of our compound. To this end, we envisaged carrying out two separate SAR 
studies. The first SAR study would focus on eliminating the possibility to attain hydrogen bonding with the 
backbone of Lys101 (Figure 39). The second SAR study would focus on removing the ability to form π-
interactions with Trp229 and Tyr188. 
 
Figure 39 By carrying out two series of SAR studies we hoped to validate the binding mode of our second-generation 
benzimidazolone compounds within the NNIBP. 
 
3.8.1. SAR 1: Removing the possibility of hydrogen bonding between the core scaffold and 
Lys101 
For our first SAR study to corroborate the predicted binding mode of lead compound 50 in the NNBIP we 
aimed to eliminate the possibility for hydrogen bonding to the backbone of Lys101. We envisaged that 
this could be achieved by replacing the hydrogen bond donor, the urea portion of the benzimidazolone 
scaffold, with a suitable hydrogen bond acceptor. To this end, we decided to replace the benzimidazolone 
core (50) with the corresponding benzoxazolone 79 (Figure 40).  
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For the synthesis of 79 we envisaged starting from commercially available 2-nitroresorcinol 80 which 
could be reduced to 2-aminoresorcinol 81 (Scheme 41). Previous research within our department 
demonstrated that the amine of 2-aminoresorcinol could be chemoselectively acylated to afford 82 
without the need for protecting groups to be introduced onto the phenols.216 The resulting secondary 
amide could then be reduced to the amine with LiAlH4 and AlCl3 to afford the N-alkylated product 83.217 
Penultimately a ring closing reaction with CDI would afford the benzoxazolone precursor 84 which could 
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3.8.1.1. Synthesis of N-(2,6-dihydroxyphenyl)acetamide (82) following the reduction of 2-
nitroresorcinol (80) to 2-aminoresorcinol (81) 
The reduction of 80 by employing palladium on carbon under an atmosphere of hydrogen occurred readily 
to afford the corresponding amine 81 in a yield of 96% (Scheme 42). As 81 is a known compound in the 
literature we were able to compare the spectral data obtained experimentally with that reported in the 
literature and found that the data correlated favourably.218 
For the subsequent chemoselective acylation reaction, 81 was treated with acetyl chloride and 
triethylamine in THF. After 18 hours the reaction was purified by column chromatography to afford the 
product 82 in 80% yield.  
 
Scheme 42 
The most notable feature in the 1H NMR spectrum of 82 was the presence of a singlet at 2.11 ppm which 
integrated for three protons and could be attributed to the methyl group on the acetyl of 82. The 
chemoselectivity of this reaction was validated due to the presence of a triplet and doublet observed at 
6.87 ppm and 6.35 ppm which integrated for one and two protons respectively, which attested to there 
being symmetry in the molecule.  
 
3.8.1.2. Synthesis of 2-(ethylamino)benzene-1,3-diol (83) 
For the reduction of the secondary amide we decided to employ conditions reported by Chiellini et al.217, 
219 To this end 82 was added to a suspension of LiAlH4 and AlCl3 in THF and the reaction was carried out 
under reflux for 18 hours (Scheme 43). Subsequent quenching with aqueous HCl and purification by 
column chromatography afforded the reduced product 83 in a moderate yield of 61%. 
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Analysis of the 1H NMR spectrum of 83 revealed the presence of a quartet and triplet at 3.12 ppm and 
1.02 ppm which integrated for two and three protons respectively and could be attributed to the N-ethyl 
group on 83. These signals, in addition to the notable absence of the methyl signal observed for 82, 
indicated that the reduction of the secondary amide had occurred successfully. In the 13C NMR spectrum 
the carbon signals belonging to the ethyl group were observed at 41.6 ppm and 17.0 ppm. 
 
3.8.1.3. Ring-closing with CDI to afford 3-ethyl-4-hydroxybenzo[d]oxazol-2(3H)-one (84)  
With 83 in hand, we could attempt the subsequent ring-closing reaction with CDI. To this end 83 was 
treated with CDI. After 18 hours, the formation of a white precipitate indicated that the reaction had 




In this instance there was no characteristic urea proton signal to indicate that the ring-closing reaction 
had occurred successfully. Furthermore, due to the use of deuterated methanol as a co-solvent in order 
to fully dissolve 84 for NMR analysis, we were unable to visualize the unreacted phenolic proton signal. 
However, all expected carbon signals for 84 were observed in the 13C NMR spectrum and HRMS which 
provided a mass of 180.0654 amu (theoretical mass was 180.0661 amu) attested to the fact that 84 had 
been obtained successfully. 
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3.8.1.4. Synthesis of target compound 3-chloro-5-((3-ethyl-2-oxo-2,3-dihydrobenzo[d]oxazol-4-
yl)oxy)benzonitrile (79) 
The final SNAr reaction between 51 and 84 was carried out in the presence of Cs2CO3 at 100 °C for 2 hours. 
Surprisingly, following workup and purification by column chromatography, this reaction provided the 
desired compound 79 in a disappointing yield of 42% (Scheme 45). Nevertheless, enough material was 
obtained to carry out full characterization and evaluate for activity in a whole cell phenotypic assay. 
 
Scheme 45 
For compound 79 the presence of three additional aromatic proton signals in the 1H NMR spectrum and 
the presence of seven additional aromatic carbon signals in the 13C NMR spectrum attested to the 
successful coupling of 51 to 84. This was validated by HRMS which provided a mass of 315.0536 amu 
which correlated with the theoretical mass of 315.0536 amu. 
 
3.8.2. SAR 2: Removing the potential for π-π stacking to Tyr188 and Trp229 
With compound 79 in hand we could turn our focus to our second SAR study in which we aimed to replace 
the substituted aryl group at position 7 with substituents that could not effectively achieve π-stacking 
interactions with Tyr188 and Trp229. One example of this would be to install a simple methoxy group (85) 
onto position 7 of the benzimidazolone scaffold (Figure 41). In addition, we decided to install a slightly 
larger group that could, at least, occupy the region in the vicinity of Tyr188 and Trp229. To this end, we 
chose to introduce a prenyl substituent (86) at the 7-position on the benzimidazolone scaffold. It is worth 
mentioning that the prenyl substituent was originally introduced on the TIBO NNRTI tivirapine, which was 
briefly mentioned in Chapter 1. On tivirapine the prenyl reportedly occupies the region in the vicinity of 
Tyr188 and Trp229 and forms weak hydrophobic interactions with the surrounding residues.220 
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For the synthesis of compounds 85 and 86 we envisaged following the same synthetic route described for 
all previously synthesized benzimidazolones by introducing the methyl and prenyl substituents onto the 
N-SEM protected benzimidazolone precursor 38 and subsequently removing the SEM group with BF3OEt2 




3.8.2.1. Attempted synthesis of 85 and 86 starting from benzimidazolone precursor 38 
For the synthesis of compounds 87 and 88, 38 was reacted with methyl iodide or prenyl bromide in the 
presence of NaH and K2CO3 respectively (Scheme 47). Compound 87 was obtained in an excellent yield of 
92%, while 88 was obtained in a moderate yield of 65%. 
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In the 1H NMR spectrum for compound 87, the most notable feature was the presence of a singlet at 3.90 
ppm which integrated for three protons, and could therefore be attributed to the methoxy group at 
position 7. In the 1H NMR spectrum for compound 88, three additional protons were observed that could 
be attributed to the prenyl substituent. These included a multiplet integrating for one proton at 5.49 ppm, 
a doublet integrating for two protons at 4.61 ppm and, finally, two singlets integrating for three protons 
each at 1.77 ppm. Carbon signals for the methyl and prenyl substituents were also observed in the 
respective 13C NMR spectra for compounds 87 and 88. 
Unfortunately, when we attempted the subsequent SEM deprotection of 87 and 88 with BF3OEt2 and 
NaOH, we were unable to isolate any significant amount of product (Scheme 48).  
 
Scheme 48 
As all the starting material had been consumed (as determined by TLC) we were concerned that the 
BF3OEt2 may have removed the methyl and prenyl substituents in addition to the SEM protecting group. 
 
3.8.2.2. Attempted synthesis of 85 and 86 starting from benzimidazolone precursor 89 
In an attempt to overcome this issue, we decided to try and install the prenyl and methyl substituents 
onto the unprotected benzimidazolone precursor 90 which was obtained by carrying out a debenzylation 
of 36 with palladium on carbon under an atmosphere of hydrogen (Scheme 49).  
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Fortunately, by employing the same reaction conditions reported in Scheme 47, we were able to obtain 
the desired compounds 85 and 86, albeit in low yields. However, for both compounds we were able to 
obtain full characterization data with enough compound left over to evaluate in a phenotypic assay. 
In the 1H NMR spectrum of compound 85 the presence of a singlet which integrated for three protons at 
3.91 ppm attested to the successful introduction of a methyl group onto benzimidazolone 89. In the case 
of compound 86, the identification of the characteristic prenyl signals at 5.50, 4.61 and 1.78 ppm in the 
1H NMR spectrum gave testimony to the success of the alkylation reaction with prenyl bromide. Moreover, 
the characteristic urea signal observed at 10.10 ppm and 10.41 ppm in the 1H NMR spectra of 85 and 86 
repectively was indicative that alkylation had occurred exclusively at the phenol. 
 
3.8.3. Evaluation of compounds 79, 85 and 86 in a whole cell phenotypic assay 
With compounds 79, 85 and 86 in hand we could evaluate their efficacies in a whole cell assay and, from 
the results, determine whether we could validate the proposed binding mode of our second-generation 
benzimidazolone compounds, such as lead compound 50, in the NNIBP. 
For our first SAR study we set out to investigate the effect of removing the hydrogen bond donor 
responsible for forming a hydrogen bond with the backbone of Lys101. To this end, compound 79, for 
which the hydrogen bond donating urea was exchanged with a hydrogen bond accepting carbamate, was 
synthesized. As expected, evaluation of 79 revealed a significant loss in potency (>300 fold), indicative 
that the hydrogen bond with the backbone of Lys101 was beneficial to the binding of the inhibitor in the 
NNIBP (Figure 42). 
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Our second SAR study focused on the removal of the aryl group at position 7 which contributed to the 
binding of the inhibitor within the NNIBP by achieving π-π interactions with nearby amino acid residues 
Trp229 and Tyr188. To this end compounds 85 and 86, for which the aryl functionality was replaced with 
a methyl and prenyl substituent respectively, were synthesized. For compound 85, the complete removal 
of the aryl functionality had a substantially detrimental effect on the potency. Interestingly, although 
compound 86 suffered a greater than 30-fold loss in potency compared to lead compound 50, it was still 
able to maintain submicromolar activity against HIV RT. The ability of 86 to retain some activity could be 
attributed to the fact that, although unable to form π-interactions with Trp229 and Tyr188, the prenyl 
could facilitate weak hydrophobic interactions with the surrounding amino acid residues. 
As expected, by disrupting key interactions between the ligand and NNIBP, a detrimental effect on the 
potency of these compounds was observed. Fortunately, by carrying out these SAR studies, we were able 
to lend testimony to the predicted binding mode of our second-generation benzimidazolone compounds. 
 
3.9. Metabolic stability testing of lead compound 50 against human and mouse liver 
microsomes 
Of all the compounds synthesized in our small series of second-generation benzimidazolone compounds, 
compound 50 remained the most potent compound against wild-type and resistant strains of HIV RT. As 
a result, we decided to evaluate how compound 50 might perform in vivo by testing its metabolic stability 
towards human and mouse liver microsomes. To this end, compound 50 was incubated with human and 
mouse liver microsomes and subsequently analysed by LC-MS over 5-minute intervals for a total of 30 
minutes. Pleasingly, in the presence of both human and mouse liver microsomes, compound 50 remained 
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relatively unaffected. From Table 5 it can be seen that after 30 minutes, approximately 90% of compound 
50 still remained in both liver microsome assays. These results are highly encouraging for the 
advancement of these compounds towards drug candidacy. 
 % Remaining after 30 minutes 
 Mouse liver microsomes Human liver microsomes 
Compound 50 89 93 
Verapamil (positive control) - 7.0 
Diphenhydramine (positive control) 51 - 
Table 5 
 
3.10. Concluding remarks  
In an attempt to overcome susceptibility to the Y181C resistant strain experienced by our first-generation 
benzimidazolone compounds, we decided to transpose the aryl functionality from position 1 to position 
7 on the benzimidazolone scaffold. In doing so these compounds would no longer rely on π-π stacking 
interactions with Tyr181 but would form π-π interactions with Tyr188 and immutable Trp229. To this end 
a small library of second-generation benzimidazolone compounds was synthesized. Of these compounds, 
compound 50 was found to be the most potent with an IC50 value of 22 nM against wild-type HIV RT. 
Furthermore, compound 50 was able to maintain potency in the presence of the Y181C, Y188C and 
K103N/Y181C resistant strains. Unfortunately, compound 50 showed a 4-fold decrease in potency to the 
globally prevalent K103N resistant strain. Finally, compound 50 was found to be highly stable towards 
human and mouse liver microsomes. 
As a means to optimize the activity of our second-generation benzimidazolone compounds against wild-
type and resistant strains of HIV, we envisaged designing compounds that would be able to introduce 
additional interactions within the NNIBP. This will be discussed in the following two chapters. 
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Chapter 4: Lead Optimization Through the Introduction of Additional 
Electrostatic Interactions within the NNIBP – Part 1 
 
4.1. Targeting Lys223 in an attempt to improve the potency of 50 
From the library of compounds discussed in Chapter 3, compound 50 was found to be the most potent 
compound of the series with an IC50 value of 22 nM. In addition, 50 exhibited the best resistance profile, 
maintaining potency against the Y181C resistant strain as well as the double mutant K103N/Y181C. 
Nevertheless, we envisaged that we could further boost the potency of 50 against wild-type and resistant 
strains of HIV through the introduction of additional electrostatic interactions within the NNIBP.  
To this end, we considered targeting a lysine residue (Lys223) located at the top of a small hydrophobic 
chimney towards the back of the NNIBP formed by amino acid residues Trp229, Tyr188 and Phe227 (Figure 
43). In order to achieve hydrogen bonding with Lys223 it was necessary to identify an appropriate 
substituent to install onto the “upper” aryl ring of the benzimidazolone scaffold that would be long 
enough to introduce a hydrogen bond acceptor at an approximate distance of 2.2 Å from the lysine 
residue. Although a few NNRTIs in the literature have been described as being able to occupy this chimney 
region, as of yet none have been able to protrude deep enough to attain satisfactory hydrogen bonding 
with Lys223.221-222  
With the aid of molecular modelling we were able to identify the cyanoacetylene group (compound 90) 
as a suitable substituent to achieve hydrogen bonding interactions with the targeted residue Lys223 
(Figure 43). The cyanoacetylene group was postulated to be sufficiently narrow and rigid to fit readily into 
the narrow chimney region and would be long enough to bring the nitrile into close enough proximity 
with Lys223. Encouragingly, docking studies and binding energy calculations using Schrodinger’s Prime 
MM/GBSA (molecular mechanics energies combined with generalized Born and surface area continuum 
solvation) revealed that the cyanoacetylene substituent would be able to achieve hydrogen bonding with 
Lys223 at a calculated distance of 2.3 Å and, at the same time, the rest of the molecule would maintain 
the crucial electrostatic interactions with residues Trp229, Tyr188 and Lys101.  
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Furthermore, the binding energies of compounds 50 and 90 were compared and found to be similar for 
both compounds at -89.657 and -91.481 kcal/mol respectively, which implied that 90 would be as effective 
an inhibitor as 50. 
 
Figure 43 The introduction of a cyanoacetylene substituent would enable the formation of a hydrogen bond to Lys223 situated 
at the top of a narrow hydrophobic chimney. The similar binding energies of compounds 50 and 90 indicated that the 
cyanoacetylene substituent would be well accommodated in the NNIBP. Images were created using PDB file 2JLE in Discovery 
Studio. 
 
4.2. Envisaged approach to the synthesis of target compound 90 
For the synthesis of compound 90, we envisaged starting from commercially available 3-bromo-5-
fluorobenzonitrile 91 (Scheme 50). Unfortunately, the preferred iodo-analogue of this reagent was not 
available. However, we envisaged that the presence of the electron-withdrawing nitrile situated meta to 
the bromide would activate the aryl system enough to compensate for the presence of the slightly less 
reactive halogen.223  
We envisaged that the first step in the synthetic sequence (Scheme 50) would involve a Sonogashira 
coupling between 91 and propiolamide to afford the amide acetylene precursor 93. Subsequent 
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dehydration of the amide with phosphorous oxychloride would provide cyanoacetylene 94 which could 
then undergo an SNAr reaction with the benzimidazolone precursor described in Chapter 3 to afford the 
target compound 90.  
Unfortunately, there existed a slight drawback to this approach in that the starting reagent 91 was 
expensive. Consequently, we decided to first synthesize an analogue of compound 90 without the nitrile 
present. Not only would this route provide us with a proof-of-concept compound, but would also allow 
us to optimize all steps within the synthetic scheme prior to the use of the more costly material.  
To this end, we envisaged that the proof-of-concept analogue 97 could be synthesized starting from 
cheaply and readily available 3-fluoroiodobenzene 92. Subsequent steps for the synthesis of 97 would 
once again follow the route of a Sonogashira reaction between 92 and propiolamide to afford 94, 
subsequent dehydration of the amide to the nitrile 96 and an SNAr reaction with the benzimidazolone 
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4.3. Alkynylation through the use of the Sonogashira reaction 
The Sonogashira reaction, discovered in 1975 by Sonogashira, Tohda and Hagihara as an extension of the 
Heck reaction, is considered to be one of the most prevalent and reliable methods for the coupling of an 
sp hybridized carbon from a terminal acetylene and an sp2 hybridized carbon from a vinyl or aryl halide.224-
225 Generally the Sonogashira reaction is carried out at room temperature using a palladium catalyst with 
co-catalytic copper. The introduction of co-catalytic copper was a means to increase the reactivity of the 
system which allowed for it to be carried out under mild reaction conditions.225 
Although the exact mechanism of the copper co-catalysed Sonogashira reaction is not yet fully 
understood, it has been generally accepted that the mechanism occurs through two independent catalytic 
cycles.226 The first cycle (Cycle A, Figure 44), which is a classical example of a palladium catalysed C-C cross-
coupling formation, is initiated by oxidative addition of an aryl or vinyl halide II to a catalytically active 
Pd(0)L2 species I, such as Pd(PPh3)4224, 227  This stage is generally accepted as the rate-limiting step of the 
Sonogashira reaction and is largely dependent on the nature of the aryl halide II. In this instance the order 
of increasing reactivity of aryl halides is as follows: ArCl < ArBr < ArI. The resulting palladium adduct III 
then undergoes transmetallation with copper acetylide XI, formed from the copper cycle (Cycle B, Figure 
44), to form the palladium-acetylide adduct IV. Subsequent cis/trans isomerization of adduct IV to V and 
reductive elimination of adduct V yields the desired alkyne VI and regenerates the palladium catalyst I.224 
The copper-cycle is less well-understood. It has been hypothesized that the copper salt VII (usually 
copper iodide) and terminal acetylene VIII associate to generate the π-alkyne copper complex IX. This 
association supposedly increases the acidity of the alkyne proton enabling it to be extracted by the amine 
base X (typically triethylamine) and subsequently form the copper acetylide XI.224 
Stellenbosch University  https://scholar.sun.ac.za
Chapter 4: Lead Optimization Through the Introduction of Additional Electrostatic Interactions within 




Figure 44 It has been generally accepted that the copper co-catalysed Sonogashira reaction mechanism is comprised of two 
independent catalytic cycles. These include the palladium catalysed cycle (A) and the copper cycle (B). This image was adapted 
from Chinchilla et al.226 
 
4.3.1. Attempted synthesis of 3-(3-fluorophenyl)propiolamide (94) 
For the Sonogashira reaction between 92 and propiolamide we were careful to ensure that the reaction 
was kept under inert conditions. Due to the employment of copper iodide, the presence of oxygen in the 
reaction could lead to the occurrence of the Hay/Glaser reaction which would result in the homocoupling 
of terminal acetylenes to form a dimer.224 This undesired side reaction would encumber the formation of 
the Sonogashira product 94. 
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The Sonogashira alkynylation reaction between 92 and propiolamide was carried out in the presence of 
Pd(PPh3)4, co-catalyst CuI and triethylamine in toluene (Scheme 51). Monitoring the reaction by TLC 
revealed that, after 18 hours at room temperature, all the starting material had been consumed. Despite 
this, following the workup of the reaction and purification by column chromatography, the Sonogashira 
product 94 was obtained in a disappointingly low yield of 13%.  
For 94 the main distinguishing feature in the 1H NMR spectrum were two broad singlets at 5.98 ppm which 
could be attributed to the amide and the restricted rotation about the amide bond. The 13C NMR spectrum 
gave a clearer indication that the desired product had been formed. A doublet and singlet located at 84.5 
and 82.9 ppm respectively could be attributed to the presence of the acetylene. The doublet observed at 
84.5 ppm is a result of the 13C-19F coupling effect which extends to the acetylene carbon directly attached 
to the aryl ring. In addition, a signal at 154.7 ppm could be attributed to the amide carbonyl carbon atom.  
Regrettably, the low yield obtained for the Sonogashira product 94 hampered our ability to continue on 
to the dehydration step described in Scheme 50. We feared that despite our efforts to ensure an oxygen-
free environment, the low yield was a result of the dimerization of the propiolamide. Unfortunately, we 
struggled to isolate and identify any by-product that may have formed. We were concerned that due to 
the polarity of the propiolamide, any by-product formed had been lost during the aqueous workup of the 
Sonogashira reaction.  
 
4.3.2. Attempted synthesis of ethyl 3-(3-fluorophenyl)propiolate (98) 
In an attempt to identify the formation of any by-product we decided to carry out the Sonogashira 
reaction again, but this time using the less polar ethyl propiolate (Scheme 52). If dimerization occurred in 
this instance we hypothesized that it would be easier to isolate and characterize the ethyl propiolate 
dimer, thereby allowing us to optimize reaction conditions in order to prevent dimer formation. 
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The Sonogashira reaction between 92 and ethyl propiolate afforded 98 in an even lower yield of 4% 
(Scheme 52). However, as we had hoped, the major by-product formed in this instance was readily 
isolated and characterized by NMR spectroscopy. Surprisingly, the ethyl propiolate had not undergone a 
homocoupling as expected but had reacted with itself in a Michael addition reaction to afford the product 
99.  
For the 1H NMR spectrum of 98 the presence of aromatic signals, in addition to a quartet and triplet at 
4.31 and 1.36 ppm respectively, was indicative that the Sonogashira coupling between 92 and ethyl 
propiolate had occurred, albeit in a low yield. This observation was further justified by the identification 
of the alkyne signals in the 13C NMR spectrum at 84.6 and 81.5 ppm. The 13C-19F coupling observed for 
compound 94 was also observed for 98. Fortunately, as this was a known compound in the literature we 
were able to compare the chemical shifts obtained in the 1H and 13C NMR spectra and found them to 
compare favourably.228 
In the 1H NMR spectrum for 99, no aromatic signals were observed. Instead the presence of two doublets, 
one at 6.74 ppm and one at 6.42 ppm integrating for one proton each was indicative of the formation of 
an alkene. Furthermore, the coupling constants for both doublets was 16 Hz which suggested that the 
alkene possessed a trans configuration. Two multiplets located at 4.23 and 1.29 ppm were found to 
integrate for four and six protons respectively which could be attributed to the presence of two non-
equivalent ethyl esters. As with 98, 99 was known in the literature and the chemicals shifts obtained were 
found to correlate well with the chemical shifts reported in the literature.229 
Interestingly, a review of the literature revealed that poor yields are often associated with alkynes 
substituted with electron-withdrawing substituents.230 This occurs as a result of the fact that electron-
withdrawing substituents can significantly polarize the alkynyl π-bond. Consequently, alkynes such as 
ethyl propiolate and propiolamide are generally poor nucleophiles in the Sonogashira reaction but act as 
better electrophiles which enables them to readily undergo a Michael addition reaction.231 
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However, in the literature it has been suggested that this issue could be overcome by carrying out the 
alkynylation under Negishi conditions (Scheme 53).230, 232 Generally, in the case of electron-deficient 
alkynes, the use of zinc has been found to exhibit superior reactivity and product yield when compared to 
copper and other metals such as tin, magnesium and aluminium.233 The Negishi reaction typically employs 
zinc salts, such as zinc bromide or chloride, to form the alkynylmetal II from I which can then, in a similar 




To this end, we attempted the coupling of 92 with ethyl propiolate under the conditions reported by 
Anastasia and Negishi in 2003 (Scheme 54).230 Herein, they reported the use of LDA and ZnBr2 to generate 




Unfortunately, in our hands and under these conditions we were only able to slightly improve the yield of 
98. Despite the reported advantage of using zinc in place of copper, we observed that the major product 
of this reaction (100) was a result of another Michael addition onto the alkyne. Astonishingly, the 
nucleophile in this instance appeared to be diisopropylamide. 
As with 99, two doublets attributed to the alkene were observed in the 1H NMR spectrum for 100. 
Furthermore, in addition to a quartet and triplet integrating for two and three protons respectively which 
were associated with the ethyl ester, a singlet and doublet integrating for two and twelve protons at 3.61 
and 1.17 ppm respectively were identified as belonging to the diisopropylamide. Fortunately, 100 was 
also a known compound in the literature and the chemical shifts reported were found to compare 
favourably with those obtained experimentally.234 
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In the paper by Anastasia and Negishi, the use of triethylamine as an alternative to LDA was also reported. 
230 Although we re-attempted the Negishi reaction with triethylamine, we were unable to obtain any of 
the desired product 98. 
 
4.4. Alternative methods towards the synthesis of the cyanoacetylene precursor 96 
In the meantime, while struggling to find optimal conditions for the introduction of an electron-deficient 
acetylene onto 92, we decided to turn our attention to the possibility of altering our synthetic strategy by 
introducing more electron rich acetylenes.  
 
4.4.1. Strategy 1: Alkynylation with TMS-acetylene 
One such alternative strategy involved the attempted synthesis of cyanoacetylene 96 by coupling 92 with 
trimethylsilylacetylene (TMS-acetylene) (Scheme 55).  
 
Scheme 55 
The first step in this synthetic scheme would involve the coupling of TMS-acetylene to 92 under 
Sonogashira reaction conditions. The resulting coupled product 101 would then undergo a deprotection 
of the TMS group with potassium carbonate in MeOH to afford the terminal acetylene 102. Following 
deprotection, precursor 102 could then be cross-coupled with copper cyanide to yield the desired 
cyanoacetylene precursor 96.235-236  
With a synthetic strategy in mind, we could embark upon the first step which involved the Sonogashira 
cross-coupling between 92 and TMS-acetylene under conditions described for the synthesis of 94 and 98 
(Scheme 56). 
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Encouragingly, the coupling of 92 to TMS-acetylene was carried out successfully and the Sonogashira 
product 101 was obtained in quantitative yield.  
The most distinguishing feature in the 1H NMR spectrum of 101, in addition to the expected aromatic 
signals, was the presence of a large singlet located at 0.24 ppm which integrated for 9 protons. This was 
attributed to the presence of the TMS group. In the 13C NMR spectrum a doublet at 103.8 ppm, a singlet 
at 95.5 ppm and another singlet at 0.0 ppm attested to the presence of the TMS-acetylene. As this was a 
known compound in the literature we were able to correlate the chemical shifts observed experimentally 
with those obtained from the literature which assured us that we had obtained the desired product 101.228 
Unfortunately, despite the precedence for this reaction in the literature, in our hands the subsequent 
deprotection of the TMS-acetylene with potassium carbonate was unsuccessful (Scheme 57).237-238 
Although monitoring the reaction by TLC indicated that all of 101 had been consumed, upon workup we 
were unable to isolate any product at all. Another attempt at the deprotection using tetrabutylammonium 





4.4.2. Strategy 2: Alkynylation with propargyl alcohol 
Another approach to the synthesis of the desired cyanoacetylene compound 96, which was described 
prominently in the literature, involved a one-pot conversion of an activated alcohol to the corresponding 
nitrile.239-243 This direct conversion of an alcohol to a nitrile was originally introduced by Lai et al. in 2000 
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but was described only for benzylic alcohols.239 Inspired by this method, McAllister et al. extended this 
methodology further by applying it to various propargyl alcohols.240 This transformation is initiated by the 
oxidation of propargyl alcohol 103 to the corresponding aldehyde 104 (Scheme 58). It has been postulated 
that the aldehyde 104 then reacts with ammonia affording the analogous imine 105, which is 
subsequently oxidized in situ to afford the desired nitrile 106.240 
 
Scheme 58 
In order to employ these conditions for our purposes we would have to first install propargyl alcohol onto 




To this end, 92 was treated with propargyl alcohol in the presence of Et3N, Pd(PPh3)4 and CuI under inert 
conditions and after 18 hours at room temperature TLC determined that the reaction had reached 
completion. Subsequent workup and purification by column chromatography afforded the desired 
compound 107 in 97% yield (Scheme 59).  
Distinguishing features in the 1H NMR spectrum of 107 included a doublet and triplet located at 4.50 and 
2.43 ppm which integrated for two and one proton respectively. These observed signals could be 
attributed to the presence of the methyl alcohol portion of propargyl alcohol. In the 13C NMR spectrum 
signals at 88.3, 84.5 and 51.5 ppm provided further testament that the Sonogashira coupling had occurred 
successfully.  
With the propargyl alcohol precursor 107 in hand we could attempt to carry out the conversion of 107 to 
96 by utilizing the one-pot reaction conditions described by McAllister et al.240 To this end, treatment of 
107 with a solution of ammonia in iso-propanol in the presence of anhydrous magnesium sulfate was 
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followed by the addition of manganese dioxide. The reaction was closely monitored by TLC, but 
unfortunately after 18 hours revealed that no reaction had taken place. Seemingly, the desired 
cyanoacetylene 96 could not be obtained using this methodology. 
 
4.5. Alkynylation using “copper-free” Sonogashira conditions 
Although we had so far been unsuccessful in our endeavour to synthesize the cyanoacetylene 96 we 
decided to persevere and revisit the coupling of propiolamide and 92. Although the by-products that were 
isolated from the Sonogashira and subsequent Negishi couplings did not appear to be a result of copper-
catalysed homocoupling of the terminal alkynes, we thought it could be worthwhile to attempt a “copper-
free” Sonogashira reaction, also known as the Sonogashira-Heck-Cassar reaction or Heck alkynylation 
reaction.224  
As with the copper co-catalysed Sonogashira reaction mechanism, the mechanism for the “copper-free” 
reaction is not well known.226 It is generally accepted that this mechanism, like the mechanism described 
in Figure 44 begins with the oxidative addition of the aryl halide II to the catalytic [Pd(0)L2] species I to 
form III (Figure 45).226 It has been proposed that the subsequent step involves the displacement of a 
ligand through reversible π-coordination of the alkyne IV to form the intermediary complex V.244 This 
complex is thought to serve a similar purpose to the copper acetylide complex formed in Cycle B in Figure 
44, in that the acetylene proton is acidified which facilitates its removal by an amine base VI to give the 
complex VII.226 Once again, cis/trans isomerization to afford VIII, is followed by reductive elimination of 
the complex VIII which releases the cross-coupled product IX and reforms the catalytic palladium 
species I.224  
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Figure 45 The proposed mechanism for the copper-free Sonogashira reaction is shown here.226 
The “copper-free” Sonogashira coupling between 92 and propiolamide was performed in the presence of 
Pd(OAc)2, triphenylphosphine and triethylamine which could facilitate the in situ reduction of the Pd(II) 
species to the catalytically active Pd(0) species (Scheme 60).245 Unlike the copper co-catalysed 
Sonogashira reaction which was carried out at room temperature, this coupling had to be carried out at 
an elevated temperature of 70 ˚C. 
 
Scheme 60 
To our astonishment, under these conditions we were able to obtain the desired compound 94 in a 
significantly improved yield of 69% which enabled us to continue with the synthesis of compound 96 as 
described in Scheme 50. Unfortunately, at the time we did not have access to POCl3 which was required 
for the dehydration of amide 94 to the corresponding nitrile 96. As a result, an alternative dehydration 
method had to be identified. To this end, we came upon a paper by Nakajima and Ubukata which 
described the use of Swern oxidation conditions for the dehydration of amides to the corresponding 
nitriles.246 In general, the Swern reaction is used for the oxidation of various alcohols to the corresponding 
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carbonyls; however it has found application in the dehydration of oximes, hydroxylamines and amides.246-
249  
The mechanism for the dehydration of amides begins with the formation of the chlorosulfonium species 
111 (Scheme 61).  
 
Scheme 61 The proposed mechanism for the dehydration of amide under Swern oxidation conditions.246-247 
For this to occur DMSO (108) reacts with oxalyl chloride (109) to form the intermediate 110 which readily 
decomposes, giving off carbon dioxide and carbon monoxide, to afford the chlorosulfonium species 
111.250 The chlorosulfonium species 111 then reacts with the amide carbonyl of 94 to form the sulfonium 
salt 112. In the presence of triethylamine the sulfonium salt 112 is converted into the ylide 113.247 
Intramolecular proton-abstraction from the ylide 113 then results in the formation of the desired nitrile 
96 and the regeneration of DMSO.247  
 
Scheme 62 
In preparation for the dehydration of 94 to 96 using Swern oxidation conditions, oxalyl chloride was 
treated with DMSO at -78 °C to form the active chlorosulfonium species (111 in Scheme 61). This was 
followed by the addition of 94 and, after approximately 20 minutes, the addition of triethylamine to 
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facilitate dehydration to the nitrile. The reaction was closely monitored by TLC and after 1 hour the 
reaction had reached completion. After purification we were finally able to obtain the elusive 
cyanoacetylene compound 96 in a satisfactory yield of 69% (Scheme 62). 
In the 1H NMR spectrum of 96 the absence of the broad doublet belonging to the amide was the only clear 
indication that the dehydration reaction had occurred. This observation was further supported by the loss 
of the carbonyl carbon signal in the 13C NMR spectrum and the occurrence of an additional more shielded 
carbon signal in the aromatic region. Unfortunately, attempted analysis through HRMS did not provide an 
accurate mass. As a means of determining with certainty that 96 had been synthesized, we decided to 
obtain and compare the FTIR spectra of 94 and 96. The 2 bands at 3164 and 3378 cm-1 that correspond to 
an amide stretch for 94 were not observed in the IR spectrum for 96. Instead, a clear band at 2259 cm-1 
could be attributed to the nitrile expected for 96.  
 
4.6. The attempted synthesis of target compound 97  
Finally, with the desired cyanoacetylene 96 in hand we could attempt the much anticipated SNAr reaction, 
using the reaction conditions described in Chapter 3, with the benzimidazolone precursor 38 to obtain the 
penultimate product 114 (Scheme 63).  
Surprisingly, upon addition of 96 to a mixture of 38 and Cs2CO3 at room temperature, an immediate colour 
change was observed. This was an unusual observation as these reactions have required elevated 
temperatures to occur at all in the past. Nonetheless, analysis of the reaction by TLC revealed that all the 
starting material had been consumed and that a single product had formed. 
 
Scheme 63 
Stellenbosch University  https://scholar.sun.ac.za
Chapter 4: Lead Optimization Through the Introduction of Additional Electrostatic Interactions within 
the NNIBP – Part 1 
100 
 
Unfortunately, the spectral data for the compound obtained were not consistent with those of the desired 
product 114. Analysis of the 1H and 13C NMR spectra, in addition to HRMS, revealed that the product 
obtained was in fact 115, a result of a Michael addition of 38 onto the cyanoacetylene substituent of 96 
(Scheme 63). 
The clearest indication that the desired SNAr did not occur was observed in the 13C NMR spectrum of 115. 
The fact that we still observed the doubling up on carbon signals as a result of 13C-19F coupling indicated 
that the fluorine was still present on the compound. Furthermore, in the 1H NMR spectrum of 115 the 
presence of an unexpected singlet at 4.72 ppm which integrated for one proton was indicative that a vinyl 
proton was present. The presence of a single vinyl proton signal implied that only a single stereoisomer 
had been formed; however, with the information we had we were unable to conclusively assign the 
resulting alkene as cis or trans. HRMS analysis of 115 provided a mass of 454.1948 amu which coincided 
with the expected mass of 454.1962 amu.  
The formation of 115 confirmed the suspicions we had with regards to the reactivity of the cyanoacetylene 
group as a Michael acceptor. Unfortunately, this observation implied that target compounds 90 and 97 
could be involved in off-target effects due to their ability to act as Michael acceptors and, therefore, would 
be toxic in a whole cell assay. However, we were not ready to abandon the idea of targeting Lys223 
altogether and, as a result, decided to change tactics by introducing a less reactive substituent onto the 
“upper” aryl ring of the benzimidazolone scaffold. 
 
4.7. A change in tactics: Introducing a cyanovinyl group as an alternative for the 
cyanoacetylene group 
In our search for a suitable bioisostere to replace the reactive cyanoacetylene substituent, we identified 
the cyanovinyl group (compound 116) (Figure 46). At first glance the cyanovinyl group, another 
unsaturated nitrile, does appear to be a potential Michael acceptor. However, in a publication by Fleming 
and Wan, the cyanovinyl group is described as recalcitrant in that reactive organometallic nucleophiles 
are required for conjugate addition to occur.251  
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We were further encouraged by the fact that rilpivirine, a potent FDA-approved NNRTI which possesses a 
cyanovinyl group on one of its terminal aryl rings, has a selectivity index of >8000 in vitro indicative of its 
selectivity for HIV RT (Figure 47).252 The cyanovinyl group has also found precedence in other NNRTIs such 
as compounds 117 and 118. In both instances, the introduction of the cyanovinyl group was found to 
considerably improve potency.221, 253 In the case of 117 this improvement was particularly significant as 
the introduction of the cyanovinyl group led to picomolar activity.221 
 
Figure 47 The introduction of the cyanovinyl group considerably improved the potency of a number of NNRTIs. 
In order for compound 116 to be an effective inhibitor of RT it was imperative that the cyanovinyl 
substituent, as with the cyanoacetylene, be able to extend into the chimney region deep enough to 
facilitate a strong enough hydrogen bond with Lys223 and, at the same time, maintain the binding 
orientation of lead second-generation benzimidazolone 50 within the NNIBP. To this end, with the 
purpose of validating the incorporation of the cyanovinyl group on our benzimidazolone scaffold, docking 
studies were conducted on compound 116. These studies revealed that, in the trans configuration, the 
cyanovinyl group was able to comfortably occupy the chimney region formed by Trp229, Tyr188 and 
Phe227 and achieve hydrogen bonding with the target Lys223 residue at an acceptable calculated distance 
of 2.3 Å (Figure 48). Furthermore, compound 116 was able to maintain other important electrostatic 
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interactions such as π-interactions with Tyr188 and conserved residue Trp229, as well as hydrogen 
bonding with the backbone of Lys101. Encouragingly, when the binding energies calculated for 
compounds 116 and 97 were compared, the difference in binding energies between the two compounds 
was found to be negligible. This result provided further testimony to the fact that the cyanovinyl 
substituent was a suitable replacement for the cyanoacetylene group. 
 
Figure 48 Docking studies of target compound 116 in the NNIBP revealed that the cyanovinyl substituent of 116 would be able 
to occupy the chimney region formed by Trp229, Tyr188 and Phe227. Furthermore, 116 would be able to achieve hydrogen 
bonding with the target lysine residue and, at the same time, maintain the important interactions to Trp229, Tyr188 and 
Lys101. Images were created using PDB file 2JLE in Discovery Studio. 
For the synthesis of compound 116 we envisaged that we could follow the same procedure described for 
the synthesis of 97 in Scheme 50. However, in place of the Sonogashira coupling reaction the first step in 
the reaction sequence would involve the cross-coupling of 92 with acrylamide by way of a Heck reaction 
to obtain 119 (Scheme 64). As with 97, subsequent steps would involve dehydration of 119 under Swern 
conditions to afford 120 which could then undergo an SNAr reaction with benzimidazolone precursor 38 
and a subsequent SEM deprotection to yield the desired product 116. 
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4.7.1. Synthesis of (E)-3-(3-fluorophenyl)acrylamide (119) by way of a Heck cross-coupling 
reaction 
The Heck or Mizoroki-Heck reaction is an efficient, versatile and popular method for the cross-coupling of 
aryl halides and alkenes.254 We have already described the mechanism for the Heck coupling reaction 
between alkynes and aryl halides in Section 4.5 and for the first few steps (I - V) this mechanism is much 
the same for the coupling between aryl halides and alkenes (Figure 49).254-255 However, following the 
carbopalladation step leading to V, an internal C-C bond rotation occurs which brings the β-hydrogen into 
a syn position relative to the palladium (VI). This allows for a syn β-hydride elimination to occur which 
affords the ligated complex VII.255 Finally, after dissociation of the alkene VIII from the complex, 
reductive elimination of IX regenerates the active palladium species I.255  
One of the major benefits of the Heck reaction is the propensity for delivering predominantly the trans 
product due to the occurrence of the syn β-hydride elimination step in the mechanism.254 In our case, this 
was incredibly important as only the trans configuration of the cyanovinyl group would be able to occupy 
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Figure 49 Proposed mechanism of the Heck reaction.255 
For the Heck reaction we decided to employ the conditions used to synthesize compound 94. To this end, 
92 and acrylamide were treated with Pd(OAc)2, PPh3 and Et3N and then heated to 70 °C (Scheme 65). After 
18 hours TLC indicated that all of 92 had been consumed and that a single, significantly more polar, 
product had formed. This product was purified by column chromatography to afford the desired product 
119 in a quantitative yield. 
 
Scheme 65 
Analysis of the 1H NMR spectrum of 119 confirmed that only the desired trans isomer had been 
synthesized. Two doublets observed at 7.62 and 6.49 ppm, both integrating for one proton, could be 
attributed to the two vicinal vinyl protons and the J-coupling constants of both doublets were found to be 
16 Hz which indicated that the stereochemistry of the alkene was in the trans configuration. It is well 
known that the J-coupling constants for vinyl protons in the trans configuration are often within the range 
of 12 – 18 Hz, while cis protons are in the range of 6 – 12 Hz.256 In addition, two broad singlets at 5.99 ppm 
integrating for 2 protons altogether, provided a further indication that the Heck reaction had successfully 
introduced propiolamide onto 92. Although we were unable to unambiguously assign the signals in the 
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13C NMR spectrum, all expected carbon signals for 119 were observed. Furthermore, HRMS analysis of 
119 provided a mass of 166.0667 amu which coincided with the expected mass of 166.0668 amu. 
 
4.7.2. Synthesis of (E)-3-(3-fluorophenyl)acrylonitrile (120) 
With 119 in hand, we could carry out the subsequent dehydration using the same Swern conditions 
employed for the synthesis of 96. To this end, the active chlorosulfonium species, formed in situ with 
DMSO and oxalyl chloride, was treated with 119 and triethylamine to afford the cyanovinyl product 120 
in a rather disappointing yield of 45% (Scheme 66). Nevertheless, we had enough material in hand to 
attempt the subsequent SNAr reaction. 
 
Scheme 66 
As with 96, analysis of the 1H NMR spectrum for 120 revealed an absence of the two broad singlets 
attributed to the presence of the amide. This observation in conjunction with the loss of the amide 
carbonyl signal in the 13C NMR spectrum verified that the dehydration of 119 had occurred. Additional 
confirmation came from HRMS which gave a mass of 148.0557 amu, coinciding with the calculated mass 
of 148.0563 amu. 
 
4.7.3. Attempted synthesis of (E)-3-(3-((3-ethyl-2-oxo-1-((2-(trimethylsilyl)ethoxy)methyl)-
2,3-dihydro-1H-benzo[d]imidazol-4-yl)oxy)phenyl)acrylonitrile (121) 
For the SNAr reaction the benzimidazolone precursor 38 and 120 were treated with Cs2CO3 in DMF 
(Scheme 67). Encouragingly in this instance, no evident reaction had occurred prior to the introduction of 
heat which seemed to verify the claim, discussed in section 4.7, that the cyanovinyl group was less reactive 
than the corresponding cyanoacetylene group and therefore, not prone to Michael addition. However, 
after 2 hours at 100 °C still no reaction had taken place, a situation which did not change even after 18 
hours at 100 °C. 
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In an attempt to explain the lack of product formation, we considered the possibility that the cyanovinyl 
aryl group 120 was not activated enough for the SNAr reaction to occur. We knew from Chapter 3 that the 
presence of an electron-withdrawing group such as a nitrile would activate the fluoro-containing aryl ring 
sufficiently for the SNAr to occur albeit at high temperatures. As a result, we realized that we would have 
to employ the starting reagent 91 described earlier in the chapter which contained the additional nitrile 
functionality (Section 4.2). Fortunately, we knew that we could readily install the cyanovinyl group onto 
91 using the conditions described for the synthesis of precursors 119. 
 
4.7.4. Attempted synthesis of (E)-3-(3-cyano-5-fluorophenyl)acrylamide (122). 
As with 3-iodo-fluorobenzene 92, 91 with acrylamide was treated with Pd(OAc)2, PPh3 and Et3N and 
heated to 70 °C for 18 hours (Scheme 68). However, following purification the desired cyanovinyl 
compound 122 was obtained in a frustratingly poor yield of 17%, in contrast to the quantitative yield 
obtained for 119. 
 
Scheme 68 
In order to optimise this reaction, we had to consider the possibility that the bromide, in comparison to 
the iodide, was considerably less amenable to the initial oxidative addition step with the palladium 
catalyst, despite the presence of the nitrile on the ring. Therefore, in an attempt to increase the yield of 
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122 we re-attempted the Heck coupling of 91 and acrylamide using P(o-tolyl)3 as the ligand in place of 
PPh3. In 1978 it was discovered that the utilization of substituted triarylphosphines such as P(o-tolyl)3 in 
conjunction with Pd(OAc)2 was superior to the use of PPh3 when the reaction involved the use of aryl 
bromides.255, 257  
To this end, P(o-tolyl)3 and Pd(OAc)2 were introduced to a mixture of 91, acrylamide and Et3N under inert 
conditions (Scheme 69). Unfortunately, after 18 hours a poor yield of impure 122 was obtained despite 
attempted purification by column chromatography. 
 
Scheme 69 
In the 1H NMR spectrum of 122, two doublets observed at 7.58 and 6.77 ppm, each integrating for one 
proton could be attributed to the presence of the vicinal vinyl protons from the acrylamide portion of 122. 
Moreover, the coupling constants for both doublets was reported as 16 Hz, indicative that the vinyl 
protons were arranged in the desired trans configuration. The coupling of 91 to acrylamide was further 
validated by HRMS analysis which gave a mass of 191.0615 amu coinciding with the theoretical mass of 
122 which was 191.0615 amu. 
 
4.7.5. The use of a phosphine-free Heck cross-coupling reaction 
For the past several years researchers have explored the use of phosphine-free Heck reactions in an 
attempt to overcome the various challenges faced when using phosphine-based ligands which include 
toxicity, air sensitivity and degradation at high temperatures.258-260 A paper by Cui et al. described the use 
of N-phenylurea as an inexpensive and highly efficient ligand for palladium catalysed Heck and Suzuki 
reactions.258 Herein they reported high yields for Heck reactions between electron-rich or deficient aryl 
halides, featuring a bromide or iodide, and styrene or butyl acrylate. We decided to employ the reaction 
conditions described by Cui et al. in the hope that we would be able to obtain compound 122 in similarly 
high yields.    
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To this end, a mixture of 91, acrylamide and N-phenylurea in DMF was treated with Pd(OAc)2 and K2CO3 
(Scheme 70). Astonishingly, after just 2 hours at 130 ˚C, TLC analysis revealed that all of 91 had been 
consumed. A subsequent aqueous workup and purification by column chromatography afforded 122 in a 




4.7.6. Synthesis of (E)-3-(2-cyanovinyl)-5-fluorobenzonitrile (123) 
Finally, with compound 122 in hand, we could carry out the dehydration of the amide to the corresponding 
nitrile 123 using the Swern conditions reported for the synthesis of compound 96. Therefore, compound 
122 and Et3N were introduced to a mixture of DMSO and oxalyl chloride in DCM. After 1 hour, TLC 
indicated that all of 122 had been consumed to produce a single product. Nevertheless, following 
purification the dehydration of 122 afforded compound 123 in a disappointingly poor yield of 29% 
(Scheme 71).  
 
Scheme 71 
Fortunately, by this stage we had access to POCl3 and could, therefore, re-attempt the transformation of 
122 to 123 using the more classical dehydration method. To this end, compound 122 was suspended in 
neat POCl3 at 0 °C and then warmed to room temperature (Scheme 71). After several hours the suspension 
had completely cleared and subsequent monitoring by TLC revealed that 122 had been consumed. 
Fortunately this time, under these conditions the desired cyanovinyl compound 123 was obtained in 76% 
yield.  
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In the 1H NMR spectrum of 123 the most obvious confirmation that the dehydration had occurred 
successfully was the absence of signals belonging to the exchangeable amide protons. In the 13C NMR 
spectrum this observation was corroborated by the absence of the amide carbonyl carbon signal. HRMS 
analysis further confirmed the successful synthesis of 123 by providing a mass of 173.0509 amu which 
corresponded with the expected mass of 173.0506 amu. 
Finally, with 123 in hand we could attempt the greatly anticipated SNAr reaction with the benzimidazolone 
precursor 38 (Scheme 72). We were confident that, with the nitrile functionality present, the SNAr reaction 
would occur readily. To our dismay however, when 38 and 123 were heated to 100 °C in the presence of 




4.8. A final attempt  
Although the synthesis of the target cyanovinyl product was proving to be more problematic than 
originally anticipated, through perseverance we decided to introduce the cyanovinyl group only after 91 
had been installed onto benzimidazolone scaffold 38, in a final effort to obtain the desired cyanovinyl 
containing benzimidazolone compound 116. We reasoned that due to the success of the SNAr reaction 
between 38 and the 3-chloro-5-fluorobenzonitrile compound 51 described in Chapter 3, the same reaction 
between 38 and 91, essentially a bromide-containing analogue of 51, should occur just as readily to afford 
the coupled product 125 (Scheme 73). Furthermore, we hoped that, having optimized the conditions for 
the Heck and subsequent dehydration reactions, the desired acrylamide (126) and cyanovinyl (124) could 
be readily obtained and we could, finally, carry out the ultimate N-SEM deprotection step to afford the 
elusive target product 127. 
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4.8.1. Synthesis of 3-bromo-5-((3-ethyl-2-oxo-1-((2-(trimethylsilyl)ethoxy)methyl)-2,3-
dihydro-1H-benzo[d]imidazol-4-yl)oxy)benzonitrile (125) 
For the SNAr reaction to afford 125, benzimidazolone precursor 38 and 91 were heated to 100 °C in the 
presence Cs2CO3 (Scheme 74). Reassuringly, monitoring the reaction by TLC after 2 hours revealed 
complete consumption of 38. To our delight subsequent workup and purification by column 
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In the 1H NMR spectrum of 125, the absence of the broad singlet belonging to the OH of 38, in conjunction 
with the presence of three new aromatic, protons provided the clearest indication that the SNAr reaction 
had occurred. The occurrence of 7 additional carbon signals in the 13C NMR spectrum of 125 gave further 
testament to the success of the reaction.  
 
4.8.2. Synthesis of (E)-3-(3-cyano-5-((3-ethyl-2-oxo-1-((2-(trimethylsilyl)ethoxy)methyl)-2,3-
dihydro-1H-benzo[d]imidazol-4-yl)oxy)phenyl)acrylamide (126) 
For the Heck cross-coupling reaction we employed the phosphine-free conditions described for the 
synthesis of 122, which involved treatment of 125 and acrylamide with Pd(OAc)2, N-phenylurea and K2CO3 
(Scheme 75). As we had hoped, under these optimized conditions, we were able to obtain the coupled 
product 126 in a very good 89% yield.  
 
Scheme 75 
In the 1H NMR spectrum of 126 two doublets, each integrating for one proton, at 7.54 and 6.50 ppm and 
a broad singlet integrating for two protons at 5.94 ppm attested to the presence of the acrylamide. The 
desired trans configuration of the acrylamide was confirmed by the fact that both doublets expressed 
coupling constants of 16 Hz. In addition to these signals, all other proton signals expected for 126 were 
observed. This observation was mirrored in the 13C NMR spectrum of 126.  
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4.8.3. Attempted synthesis of (E)-3-(2-cyanovinyl)-5-((3-ethyl-2-oxo-1-((2-
(trimethylsilyl)ethoxy)methyl)-2,3-dihydro-1H-benzo[d]imidazol-4-yl)oxy)benzonitrile 
(124) 
With compound 126 in hand we could attempt to carry out the subsequent transformation of amide 126 
to 124 using POCl3 (Scheme 76). Interestingly, after 18 hours in POCl3 we still observed by TLC the presence 
of unreacted 126 and, contrary to what we anticipated, the presence of a more polar product relative to 
126. This observation indicated that the dehydration reaction had not proceeded as expected. 
 
Scheme 76 
Unfortunately, analysis of the 1H NMR spectrum of the unexpected product revealed that, despite 
attempted purification by column chromatography, we had obtained an impure and inseparable mixture 
of products. 
Due to the challenges faced with the dehydration of 126 in the presence of the SEM protecting group, we 
decided to purposefully carry out the deprotection of the SEM group prior to the dehydration of the 
amide. Furthermore, as the N-SEM deprotection was not the final step in this strategy we decided to 
utilize the single-step deprotection method with TBAF described in Chapter 3. To this end 126 was stirred 
in TBAF for 18 hours which afforded compound 128 in a relatively low yield of 32% after purification 
(Scheme 77). Nevertheless, we had obtained enough of 128 to continue with the subsequent dehydration 
with POCl3.  
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In the 1H and 13C NMR spectra of 128 the notable absence of all signals pertaining to the SEM protecting 
group attested to the successful removal of the SEM group from 126. Unfortunately, due to the fact that 
deuterated methanol was utilized for the NMR sample of 128, the characteristic urea signal was not 
observed. However, HRMS analysis of 128 delivered a mass of 349.12955 amu which coincided with the 
calculated mass 349.12952 amu and thereby validated the observation that 128 had been successfully 
synthesized. 
 
4.8.4. The final step towards the synthesis of the elusive cyanovinyl product 127 
Having successfully synthesized precursor 128 we could embark upon the final step in our strategy 
towards the synthesis of target compound 127. Having attempted countless methods to synthesize this 
compound we were eager and, at the same time, apprehensive about setting up the conversion of the 
amide 128 to the cyanovinyl compound 127 using POCl3. Nevertheless, necessity dictated our actions and 
128 was suspended in neat POCl3 (Scheme 78). The reaction was closely monitored by TLC and after 2 
hours we observed that 128 had been completely consumed. Gratifyingly, following purification by 
column chromatography we were able to isolate the desired product in a yield of 41%. 
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Analysis of the 1H NMR spectrum of 127 revealed that all expected proton signals were present. Of these, 
the most distinguishing signals included a broad singlet integrating for one proton at 10.01 ppm belonging 
to the urea and two doublets at 5.94 and 6.68 ppm each integrating for one proton which attested to the 
vinyl protons on the cyanovinyl group. In the 13C NMR spectrum of 127 the presence of only one carbonyl 
carbon signal indicated that only the urea carbonyl was present, and that the amide had been successfully 
dehydrated to the corresponding nitrile. Finally, HRMS gave a mass of 331.1188 amu which coincided with 
the theoretical mass of 331.1190 amu. 
 
4.9. Evaluation of target compound 127 against wild-type and resistant strains of HIV 
Having successfully synthesized the desired cyanovinyl compound 127, we could finally evaluate its 
efficacy against wild-type HIV RT in the hope that we would observe a marked improvement in potency.  
Disappointingly, although compound 127 was found to be a potent inhibitor of HIV with an IC50 value of 
49 nM, we were not able to achieve the desired improvement on the potency exhibited by our lead 
benzimidazolone compound 50 (IC50 = 26 nM). Nevertheless, we decided to evaluate this compound 
against a panel of clinically relevant resistant strains in the hope that compound 127 might exhibit an 
improved resistance profile in comparison to 50 (Figure 50). However unremarkably, analysis of the 
activity results against a panel of resistant strains revealed that overall, compound 127 was found to 
exhibit a very similar resistance profile to compound 50. For example, against the most problematic K103N 
resistant strain which exhibits high-levels of resistance to NNRTIs nevirapine and efavirenz, compound 
127 suffered only a 3-fold loss in potency while against Y181C, Y188C and the K103N/Y181C resistant 
strains, 127 was able to maintain potency. From Figure 50 it can be seen that these results closely mirror 
the activity results reported for lead compound 50. 
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Figure 50 Compound 127 was found to be a potent inhibitor of HIV RT. Furthermore, the potency of 127 dropped only 3-fold 
against the K103N resistant strain and was maintained against Y181C, Y188C and the double mutant K103N/Y181C. 
 
4.10. Concluding remarks 
In an attempt to optimize the potency of lead compound 50 against wild-type and resistant strains of HIV, 
we envisaged introducing substituents onto the “upper” aryl ring that would be able to occupy a narrow 
hydrophobic chimney formed by Trp229, Tyr188 and Phe227 and form an additional hydrogen bond with 
the lysine residue located at the top of this chimney. To this end we were eventually able to synthesize 
the cyanovinyl containing compound 127. However, evaluation of 127 in a phenotypic assay revealed that, 
using this design approach, we were unable to achieve any improvement on the potency exhibited by lead 
compound 50 against wild-type or resistant strains of HIV. 
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5.1. A molecular hybridization approach to re-introduce additional hydrogen bonding to 
the backbone of Lys101 
In our continued effort to improve the potency of lead compound 50, we decided to focus on modifying 
our structure to re-introduce the double hydrogen bonds to the backbone of Lys101, a feature imperative 
to the potency of the indole compounds discussed in Chapter 2. We envisaged that, by way of a molecular 
hybridization approach facilitated by molecular modelling, a hybrid of lead compound 50 and licensed 
NNRTI efavirenz would furnish a new scaffold 129 capable of forming the desired double hydrogen bond 
to the backbone of Lys101. Moreover, this new hybrid compound would be able to maintain the important 
interactions with Tyr188 and conserved residue Trp229 (Figure 51). This approach was based on the 
observation that the benzoxazin-2-one scaffold of efavirenz repositions the carbonyl at position 2 in a 
manner that favours hydrogen bonding with Lys101.102 
 
Figure 51 Generic compound 129 was designed using a molecular hybridization approach between lead compound 50 and 
efavirenz as a means to reintroduce additional hydrogen bonding to the backbone of Lys101. 
Fortunately, molecular modelling was able to validate this approach. Docking studies of the new hybrid 
compound within the NNIBP revealed that this new scaffold was able to accomplish the desired double 
hydrogen bonding interaction with the backbone of Lys101, while maintaining the crucial π-interactions 
between the substituted aryl ring and Trp229 and Tyr188 (Figure 52). 
In order to establish a proof-of-concept compound to synthesize, we had to decide on appropriate 
substituents to occupy position 4 on the new benzoxazin-2-one template (Figure 51).  These substituents 
would have to occupy the small hydrophobic pocket in the vicinity of Val179 without altering the binding 
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orientation of the compound in the NNIBP and, for the sake of avoiding synthetic complexity, would have 
to be non-chiral. To this end, we decided to introduce the dimethyl substituents shown in Figure 52.  
Docking studies revealed that the benzoxazin-2-one scaffold with the dimethyl substituent at position 4 
(130) would be well-tolerated in the NNIBP. Moreover, the difference in binding energies calculated for 
50 (-96.51 kcal/mol) and 130 (-96.44 kcal/mol) was found to be negligible which implied that the efficacy 
of 130 would be comparable with that of 50. 
  
Figure 52 Docking studies revealed that the new benzoxazin-2-one scaffold would be able to facilitate double hydrogen bonding 
to the backbone of Lys101 while maintaining the important π-interactions with Tyr188 and Trp229. 
 
5.2. Proposed synthesis of the proof-of-concept compound 130 
For the synthesis of compound 130, we envisaged starting from 1-(benzyloxy)-2-iodo-3-nitrobenzene 131, 
which in turn, could be synthesized by way of a Sandmeyer reaction from the benzylated 2-amino-3-
nitrophenol 33 synthesized in Chapter 3 (Scheme 79). We decided to introduce the halogen as a means 
of directing the subsequent acylation to the desired position between the phenol and nitro group. With 
the halogen in place we envisaged that lithium-halogen exchange with n-BuLi and quenching with an 
appropriate acyl group would afford the desired acylated product 132. Subsequent reduction of the nitro 
group to the amine 133 and a Grignard reaction with methyl magnesium bromide would provide the 
tertiary alcohol 134. A ring-closing reaction with CDI would then afford the precursor 135, which could 
subsequently be protected with a SEM group to provide 136 in preparation for debenzylation to the 
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benzoxazin-2-one precursor 137. Penultimately, 137 would be coupled to 3-chloro-5-fluorobenzonitrile 
51 to afford 138. Finally, removal of the SEM group using the deprotection methods described in Chapter 




5.2.1. Synthesis of 1-(benzyloxy)-2-iodo-3-nitrobenzene (131) by way of a Sandmeyer 
reaction 
For the Sandmeyer reaction we decided to utilize conditions reported by Dai et al.261 Under these 
conditions the amine 33 was activated to the corresponding diazonium salt in the presence of sodium 
nitrite (NaNO2) and H2SO4 (Scheme 80). Subsequent quenching of the diazonium salt with potassium 
iodide afforded the iodo compound 131 in a moderate yield of 60%.  
 
Scheme 80 
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The notable absence of the amine proton signals in the 1H NMR spectrum of 131 gave testimony to the 
conversion of 33 to the corresponding iodo-compound 131. A survey of the literature revealed that the 
carbon signal for the aromatic carbon directly attached to the iodine on very similar systems is often 
located between 79 and 82 ppm.262-264 As a result, we were confident that the signal observed at 80.86 
ppm in the 13C NMR spectrum for 131 could be attributed to the iodo-bound carbon. Finally, the mass 
obtained by HRMS analysis coincided well with the calculated mass for 131.  
 
5.2.2. Attempted synthesis of the acylated compound 132  
As we were confident that the iodo-compound 131 had been successfully synthesized, we could attempt 
the conversion to the desired ketone 132 by way of lithium-halogen exchange with n-BuLi and subsequent 
quenching with the Weinreb amide 139 (Scheme 81).  
 
Scheme 81 
To this end, freshly titrated n-BuLi was added to 131 in dry THF at -78 ˚C. A notable colour change from 
yellow to red implied that lithium-halogen exchange had occurred and 139 was introduced into the 
reaction. The reaction was closely monitored by TLC which revealed the formation of two products. The 
reaction was subsequently quenched and the two products were isolated and purified by column 
chromatography. Unfortunately, analysis by 1H and 13C NMR spectroscopy indicated that neither product 
was the desired acylated product 132 as no signals attributed to the ketone were observed.  
For the one product, only an additional aromatic proton signal was observed in the 1H NMR spectrum. 
This observation, in addition to the absence of the CAr-I signal in the 13C NMR spectrum, indicated that 
although lithium-halogen exchange had occurred, the lithiated product had been quenched to afford 140 
(Scheme 82). 
In the 1H NMR spectrum of the second product, four additional aliphatic signals were observed indicative 
that a butyl group had been added onto the aromatic ring. These additional signals included two triplets 
at 2.73 and 0.92 ppm which integrated for two and three protons respectively and two multiplets at 1.60 
and 1.37 ppm both integrating for two protons. Moreover, the multiplicity observed for the aromatic 
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protons in the 1H NMR spectrum of this product suggested that the butyl group had been introduced at 
positions para or ortho to the phenol as indicated by compounds 141 and 142 in Scheme 82. A doublet of 
doublets at 7.79 ppm which could be attributed to the proton at position 6 on 141 or 4 on 142 had coupling 
constants of 8.2 Hz and 2.1 Hz. This proton was clearly partnered with a small doublet at 7.75 ppm with a 
coupling constant of 2.1 Hz which could be attributed to the proton at position 2. Finally, a doublet with 
a coupling constant of 8.2 Hz and no observable long-range coupling was observed at 7.27 ppm which 
could be attributed to the proton at position 5 on 141 and 142. 
 
Scheme 82 
When we attempted the reaction for a second time, monitoring the reaction by TLC prior to the addition 
of the Weinreb amide, revealed that the by-products isolated previously had already formed.  
As a result, we decided to change tactic and carry out the acylation by way of a transmetallation reaction 
with isopropylmagnesium chloride to form the aryl Grignard reagent in situ and subsequently quench with 
139 (Scheme 83). Unfortunately, under these conditions no reaction occurred. 
 
Scheme 83 
At this point, we considered the possibility that the nitro-group might be incompatible with the 
organometallic reagents introduced in Scheme 81 and Scheme 83. In fact, in validation of this concern 
while surveying the literature we came across papers by Bartoli et al. which describe the 1,4 or 1,6-
conjugate addition of alkyl magnesium halides onto nitroarenes, a phenomenon which later led to the 
identification of the Bartoli indole synthesis.265-267 A generic representation of the conjugate addition of 
Grignard reagents onto nitroarenes is given in Scheme 84. According to Bartoli this reaction proceeds 
through two steps. The first involves the formation of nitronate compounds 144 and 145 from the 1,4 and 
1,6 conjugate addition of an akyl magnesium halide (RMgX) onto nitroarene 143. Subsequent 
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decomposition of 144 and 145 then leads to the formation of products 146 and 147.265 Although this 
reaction is specific to the conjugate addition of RMgX onto nitroarenes we envisaged that, with regards 
to the reaction of 131 with n-BuLi, that a similar phenomenon had occurred leading to the unexpected 
formation of butylated compound 141 or 142 (Scheme 82). 
 
Scheme 84 
In an attempt to circumvent the issue of possible interference from the nitro group, we decided to reduce 
the nitro to the corresponding amine prior to acylation using the reaction conditions reported in Scheme 
81. To this end 131 was exposed to ultrasonic irradiation in the presence of SnCl2.2H2O (Scheme 85). The 
reaction was monitored closely by TLC and after two hours the reaction appeared to have gone to 
completion, affording only a single product. 
 
Scheme 85 
At first glance, a broad singlet at 3.60 ppm in the 1H NMR spectrum which integrated for two protons 
implied that the reduction of the nitro group had been successful. However, analysis of the aromatic 
region in the 1H NMR spectrum revealed an additional proton than would have been expected for 148. 
This observation in conjunction with the absence of a carbon signal around 80 ppm in the 13C NMR 
spectrum indicated that, although the reduction of the nitro had been successful, the iodine had been 
removed to afford the product 149 (Scheme 86). As this is a known compound we were able to confirm 
this by comparing our spectroscopic data with the data reported in the literature.268 
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Nevertheless, although we were unable to synthesize the desired compound 148 with the iodine in place, 
we desired to press on with 149 and direct ortho acylation by introducing a Boc protecting group onto the 
amine. We understood that, under these circumstances, we could end up with competitive acylation at 
the ortho and para positions relative to the phenol. However, we reasoned that this route could provide 
a means to determine whether the acylation would occur without the nitro present and that we could 
optimize regioselectivity at a later stage. 
The installation of the Boc protecting group onto the amine 149 was carried out readily in the presence 
of DMAP affording 150 in a high yield of 90% (Scheme 87). In the 1H NMR spectrum of 150, the presence 
of a singlet integrating for nine protons at 1.36 ppm and a broad singlet integrating for one proton at 
10.96 ppm could be attributed to the introduction of only a single Boc group onto the amine.  
 
Scheme 87 
With 150 in hand we could attempt to carry out the acylation using conditions reported in Scheme 81. 
Only, in this instance we expected to obtain a mixture of products, namely 151 and 152 as shown in 
Scheme 88. When monitored by TLC, although the reaction had not gone to completion, only a single 
product appeared to have formed. However, when this product was analysed by 1H and 13C NMR 
spectroscopy we realized that the Boc group had simply been removed and that we had regenerated the 
unprotected amine 149. 
Stellenbosch University  https://scholar.sun.ac.za
Chapter 5: Lead Optimization Through the Introduction of Additional Electrostatic Interactions within 






5.3. Changing tactics: The introduction of an acyl group onto the aryl ring through the 
oxidation of an activated toluene 
While struggling to introduce the acyl group onto our aryl ring using organometallic methods we decided 
to turn our attention to alternative methods, namely the oxidation of an activated toluene to the 
corresponding aldehyde or carboxylic acid. A review of the literature revealed a vast number of methods 
whereby this could be achieved when the aromatic methyl group was situated ortho to a nitro group.269-
273  
For our purposes we envisaged starting from commercially available 2-methyl-3-nitrophenol 153 (Scheme 
89). After the introduction of a suitable protecting group, we decided that we would attempt the oxidation 
of 154 to the corresponding aldehyde 155 and the carboxylic acid 156 as we knew that both functional 
groups could be directly and readily converted into the corresponding ester 157.274-275 We envisaged that, 
following the reduction of the nitro group to the corresponding amine 158, the ester could be reacted 
with an excess of methylmagnesium bromide to afford the desired tertiary alcohol precursor 159, which 
could then undergo a ring-closing reaction with CDI providing the benzoxazin-2-one precursor 160.  
 
Scheme 89 
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5.3.1. Oxidation of the activated toluene to the corresponding aldehyde 167 
For the oxidation of 153 to the corresponding aldehyde 155 we decided to employ conditions reported 
by Caron and Vazquez in 2003.270 Herein, Caron and Vazquez described the preparation of o-
nitrobenzaldehyde 164 from the activated aryl methyl group 161 by way of a one-pot reaction which 
involved the formation of an enamine intermediate 163 using N,N-dimethylformamide dimethyl acetal 
(DMF.DMA) 162 and subsequent oxidative cleavage to the aldehyde 164 with sodium periodate (NaIO4) 
(Scheme 90). This procedure came about as a slight modification of a two-step process originally reported 
by Vetelino and Coe from Pfizer in 1994.269 Interestingly, in the original 1994 publication it was reported 
that, although the oxidative cleavage of an alkene to the aldehyde typically requires catalytic amounts of 
osmium tetroxide to hinder over-oxidation to the carboxylic acid, in this instance the utilization of osmium 
tetroxide was found to be superfluous.269, 276  
 
Scheme 90 
In Scheme 89 it is shown that the phenol of 153 required the introduction of a suitable protecting group 
prior to carrying out the oxidation of the activated methyl to the aldehyde. This was to ensure that 162, 
which can also act as a methylating agent, would not be competitively targeted by the phenol.277 To this 
end we decided to introduce a benzyl protecting group on the phenol of 153. This was readily achieved 
with benzyl bromide and K2CO3 to afford 165 (Scheme 91). 
 
Scheme 91 
The identification of five additional aromatic proton signals in the 1H NMR spectrum of 165, in addition to 
a singlet at 5.11 ppm which integrated for two protons, were indicative that the benzyl protecting group 
had been successfully installed. This observation was mirrored by the identification of four additional 
aromatic and one additional aliphatic carbon signal in the 13C NMR spectrum of 165.  
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With 165 in hand we could attempt the conversion of the activated methyl into the corresponding 
aldehyde using the one-pot reaction conditions described by Caron and Vazquez.270 To this end, 165 and 
162 in DMF were heated at 135 ˚C for 18 hours, after which the reaction was monitored by TLC to reveal 
that all starting material had been consumed and a single product, assumed to be the enamine 166, had 
formed. The reaction was subsequently cooled and NaIO4 was added. After an additional 18 hours, the 
product assumed to be 166 had disappeared and two new products had formed. However, following 
workup and purification by column chromatography we were only able to isolate a single product. 
Fortunately, analysis of the 1H and 13C spectroscopic data obtained for the uknown product, revealed that 
we had in fact isolated the desired aldehyde 167, albeit in a very poor yield of 15% (Scheme 92). 
 
Scheme 92 
The most distinguishing feature observed in the 1H NMR spectrum of 167 was a highly deshielded singlet 
at 10.43 ppm which could be attributed to the proton of the aldehyde. In the 13C NMR spectrum of 167 a 
carbon signal located at 187.7 ppm could be attributed to the aldehyde carbonyl carbon. Moreover, this 
spectroscopic data was compared to the spectroscopic data available in the literature and was found to 
compare favourably, confirming that 167 had been synthesized.278   
Although we were able to obtain the desired aldehyde 167 using the conditions reported by Caron and 
Vazquez, the yield was unfortunately very low and, therefore, we were not able to isolate enough material 
to proceed to the subsequent esterification step. As a result, we decided to attempt oxidation of the 
activated methyl of 165 to the corresponding carboxylic acid. 
 
5.3.2. Oxidation of the activated toluene to the corresponding carboxylic acid 169 
For the oxidation of the activated methyl to the corresponding carboxylic acid we opted to employ the 
procedure reported by Yoakim et al. which described the use of potassium permanganate (KMnO4) as the 
oxidizing agent under refluxing conditions.279 Once again it was imperative that a protecting group be 
introduced onto the phenol 153 to avoid oxidation of the phenol to the corresponding quinone. However, 
in this instance, we decided not to utilize a benzyl protecting group for fear that the benzylic position 
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would also be susceptible to oxidation under the conditions reported.280 Instead we decided to employ a 
methyl group as the ‘protecting group’ for the phenol 153. 
For the methylation reaction 153 was treated with methyl iodide in the presence of sodium hydride. This 
reaction proceeded readily to afford 168 in a high yield of 92% after 18 hours (Scheme 93). 
 
Scheme 93 
From the spectroscopic data of 168, a singlet which integrated for three protons at 3.89 ppm in the 1H 
NMR spectrum and carbon signal at 56.4 ppm in the 13C NMR spectrum provided the clearest evidence 
that the methylation of phenol 153 had occurred successfully.  
Assured that competitive oxidation of the phenol to the quinone would not occur, we could now attempt 
the desired oxidation of the activated methyl 168 to the carboxylic acid 169 using the conditions reported 
by Yoakim et al. (Scheme 94).279 To this end, an excess of KMnO4 was added to 168 in t-BuOH and H2O 
and the reaction was heated under reflux. However, after 18 hours TLC indicated that the reaction had 
not gone to completion. Nevertheless, the reaction was cooled in preparation for workup. Under the 
impression that 169 was the only product formed under these conditions we reasoned that 168 and 169 
could be separated and isolated as pure product by simple acid-base extraction techniques. As expected, 
we were able to recover unreacted 168 and isolate the desired carboxylic acid 169 without the need for 
further purification. Unfortunately, we were only able to obtain 169 in a low yield of 34%. 
 
Scheme 94 
In the 1H NMR spectrum of 169 the absence of the singlet belonging to the aromatic methyl group was 
the most notable indication that oxidation of the methyl group had occurred. In the 13C NMR spectrum of 
169 the absence of the aromatic methyl carbon signal in conjunction with the appearance of an additional 
signal at 165.0 ppm provided further testimony to the success of the oxidation reaction. Finally, HRMS 
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provided a mass of 198.03974 amu which coincided well with the calculated mass of 169 which was 
198.03970 amu.  
Of the two oxidation reactions carried out, the oxidation with KMnO4 to the carboxylic acid was only 
marginally superior to the oxidation with DMF-DMA and NaIO4 to the corresponding aldehyde. 
Nevertheless, despite the low yields, we were able to obtain enough of the carboxylic acid 169 to proceed 
to the subsequent esterification step in the synthetic route shown in Scheme 89. 
 
5.3.3. Synthesis of methyl 2-methoxy-6-nitrobenzoate (170) 
For the esterification reaction we envisaged that methyl ester 170 could be obtained by a simple 
methylation of the carboxylic acid 169. To this end, 169 was treated with methyl iodide in the presence 
of K2CO3 (Scheme 95). After 2 hours at room temperature TLC indicated that the reaction had reached 
completion. Subsequent workup and purification by column chromatography afforded the methyl ester 
170 in an excellent yield of 96%. 
 
Scheme 95 
The presence of two singlets each integrating for three protons at 3.95 and 3.90 ppm in the 1H NMR 
spectrum of 170 could be attributed to the presence of the methoxy group and methyl ester. Similarly, 
two aliphatic carbon signals observed at 56.9 and 53.3 ppm in the 13C NMR spectrum of 170 attested to 
the presence of two methyl groups on the compound. These observations, in addition to the presence of 
the ester carbonyl carbon signal at 166 ppm was indicative that the esterification reaction had occurred 
successfully. 
 
5.3.4. Synthesis of methyl 2-amino-6-methoxybenzoate (171) 
With the methyl ester 170 in hand we could endeavour to reduce the nitro group to the corresponding 
amine 171 (Scheme 96). The decision to reduce the nitro group prior to performing a Grignard reaction 
onto the ester was based on our desire to avoid complications that may arise due to the phenomena 
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reported by  Bartoli et al. which we described in section 5.2.2. For the reduction compound 170 was taken 
up in ethanol and treated with palladium on carbon under an atmosphere of hydrogen. After 18 hours the 
reaction was filtered over Celite and purified by column chromatography to afford the reduced product 
171 in 93% yield. 
 
Scheme 96 
In the 1H NMR spectrum of 171 the presence of a broad singlet at 4.93 ppm provided the clearest 
indication that the reduction of the nitro group had transpired. Furthermore the presence of two singlets 
at 3.87 and 3.79 ppm, each integrating for three protons testified to the fact that the ester had remained 
unaffected. This was corroborated by the presence of two aliphatic carbon signals at 56.1 and 51.8 ppm 
in the 13C NMR spectrum and a signal at 168.6 ppm which could be attributed to the ester carbonyl carbon. 
 
5.3.5. Synthesis of 2-(2-amino-6-methoxyphenyl)propan-2-ol (172) by way of a Grignard 
reaction with methylmagnesium bromide 
For the Grignard reaction between 171 and methylmagnesium bromide it was imperative that a large 
excess of the Grignard reagent be introduced into the reaction to ensure double addition of MeMgBr onto 
the ester to afford the desired tertiary alcohol 172. This was due to the presence of the amine and the 
fact that Grignard reagents can competitively act as a strong base. To this end, 171 was treated with five 
equivalents of MeMgBr in THF at 0 °C (Scheme 97). The reaction was closely monitored by TLC and 
revealed that, after 4 hours, the ester 171 had been completely consumed. Subsequent quenching with 
H2O and extraction afforded 172 in 91% yield without the need for further purification. 
 
Scheme 97 
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The presence of a singlet at 1.71 ppm which integrated for six protons in the 1H NMR spectrum of 172 
offered the first indication that a double addition of the Grignard reagent MeMgBr onto the ester had 
occurred successfully. This was substantiated by the presence of an additional aliphatic carbon signal in 
the 13C NMR spectrum of 172 and the absence of the carbon signal attributed to the ester carbonyl carbon. 
Finally, HRMS provided a mass of 182.11766 amu which coincided with the calculated mass of 182.11756 
amu. 
 
5.3.6. Synthesis of 5-methoxy-4,4-dimethyl-1,4-dihydro-2H-benzo[d][1,3]oxazin-2-one (173) 
For the synthesis of 173 we envisaged that we could employ the same ring-closing reaction conditions 
with CDI that were used for the formation of our first and second-generation benzimidazolone 
compounds described in Chapters 2 and 3. Therefore, treatment of 172 with CDI in MeCN resulted in the 
formation of benzoxazin-2-one compound 173 after 30 minutes at room temperature (Scheme 98). 
 
Scheme 98 
In the 1H NMR spectrum of 173 the presence of a highly deshielded singlet at 9.47 ppm integrating for 
one proton and the absence of the broad singlet attributed to the amine gave testimony to the successful 
formation of 173. The presence of an additional carbon signal in the aromatic region of the 13C NMR 
spectrum of 173 and HRMS which provided a mass of 208.09682 amu, which was in accord with the 
calculated mass, provided further validation that 173 had been formed. 
 
5.3.7. Synthesis of 5-hydroxy-4,4-dimethyl-1,4-dihydro-2H-benzo[d][1,3]oxazin-2-one (174) 
In the original proposed synthetic route for target compound 130 (Scheme 79) it was stated that following 
the formation of the  benzoxazin-2-one precursor 135 we would introduce a SEM protecting group onto 
the carbamate in preparation for the removal of the phenol protecting group and subsequent coupling to 
3-chloro-5-fluorobenzonitrile (51).  However, with the methoxy as the ‘protecting group’ for compound 
173 we were concerned that a SEM protecting group would not survive a demethylation reaction requiring 
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the use of boron tribromide. We doubted that any other N-protecting group would survive these 
conditions and, as a result, we realized that we would have to attempt the SNAr reaction without any 
protecting group on the carbamate. However empirical pKa calculations using Epik, a feature of 
Schrödinger, on the demethylated benzoxazin2-one precursor 174 (Scheme 99) predicted that the phenol 
was slightly more acidic than the carbamate. Therefore, we hoped that by controlling the amount of 51 
and base introduced into the SNAr reaction that we might be able to selectively couple 51 to the phenol 
without additional coupling to the carbamate. 
For the demethylation reaction compound 173 was treated with boron tribromide at 0 °C (Scheme 99). 
The reaction was monitored closely by TLC and after 4 hours it was observed that the starting material 
had been consumed. Unfortunately, when we attempted to purify the resulting product by column 
chromatography we observed that the product was degrading on silica gel. To overcome this problem, in 
a second experiment we decided not to purify the product following the workup. Fortunately, spectral 
analysis revealed that further purification was unnecessary and that we had successfully synthesized and 
isolated pure demethylated product 174 in 90% yield. 
 
Scheme 99 
Two highly deshielded singlets, each integrating for one proton, were observed at 9.98 and 9.85 ppm in 
the 1H NMR spectrum of 174. These singlets we attributed to the carbamate proton and the deprotected 
phenolic proton. This observation in conjunction with the absence of the methoxy proton signal in the 1H 
and 13C NMR spectra of 174 indicated that the methoxy group had been successfully removed with BBr3. 
 
5.3.8. The final step towards the synthesis of 3-chloro-5-((4,4-dimethyl-2-oxo-1,4-dihydro-
2H-benzo[d](1,3)oxazin-5-yl)oxy)benzonitrile (130) 
Having successfully demethylated compound 173 to afford the precursor 174 we could finally endeavour 
to carry out the final SNAr step towards the synthesis of target compound 130. To this end, 174 was treated 
with a single equivalent of 51 and Cs2CO3 and the reaction was heated to 100 °C. Nevertheless, monitoring 
the reaction by TLC revealed the formation of multiple products, none of which appeared to be the desired 
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product 130. We decided to re-attempt the SNAr reaction at room temperature but observed no reaction. 
We then tentatively raised the temperature to 70 °C and monitored the reaction closely. To our delight, 
after several hours we observed the formation of only a single product. Spectral analysis of the resulting 
product, following workup and attempted purification by column chromatography, revealed that we had 
successfully synthesized the final product 130, albeit impure. However, subsequent recrystallization from 
ethanol afforded pure 130 in a 13% yield (Scheme 100). Although the yield obtained was disappointingly 




In the 1H NMR spectrum of 130 the absence of a highly deshielded proton which we attributed to the 
phenol and the presence of three additional aromatic protons indicated that an SNAr reaction with 51 had 
transpired. This observation was further substantiated by the presence of seven additional carbon signals 
in the 13C NMR spectrum and analysis of HRMS which gave a mass of 329.06869 amu which concurred 
with the calculated mass of 329.06875 amu. Although all the spectral data confirmed that an SNAr reaction 
had occurred we still had to verify that 51 had been coupled to the phenol and not the carbamate. To this 
end, we decided to obtain a crystal structure of 130. To our delight, X-ray crystallography confirmed that 
the SNAr reaction had occurred between 51 and the phenol of 174 to afford our desired proof-of-concept 
compound 130 (Figure 53). 
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Figure 53 Crystal structure obtained for compound 130 (left) with a diagram of 130 rotated and numbered to correlate with the 
crystal structure for clarity (right). 
 
5.4. Evaluation of compound 130 in a whole-cell phenotypic assay 
In the evaluation of compound 130 we were overjoyed to discover that our proof-of-concept compound 
was not only slightly more potent than our lead compound 50 with an IC50 value of 17 nM but also 
exhibited a significantly higher selectivity index (> 4000) (Figure 54). Although we had not significantly 
improved upon the potency of compound 50, we believed that this might be achieved by derivatizing the 
dimethyl substituents located at position 4 on the benzoxazin-2-one scaffold. Unfortunately, we have not 
yet been able to evaluate 130 against a panel of resistant strains; however, we were encouraged by the 
results obtained against the wild-type virus which we believed would open the door to the generation of 
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5.5. Metabolic stability testing of compound 130 against human and mouse liver 
microsomes 
Having established compound 130 as another lead compound, we were curious as to how this compound 
would fare in mouse and human liver microsome assays. To this end, as with compound 50, compound 
130 was incubated with mouse and human liver microsomes and then analysed by LCMS over 5-minute 
intervals over a total of 30 minutes. We were pleased to see that compound 130 was highly stable in both 
liver microsome assays, which bodes well for this compound’s performance in vivo (Table 6).  
 % Remaining after 30 minutes 
 Mouse liver microsomes Human liver microsomes 
Compound 130 94 90 
Verapamil (positive control) - 7.0 
Diphenhydramine (positive control) 51 - 
Table 6 
 
5.6. Concluding remarks 
In conclusion, guided by molecular modelling we employed a molecular hybridization approach between 
our most potent second-generation benzimidazolone compound 50 and efavirenz to generate a new 
hybrid compound capable of achieving double hydrogen bonding interactions with the backbone of 
Lys101. By re-introducing the double hydrogen bond originally expressed by the indole compounds 
described in Chapter2, we had hoped to improve upon the potency of compound 50 against the wild-type 
virus and a variety of resistant strains. To this end, we synthesized the benzoxazin-2-one compound 130. 
Evaluation of 130 in a whole-cell phenotypic assay revealed that 130 was an equally potent inhibitor of 
RT, compared to 50, but with a much-improved selectivity index.  
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Chapter 6: Conclusion 
 
At the start of this project, we endeavoured to tackle the lability issues faced by a series of lead indole-
based compounds previously synthesized within our research group. These indole-based compounds (1), 
although potent inhibitors of HIV RT, were not suitable for drug candidacy. This was due to the presence 
of an acid-labile methoxy group situated at the 3-position on the indole scaffold and an ester at the 2-
position which, inevitably, would be susceptible to hydrolysis by cellular esterases (Figure 55). To address 
these issues, we employed a scaffold-hopping approach with the aid of molecular modelling to replace 
the indole scaffold with the bioisosteric benzimidazolone scaffold (11) (Figure 55). With this approach we 
lost the hydrogen bond acceptor in the form of the ester carbonyl and, therefore, the additional hydrogen 
bond to the backbone of Lys101. However, we envisaged that the urea carbonyl on the benzimidazolone 
scaffold would be able to compensate for the loss of this interaction by strengthening the hydrogen 
bonding capability of the urea NH. 
 
Figure 55 
In the evaluation of 11 in a whole cell HIV phenotypic assay we found that 11 was an equally potent 
inhibitor of HIV RT when compared with the lead indole compound 1, an observation which validated our 
hypothesis that the carbonyl directly adjacent to the NH would compensate for the loss of the additional 
hydrogen bond with the backbone of Lys101. However, compound 11 was found to be a poor inhibitor 
against the common K103N and Y181C resistant strains of HIV. The susceptibility of 11 to the Y181C 
mutant we attributed to the fact that the binding of this compound to the NNIBP of RT relies heavily on 
π-interactions between the aryl group, situated at the N1 position on the benzimidazolone scaffold, and 
Tyr181. In an effort to overcome the susceptibility of 11 to the Y181C resistant strain we designed a series 
of second-generation benzimidazolone compounds whereby the aryl group at the N1 position was 
transposed to the 7-position on the benzimidazolone scaffold (Figure 56). This eliminated the dependency 
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on π-interactions with the mutable amino acid residue Tyr181, while introducing π-interactions with 
Tyr188 and conserved residue Trp229. 
 
Figure 56 
The first compounds synthesized in this series, compounds 21 and 22, were unfortunately found to be 
poor inhibitors of HIV RT with micromolar activity. However, by introducing a chloride and nitrile 
substituent onto the scaffold, we were able to significantly improve the potency from 300 nM for 
compound 22 to 26 nM for compound 50 (Figure 56). Furthermore, when evaluated against a panel of 
clinically relevant resistant strains of HIV, compound 50 was found to exhibit a superior resistance profile 
compared to the first-generation compound 11. Not only was 50 able to maintain potency against the 
Y181C resistant strain, it was also found to maintain potency against the Y188C resistant strain and the 
double mutant K103N/Y181C which renders licensed NNRTIs nevirapine and efavirenz ineffective. 
Moreover, against the most prevalent and problematic K103N resistant strain, compound 50 exhibited 
only a 4-fold drop in potency. 
Having obtained a potent lead compound for our second-generation series of compounds we embarked 
upon the synthesis of a small library of compounds by derivatizing the alkyl group at position N1 and the 
aryl group at position 7. Although some of these compounds were found to be similarly potent inhibitors 
of HIV RT, compound 50 maintained superior potency against wild-type RT and, more importantly, against 
resistant strains of HIV! 
 In an attempt to further optimize the potency of lead compound 50 we next endeavoured to introduce 
additional electrostatic interactions between 50 and the NNIBP. Two different approaches were under-
taken to achieve this.  
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The first approach focused on targeting a lysine residue (Lys223) situated at the top of a narrow 
hydrophobic chimney, formed by amino acid residues Trp229, Tyr188 and Phe227, towards the back of 
the NNIBP. We envisaged that, by introducing a hydrogen bond acceptor by way of a suitably long 
substituent on the “upper” aryl ring of 50, we would be able to achieve an additional hydrogen bond with 
this residue. To this end we designed, with the aid of molecular modelling, the cyanoacetylene-containing 
compound 90 (Figure 57). However, during the synthesis of this compound it was discovered that the 
cyanoacetylene substituent, being a good Michael acceptor, was a significant liability. As a result, we 
changed tactics and synthesized compound 127 which possessed the less reactive, but bioisosteric, 
cyanovinyl substituent. Evaluation of 127 in a phenotypic assay revealed that we had synthesized another 
compound with low nanomolar activity. However, using this design approach, we were unable to meet 
our aim in improving upon the potency of lead compound 50.  
 
Figure 57 
For the second approach to improve upon the potency of lead compound 50, we focused on modifying 
our structure to re-introduce the double hydrogen bond, exhibited by the indole compounds, to the 
backbone of Lys101. To this end, compound 130 was designed using a molecular hybridization approach 
between our compound 50 and licensed NNRTI efavirenz (Figure 58). This novel hybrid compound would 
be able to achieve additional hydrogen bonding to the backbone of Lys101 due to the repositioning of the 
carbonyl on the benzoxazin-2-one scaffold of efavirenz, while maintaining the important π-stacking 
interactions with conserved residue Trp229 through the chloro-cyano-substituted aryl ring of 50. As this 
was a proof-of-concept compound, the dimethyl substituent at position 4 on the scaffold was introduced 
in order to reduce synthetic complexity. Evaluation of 130 in a HIV phenotypic assay revealed that 130 
was an equally potent inhibitor when compared to lead compound 50. Moreover, compound 130 
exhibited a significantly higher selectivity index. Unfortunately, we have not yet been able to evaluate this 
compound against a panel of resistant strains of HIV. As our first simplified proof-of-concept compound 
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was a potent inhibitor of HIV RT we envisaged that, through optimization of the substituents at position 
4 on this scaffold with the aid of molecular modelling, we would be able to further improve upon the 
potency of these compounds.  
 
Figure 58 
In conclusion, through various stages of optimization, we have successfully designed and synthesized 
three generations of potent (low nanomolar) inhibitors of HIV RT. Moreover, as compounds 50 and 130 
fared well against human and mouse liver microsomes, both scaffolds are promising for drug candidacy.  
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Chapter 7: Future Work 
 
7.1. Optimizing the potency of compound 130 
Future endeavours in this project will focus on optimizing the activity of the benzoxazin-2-one compound 
130 against wild-type and resistant strains of HIV. This we envisage, could be achieved by derivatizing the 
alkyl substituents located at position 4 on the scaffold and by introducing a halogen at position 6.  
 
7.1.1. The 4-position: Exploring various alkyl substituents to occupy the Val179 pocket 
Occupation of the small hydrophobic pocket in the vicinity of Val179 has been shown to have a significant 
influence on the activity of a compound against HIV RT.147 As a result, we will explore various alkyl 
substituents at position 4 on the benzoxazin-2-one scaffold to occupy the Val179 pocket. Preliminary 
molecular modelling has identified a few promising substituents which are represented by compounds 
175 – 177 (Figure 59). Docking studies have shown that these substituents are able to occupy the small 
Val179 pocket without altering the binding orientation of the compound within the NNIBP, and binding 
energy calculations indicate that these compounds are indeed more favourable than our first benzoxazin-
2-one lead compound 130. 
 
Figure 59 
However, of these compounds, 176 and 177 cannot be synthesized using the same synthetic procedure 
described for compound 130 in chapter 5. Instead, we would have to revisit our original strategy whereby 
we attempted to acylate an aryl halide using transmetallation reaction conditions. Although in our hands 
acylation of our 2-iodo-nitrobenze analogue 131 had been unsuccessful, it recently came to our attention 
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that this could be achieved if we employ phenylmagnesium chloride as our magnesium source (Figure 
60).281-282  
 
Figure 60 General depiction of the proposed strategy to acylate 2-iodo-nitrobenzene 131 using phenylmagnesium chloride as 
the magnesium source to obtain the desired tertiary alcohol 178. 
 
7.1.2. The 6-position: Introduction of a halogen 
Generally, inhibitors that possess a suitable halogen to occupy a small hydrophobic pocket at the back of 
the non-nucleoside inhibitor binding pocket (NNIBP) are found to exhibit improved potency.209 It has been 
proposed that the link between improved potency and the introduction of a halogen at this position is a 
result of halogen bonding between the ligand and the NNIBP.168 We envisaged that this trend could be 
translated over to our hybrid compounds by introducing a halogen, such as a fluorine, at position 6 (179, 
Figure 61). In chapter 3 it was mentioned that, according to docking studies, the introduction of chlorine 
appeared to have no significant effect on the binding energy of our benzimidazolone compounds. A similar 
observation was made for our benzoxazin-2-one compound 130. However, preliminary docking studies 
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Fortunately, a survey of the literature has revealed that the synthesis of compound 179 can be achieved 
through late stage functionalization of 130 through electrophilic fluorination of 130 with selectfluor 
(Figure 62).209  
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Chapter 8: Experimental 
 
8.1. General procedures pertaining to synthesis and characterization. 
 
8.1.1. Purification of Reagents and Solvents 
All chemicals used in the following experiments were purchased from Sigma Aldrich or Apollo Scientific. 
Solvents used for chromatographic purposes were distilled by means of conventional distillation 
procedures. All anhydrous solvents used for reaction purposes were dried over the appropriate drying 
agents and then distilled under an atmosphere of nitrogen or obtained from anhydrous septum-sealed 
DriSolv® bottles. Tetrahydrofuran (THF) was distilled over sodium metal, using benzophenone as an 
indicator. Dichloromethane and acetonitrile were distilled from calcium hydride. Other solvents were 
purchased with a ≥98% purity grade from Sigma Aldrich and then dried on activated 3Å molecular sieves.  
 
8.1.2. Chromatography 
Thin layer chromatography was performed using Merck silica gel 60 F254 coated on aluminium sheets. 
Visualization was performed with a UV lamp or using common stains such as p-anisaldehyde, ninhydrin 
(NIN) or a potassium permanganate (KMnO4) solution followed by gentle heating. Column 
chromatography was performed using a Teledyne Isco Combiflash® Rf+ automated column machine with 
Redisep® silica gel-packed columns or performed manually using Merck silica gel 60 (particle size 0.040-
0.063 mm) with one of or combinations of hexane, EtOAc, DCM or MeOH as the mobile phase. 
 
8.1.3. Spectroscopic and physical data 
NMR spectra (1H, 13C) were recorded on a 300 MHz Varian VNMRS (75 MHz for 13C), a 400 MHz Varian 
INOVA (101 MHz for 13C), a 400 MHz Varian VNMRS, a 500 MHz Varian INOVA (126 MHz for 13C) or a 600 
MHz Varian INOVA (150 MHz for 13C). Chemical shifts (δ) are reported in ppm and J - values are given in 
Hz. Multiplicities are reported as a singlet (s), doublet (d), triplet (t), quartet (q), multiplet (m) or doublet 
of doublet (dd). Chemical shifts were recorded using the residual solvent peak or external reference. All 
spectra were obtained at 25 °C unless otherwise reported. Spectroscopic data were processed using 
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MestReNova v6.0.2. Mass spectrometry was performed by the Central Analytical Facilities (CAF) of 
Stellenbosch University on a Waters SYNAPT G2 instrument, using a diode array as the detection method, 
or by the Emory University Mass Spectroscopy Center. Infrared spectra were recorded on a Thermo 
Nicolet Nexus 470 by means of Attenuated Total Reflectance (ATR) mode. Melting points were obtained 
using a Gallenkamp Melting Point Apparatus. Melting points are reported as an average. Purity was 
determined by LC-MS analysis performed on an Agilent 1200 HPLC equipped with a 6120 Quadrupole 
mass spectrometer (ESI-API) using mixtures of HPLC grade MeOH/H2O (spiked with 0.1% formic acid). The 
purity of all final compounds was found to be >95%. 
 
8.1.4. Other general procedures 
The molarity of n-BuLi was determined by titration with N-benzylbenzamide, as described in the 
literature.283 All reactions requiring inert conditions were carried out under a positive atmosphere of 
argon. All glassware was flame-dried while under vacuum or oven dried overnight before purging with 
argon. Standard Schlenk techniques were employed when necessary. Solvents were removed using a 
rotary evaporator followed by the removal of trace amounts of solvent using a high vacuum pump at ca. 
0.08 mm Hg.  
 
8.2. General procedures pertaining to metabolic stability tests 
 
8.2.1. Human Liver Microsomes 
Pooled mixed gender human liver microsomes at a concentration of 20 mg/mL were purchased from 
XenoTech (Kansas City, KS). The vials of microsomes were stored at -80 °C and thawed on ice before each 
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8.2.2. Mouse Liver Microsomes 
Pooled CD-1 mouse liver microsomes at a concentration of 20 mg/mL were purchased from XenoTech 
(Kansas City, KS). The vials of microsomes were stored at -80 °C and thawed on ice before each 
experiment. The microsomes were diluted to 1 mg/mL with 100 mM potassium phosphate buffer (pH 7.4).  
 
8.2.3. Experimental Conditions 
Test compounds were weighed and dissolved in 100% acetonitrile to make 2 mM stock solutions. 
Verapamil (human, Sigma Aldrich) and diphenhydramine (mouse, Sigma Aldrich) served as positive 
controls and were dissolved in 100% acetonitrile to make 2 mM stock solutions. The 2 mM stock solution 
of test and control compounds were further diluted in sodium phosphate buffer (100 mM, pH 7.4) to 50 
µM to ensure the acetonitrile content was < 0.2%.  
 
The liver microsome assay was prepared in a 1.5 mL Eppendorf tube (Fisher Scientific) with a final volume 
of 1100 µL. Each reaction contained sodium phosphate buffer, liver microsomes (1 mg/mL), and test 
compound resulting in a final concentration of 3 µM. Following a 5 min preincubation of drug and 
microsomes in a 37 °C shaking incubator, the reaction was initiated with NADPH (110 µL). Aliquots (100 
µL) were removed in duplicate at 0, 5, 10, 15, and 30 min time intervals and quenched in cold acetonitrile 
(200 µL). The aliquots were centrifuged at 12,000 g for 5 min and the supernatant removed and placed in 
an LCMS vial. Positive controls were conducted at a final volume of 600 µL to give each time point in a 
singlet run. A no NADPH negative control with test and control compound was conducted in singlet (150 
µL) at the longest time point. Controls were processed and analysed like test compounds.  
 
8.2.4. LC/MS Analysis  
Analysis was performed on an Agilent Technologies LCMS system consisting of an Agilent 6120 quadrupole 
mass spectrometer equipped with an Agilent 1200 binary pump, degasser, and auto sampler (Santa Clara, 
CA). The analytical column used for analysis was an Ascentis column (5 cm x 2.1 mm, 2.7 μm particle size; 
Sigma Aldrich). The mobile phase for the HPLC was 25 mM ammonium formate buffer, pH 3.5 (A) and 
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acetonitrile (B). The samples were analysed using the following 8-minute method: A linear gradient from 
10% B to 95% B for 5 minutes, with a 3 min hold at 95%. An equilibration at 10% B for 5 min was conducted 
after each run. Sample injection volume was 15 µL and the flow rate was 0.35 µL/min. Single ion 
monitoring of the mass in negative mode was conducted for the samples at 312 and 327 m/z. Each time 
point was assessed on the LCMS and the area, based on the extracted ion in negative ion mode, was 
manually integrated. The relative percent remaining was calculated using: Relative % remaining = 
AreaTime/AreaTime=0 *100.  
  
Stellenbosch University  https://scholar.sun.ac.za
Chapter 8: Experimental 
145 
 
8.3. Experimental pertaining to Chapter 2 
 
8.3.1. Synthesis of (±)-1-(phenyl)propanol (17) 
Ethyl iodide (0.75 mL, 9.4 mmol) was added dropwise to a suspension of magnesium 
turnings (229 mg, 9.42 mmol) in Et2O (5 mL). Once all the magnesium turnings had been 
consumed, benzaldehyde (0.96 mL, 9.4 mmol) in Et2O (5 mL) was added to the mixture 
dropwise at 0 °C. The reaction was then carried out at room temperature for 2 hours after which the 
reaction was quenched with a 2M solution of HCl (20 mL) and extracted twice with Et2O (2 × 50 mL). The 
organic phase was washed with brine, dried over MgSO4 and concentrated in vacuo. The crude product 
was then purified by column chromatography (5% – 20% EtAOc/hexane) to yield the product 17 as a 
colourless oil (1.08 g, 7.90 mmol, 84%). 
Rf, 0.35 (20% EtOAc/Hexane) 1H NMR (300 MHz, CDCl3) δ 7.41 – 7.26 (m, 5H, ArH), 4.58 (t, J = 6.6 Hz, 1H, 
CH), 2.43 (s, 1H, OH), 1.92 – 1.68 (m, 2H, CH2), 0.94 (t, J = 7.4 Hz, 3H, CH3). 13C NMR (75 MHz, CDCl3) δ 
144.7, 128.4, 127.5, 126.1, 76.0, 31.9, 10.2. 
This spectroscopic data compares favourably with that in the literature.157  
 
8.3.2. Synthesis of (±)-(1-iodopropyl)benzene (14)158 
BF3·Et2O (0.70 mL, 5.7 mmol) and KI (949 mg, 5.72 mmol) were added to 17 (773 mg, 5.72 
mmol) in dioxane (10 mL) and the reaction was carried out at room temperature for 18 
hours. The reaction mixture was quenched with ice cold H2O (20 mL) and extracted twice 
with Et2O (2 × 50 mL). The organic phases were combined, washed with brine (100 mL), dried over MgSO4 
and then concentrated in vacuo. The product was then purified by column chromatography (5% 
EtOAc/hexane – 20% EtAOc/hexane) to yield 14 as a red oil (938 mg, 3.83 mmol, 67%). 
Rf, 0.68 (20% EtOAc/Hexane) 1H NMR (300 MHz, CDCl3) δ 7.42 – 7.19 (m, 5H, ArH), 5.04 (t, J = 7.6 Hz, 1H, 
CH), 2.44 – 2.25 (m, 1H, CH2), 2.15 – 1.98 (m, 1H, CH2), 0.96 (t, J = 7.2 Hz, 3H, CH3). 13C NMR (75 MHz, 
CDCl3) δ 144.1, 128.8, 128.0, 127.2, 36.7, 34.9, 14.9. 
This spectroscopic data is in accordance with that in the literature.159 
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8.3.3. Synthesis of (±)-5-chloro-2-nitro-N-(1-phenylpropyl)aniline (15) 
NaH (60% in mineral oil, 46 mg, 1.2 mmol) was added to 5-chloro-2-nitroaniline (13) 
(100 mg, 575 µmol) in THF (3 mL) at 0 °C. The reaction was carried out for 30 minutes 
before (1-iodopropyl)benzene (14) (169 mg, 690 µmol) was added. The reaction was 
then carried out at room temperature for 18 hours after which NH4Cl (50 mL) was added 
to quench the reaction mixture. The crude product was extracted twice with EtOAc (2 × 50 mL), the organic 
phases were then combined and washed with brine (100 mL), dried over MgSO4 and the solvent was 
removed in vacuo. Purification was carried out by column chromatography (5% – 20% EtOAc/hexane) to 
yield 15 as a yellow wax (147 mg, 506 µmol, 88%). 
Rf, 0.51 (20% EtOAc/Hexane) 1H NMR (400 MHz, CDCl3) δ 8.57 (d, J = 5.4 Hz, 1H, NH), 8.10 (d, J = 9.1 Hz, 
1H, ArH), 7.40 – 7.24 (m, 5H, ArH), 6.64 (d, J = 2.1 Hz, 1H, ArH), 6.55 (dd, J = 9.1, 2.1 Hz, 1H, ArH), 4.44 – 
4.34 (m, 1H, CH), 2.05 – 1.86 (m, 2H, CH2), 1.01 (t, J = 7.4 Hz, 3H, CH3). 13C NMR (101 MHz, CDCl3) δ 145.4, 
142.7, 141.7, 130.9, 129.1, 128.3, 127.8, 126.3, 116.3, 114.6, 59.6, 31.7, 10.8. HRMS calc. for C15H16ClN2O2 
[M+H]+, 291.0900 found, 291.0901. IR ATR (cm-1): 3366, 2924, 1522, 1487, 1330, 1021, 699. 
 
8.3.4. Synthesis of (±)-5-chloro-N1-(1-phenylpropyl)benzene-1,2-diamine (16)160 
Iron powder (138 mg, 2.47 mmol) was added to 15 (144 mg, 495 µmol) in a mixture of 
glacial acetic acid (2 mL), ethanol (2 mL) and water (1 mL). The reaction mixture was 
then exposed to ultrasonic irradiation for 2 hours at 30 °C and monitored by TLC. When 
all starting material had been consumed, the reaction mixture was filtered through 
celite and the filtrate was neutralized with a 1 M KOH solution (20 mL). The filtrate was then extracted 
thrice with EtOAc (3 × 50 mL) and the combined organic phases were washed with brine (200 mL), dried 
over MgSO4 and concentrated in vacuo. The crude product was then purified by column chromatography 
(5 – 40% EtOAc/Hexane) to yield the diamine product 16 as a dark brown solid (100 mg, 384 µmol, 78%). 
Rf, 0.30 (20% EtOAc/Hexane) 1H NMR (400 MHz, CDCl3) δ 7.40 – 7.19 (m, 5H, ArH), 6.66 – 6.51 (m, 2H, 
ArH), 6.39 (d, J = 2.0 Hz, 1H, ArH), 5.08 (s, 3H, NH), 4.19 (t, J = 6.6 Hz, 1H, CH), 1.95 – 1.77 (m, 2H, CH2), 
0.95 (t, J = 7.3 Hz, 3H, CH3). 13C NMR (101 MHz, CDCl3) δ 143.2, 138.7, 132.0, 128.7, 127.3, 126.6, 126.2, 
117.8, 117.6, 112.8, 59.9, 31.7, 10.9. 
*Unable to obtain HRMS of this compound due to degradation. 
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8.3.5. Synthesis of (±)-6-chloro-1-(1-phenylpropyl)-1,3-dihydro-2H-benzo[d]imidazol-2-one 
(11) 
CDI (47 mg, 0.29 mmol) was added to 16 (50 mg, 0.19 mmol) in THF (2 mL). The 
reaction was carried out at room temperature for 18 hours after which the reaction 
was quenched with H2O (20 mL) and the product was extracted twice with EtOAc (2 × 
20 mL). The organic phase was then washed with brine (50 mL), dried over MgSO4 and concentrated in 
vacuo. Purification of the crude material by column chromatography (10% – 40% EtOAc/hexane) yielded 
the product 11 as a white solid (40 mg, 0.14 mmol, 73%). 
Rf, 0.29 (40% EtOAc/Hexane) 1H NMR (300 MHz, CDCl3) δ 10.54 (s, 1H, NH), 7.46 – 7.27 (m, 5H, ArH), 7.08 
– 6.99 (m, 2H), 6.84 (d, J = 1.5 Hz, 1H, ArH), 5.57 (dd, J = 9.9, 6.3 Hz, 1H, CH), 2.53 – 2.39 (m, 2H, CH2), 1.01 
(t, J = 7.3 Hz, 3H, CH3). 13C NMR (75 MHz, CDCl3) δ 156.5, 139.0, 130.0, 128.9, 127.9, 127.2, 126.9, 126.7, 
121.6, 110.5, 110.2, 57.4, 24.1, 11.4. HRMS calc. for C16H16ClN2O [M+H]+, 287.0951 found, 287.0951. IR 
ATR (cm-1): 3135, 2964, 2837, 1684, 1479, 1059. Mp: 190 °C 
 
8.3.6. Synthesis of (±)-6-chloro-1-(1-phenylpropyl)-1,3-dihydro-2H-benzo[d]imidazole-2-
thione (20) 
TCDI (51 mg, 0.29 mmol) was added to 16 (50 mg, 0.19 mmol) in THF (5 mL). The 
reaction was carried out at room temperature for 18 hours after which the reaction 
mixture was concentrated in vacuo. The crude mixture was purified by silica gel 
column chromatography (5% – 20% EtOAc/Hexane) to yield the product 20 as an off-
white solid (53 mg, 0.18 mmol, 91%). 
Rf, 0.58 (40% EtOAc/Hexane) 1H NMR (300 MHz, CDCl3) δ 11.73 (s, 1H, NH), 7.48 – 7.06 (m, 7H, ArH), 6.96 
– 6.91 (m, 1H, ArH), 6.60 – 6.51 (m, 1H, CH), 2.67 – 2.35 (m, 2H, CH2), 1.01 (t, J = 7.2 Hz, 3H, CH3). 13C NMR 
(75 MHz, CDCl3) δ 170.4, 138.0, 131.8, 129.5, 129.0, 128.5, 128.2, 127.2, 123.6, 111.3, 110.9, 59.6, 23.8, 
11.1. HRMS calc. for C16H16ClN2S [M+H]+, 303.0723 found, 303.0721. 
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8.4. Experimental pertaining to Chapter 3 
 
8.4.1. Synthesis of 2-((3,5-dimethylphenyl)amino)-3-nitrophenol (32)180 
DMSO (3 mL) was added to a Schlenk tube charged with 2-amino-3-nitrophenol (23) (1.00 
g, 6.49 mmol), K3PO4 (2.75 g, 13.0 mmol), 2-picolinic acid (160 mg, 1.30 mmol) and 5-iodo-
m-xylene (25) (2.80 mL, 19.5 mmol). The reaction mixture was then degassed for 
approximately 15 minutes under a positive flow of argon before the addition of CuI (124 
mg, 649 µmol). The reaction was then heated to 85 °C and run for 18 hours after which the reaction was 
cooled to room temperature, diluted with EtOAc (50 ml) and quenched with H2O (50 mL). The aqueous 
layer was separated and twice extracted with EtOAc (2 × 100 mL). The organic phases were then 
combined, washed with brine (200 mL) and dried over MgSO4. The organic phase was then concentrated 
in vacuo and purified by silica gel column chromatography (5% – 30% EtOAc/Hexane) to give the undesired 
product 32 as a purple solid (1.51 g, 5.85 mmol, 89%). 
Rf, 0.35 (20% EtOAc/Hexane) 1H NMR (300 MHz, CDCl3) δ 7.70 (dd, J = 8.2, 1.5 Hz, 1H, ArH), 7.33 (s, 1H, 
NH or OH), 7.29 (d, J = 1.3 Hz, 1H, ArH), 7.22 – 7.15 (m, 1H, ArH), 6.64 (s, 1H, ArH), 6.39 (s, 2H, ArH), 5.67 
(s, 1H, NH or OH), 2.24 (s, 6H, CH3). 13C NMR (75 MHz, CDCl3) δ 152.2, 141.9, 139.8, 125.7, 125.6, 124.7, 
124.5, 121.5, 119.3, 117.8, 21.5. HRMS calc. for C14H15N2O3 [M+H]+, 259.1083 found, 259.1071. IR ATR 
(cm-1): 3429, 2913, 1598, 1518, 1247, 1137. Mp: 100 °C. 
 
8.4.2. Synthesis of 2-(benzyloxy)-6-nitroaniline (33) 
 Benzyl bromide (1.85 mL, 15.6 mmol) was added to a mixture of 2-amino-3-nitrophenol (23) 
(2.00 g, 13.0 mmol) and K2CO3 (3.59 g, 26.0 mmol) in DMF (40 mL) at -10 ˚C (acetone/ice 
bath). The reaction was then warmed to room temperature and carried out for 18 hours after 
which the reaction mixture was quenched with NH4Cl (50 mL) and then extracted three times with EtOAc 
(3 × 100 mL). The organic phases were combined, washed with brine (300 mL) and dried over MgSO4. The 
organic phases were then concentrated in vacuo and the product was purified by silica gel column 
chromatography (5% – 20% EtOAc/Hexane) to yield the benzylated product 33 as an orange solid (3.01 g, 
12.3 mmol, 95%). 
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Rf, 0.31 (20% EtOAc/Hexane) 1H NMR (300 MHz, CDCl3) δ 7.73 (dd, J = 8.9, 1.2 Hz, 1H, ArH), 7.48 – 7.33 
(m, 5H, ArH), 6.96 (dd, J = 7.7, 0.8 Hz, 1H, ArH), 6.61 – 6.54 (m, 1H, ArH), 6.46 (s, 2H, NH2), 5.12 (s, 2H, 
CH2). 13C NMR (75 MHz, CDCl3) δ 147.3, 137.3, 135.9, 131.8, 128.8, 128.6, 127.8, 117.7, 115.0, 114.6, 71.3. 
HRMS calc. for C13H13N2O3 [M+H]+, 245.0926 found, 245.0918. IR ATR (cm-1): 3506, 3391, 3031, 1621, 
1519, 1202. Mp: 55 °C. 
 
8.4.3. Synthesis of 2-(benzyloxy)-N-ethyl-6-nitroaniline (34) 
Conditions A: NaH (60% in mineral oil, 197 mg, 4.91 mmol) was added to 33 (1.00 g, 4.09 
mmol) in THF (10 mL). After approximately 30 minutes ethyl iodide (0.40 mL, 4.9 mmol) was 
added to the reaction mixture and the reaction was carried out at room temperature for 18 
hours after which the reaction mixture was quenched with NH4Cl (100 mL) and extracted twice with EtOAc 
(2 × 100 mL). The organic phase was dried over MgSO4 and then concentrated in vacuo. The crude material 
was then purified by silica gel column chromatography (5% EtOAc/Hexane) to yield the product 34 as a 
red solid (472 mg, 1.73 mmol, 42%). 
Conditions B: NaH (291 mg, 7.27 mmol) was added to 33 (1.48 g, 6.06 mmol) in THF (15 mL). After 
approximately 30 minutes diethyl sulfate (0.95 mL, 7.3 mmol) was added to the reaction mixture. After 
18 hours the reaction mixture was quenched with aqueous NH4OH solution (100 mL) and then extracted 
twice with EtOAc (2 × 150 mL). The organic phase was dried over MgSO4 and then concentrated in vacuo. 
The crude material was purified by silica gel column chromatography (5% – 40% EtOAc/Hexane) to afford 
34 (1.06 g, 3.89 mmol, 64%). 
Conditions C: Using the reaction conditions described for conditions B, but with DMF as the solvent, the 
product 34 was obtained in 81% yield. 
Rf, 0.40 (20% EtOAc/Hexane) 1H NMR (400 MHz, CDCl3) δ 7.73 (dd, J = 8.8, 1.4 Hz, 1H, ArH), 7.54 (s, 1H, 
NH), 7.45 – 7.33 (m, 5H, ArH), 6.98 (dd, J = 7.8, 1.4 Hz, 1H, ArH), 6.59 (dd, J = 8.7, 7.9 Hz, 1H, ArH), 5.07 (s, 
2H, CH2), 3.57 (q, 2H,  J = 7.1 Hz, CH2), 1.18 (t, J = 7.2 Hz, 3H, CH3). 13C NMR (75 MHz, CDCl3) δ 150.0, 139.0, 
136.2, 135.5, 128.9, 128.5, 127.9, 119.2, 117.8, 115.7, 72.0, 41.9, 16.7, 0.2. HRMS calc. for C15H17N2O3 
[M+H]+, 273.1239 found, 273.1229. IR ATR (cm-1): 3323, 2978, 2361, 1609, 1510, 1345, 1241, 1169. Mp: 
49 °C. 
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8.4.4. Synthesis of 4-(benzyloxy)-1-ethoxy-2-methyl-1H-benzo[d]imidazole (46) 
NaH (60% in mineral oil, 146 mg, 3.64 mmol) was added to 33 (222 mg, 9.09 µmol) in THF 
(5 mL). After approximately 30 minutes ethyl iodide (0.29 mL, 3.6 mmol) was added to the 
reaction mixture and the reaction was carried out at room temperature for 18 hours after 
which the reaction mixture was quenched with NH4Cl (50 mL) and extracted twice with 
EtOAc (2 × 50 mL). The organic phase was dried over MgSO4 and then concentrated in vacuo. The crude 
material was then purified by silica gel column chromatography (5% EtOAc/Hexane) to yield the product 
46 as a brown oil (109 mg, 386 µmol, 42%). 
Rf, 0.22 (40% EtOAc/Hexane) 1H NMR (300 MHz, CDCl3) δ 7.53 – 7.45 (m, 2H, ArH), 7.36 – 7.24 (m, 2H, 
ArH), 7.10 – 7.04 (m, 1H, ArH), 6.96 (d, J = 8.1 Hz, 1H, ArH), 6.65 (d, J = 7.9 Hz, 1H, ArH), 5.33 (s, 2H, CH2), 
4.26 (q, J = 7.1 Hz, 2H, CH2), 2.59 (s, 3H, CH3), 1.40 (t, J = 7.1 Hz, 3H, CH3). 13C NMR (75 MHz, CDCl3) δ 150.2, 
146.5, 137.2, 132.4, 128.6, 128.4, 127.7, 127.4, 123.2, 104.8, 101.3, 74.1, 70.6, 13.7, 12.4. HRMS calc. for 
C17H19N2O2 [M+H]+, 283.1447 found, 283.1441. IR ATR (cm-1): 2977, 1593, 1330, 1238, 733. 
 
8.4.5. Synthesis of 3-(benzyloxy)-N2-ethylbenzene-1,2-diamine (35) 
Conditions A: Iron powder (555 mg, 9.93 mmol) was added to 34 (541 mg, 1.99 mmol) in a 
mixture of glacial acetic acid (4 mL), ethanol (4 mL) and water (2 mL). The reaction mixture 
was then exposed to ultrasonic irradiation for 2 hours at 30 °C and monitored by TLC. When 
all starting material had been consumed, the reaction mixture was filtered through celite and the filtrate 
neutralized with 1 M KOH solution (20 mL). The filtrate was extracted thrice with EtOAc (3 × 100 mL). The 
combined organic phases were washed with brine (300 mL), dried over MgSO4 and concentrated in vacuo. 
The crude product was purified by column chromatography (10% – 40% EtOAc/Hexane) to yield the 
reduced product 35 as an orange oil (382 mg, 1.58 mmol, 79%). 
Conditions B: Tin(II) chloride dihydrate (10.5 g, 46.6 mmol) was added to 34 (1.27 g, 4.66 mmol) dissolved 
in EtOH (20 mL). The reaction mixture was then exposed to ultrasonic radiation for approximately 15 
minutes after which TLC confirmed that all starting material had been consumed. The reaction mixture 
was then basified with 1 M KOH solution (200 mL) and extracted three times with DCM (3 × 200 mL). The 
organic phases were combined, washed with brine (500 mL), dried over MgSO4 and concentrated in vacuo. 
The crude product was purified by column chromatography (10% – 40% EtOAc/hexane) to yield the 
reduced product 35 as an orange oil (924 mg, 3.81 mmol, 82%). 
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Rf, 0.44 (40% EtOAc/Hexane) 1H NMR (300 MHz, CDCl3) δ 7.47 – 7.31 (m, 5H, ArH), 6.90 – 6.83 (m, 1H, 
ArH), 6.45 – 6.39 (m, 2H, ArH), 5.41 (s, 3H, NH), 5.08 (s, 2H, CH2), 3.06 (q, J = 7.2 Hz, 2H, CH2), 1.19 (t, J = 
7.2 Hz, 3H, CH3). 13C NMR (75 MHz, CDCl3) δ 152.7, 142.1, 137.3, 128.6, 128.0, 127.4, 124.3, 122.8, 109.6, 
102.4, 70.6, 42.0, 15.5. HRMS calc. for C15H19N2O [M+H]+, 243.1497 found, 243.1506. IR ATR (cm-1): 3425, 
3341, 2965, 1615, 1591, 1450, 1254, 728. 
 
8.4.6. Synthesis of 4-(benzyloxy)-3-ethyl-1H-benzo[d]imidazol-2-one (36) 
Conditions A: Carbonyldiimidazole (243 mg, 1.44 mmol) was added to 35 (175 mg, 722 
µmol) in THF (10 mL) at 0°C. The reaction was allowed to warm to room temperature and 
was carried out for 18 hours. The reaction was monitored by TLC and upon completion 
the reaction mixture was concentrated in vacuo and then purified by silica gel column chromatography 
(10% – 80% EtOAc/Hexane) to yield the desired benzimidazolone product 36 as a pale pink solid (128 mg, 
477 µmol, 66%). 
Conditions B: CDI (583 mg, 3.59 mmol) was added to 35 (871 mg, 3.59 mmol) in MeCN (15 mL) at room 
temperature. After 18 hours the resulting white precipitate was filtered off and dried under vacuum. No 
additional purification was required and 36 was obtained as a white solid (649 mg, 2.70 mmol, 75%). 
Rf, 0.11 (40% EtOAc/Hexane) 1H NMR (300 MHz, CDCl3) δ 10.38 (s, 1H, NH), 7.48 – 7.32 (m, 5H, ArH), 7.01 
– 6.94 (m, 1H, ArH), 6.81 (dd, J = 7.9, 0.8 Hz, 1H, ArH), 6.71 (dd, J = 8.3, 0.6 Hz, 1H, ArH), 5.17 (s, 2H, CH2), 
4.16 (q, J = 7.1 Hz, 2H, CH2), 1.31 (t, J = 7.1 Hz, 3H, CH3). 13C NMR (75 MHz, CDCl3) δ 155.6, 144.3, 136.8, 
129.7, 128.8, 128.3, 127.5, 121.9, 118.7, 105.5, 103.7, 70.9, 37.8, 15.8. HRMS calc. for C16H17N2O2 [M+H]+, 
269.1290 found, 269.1293. IR ATR (cm-1): 2969, 1681, 1626, 1470, 1237, 1117. Mp: 213 °C. 
 
8.4.7. Synthesis of 4-(benzyloxy)-3-ethyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-
benzo[d]imidazol-2(3H)-one (37) 
NaH (76 mg, 1.6 mmol) was added to 36 (213 mg, 0.794 mol) in DMF (5 mL) at 0 °C. The 
reaction was stirred for approximately 1 hour before 2-(trimethylsilyl)ethoxymethyl 
chloride (0.28 mL, 1.6 mmol) was added to the reaction mixture dropwise. The reaction 
was carried out at room temperature for 18 hours. The reaction was quenched with H2O (20 mL) and 
extracted twice with EtOAc (2 × 50 mL). The organic phases were combined, washed with brine (100 mL), 
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dried over MgSO4 and concentrated in vacuo. The crude product was purified on silica gel by column 
chromatography (5% – 30% EtOAc/Hexane) to yield the product as a clear oil (258 mg, 0.647 mmol, 82%). 
Rf, 0.53 (40% EtOAc/Hexane) 1H NMR (400 MHz, CDCl3) δ 7.47 – 7.33 (m, 5H, ArH), 7.03 – 6.98 (m, 1H, 
ArH), 6.85 (dd, J = 7.9, 0.8 Hz, 1H, ArH), 6.76 (dd, J = 8.4, 0.7 Hz, 1H, ArH), 5.30 (s, 2H, CH2), 5.17 (s, 2H, 
CH2), 4.14 (q, J = 7.0 Hz, 2H, CH2), 3.63 – 3.58 (m, 2H, CH2), 1.28 (t, J = 7.1 Hz, 3H, CH3), 0.96 – 0.88 (m, 2H, 
CH2), -0.03 (s, 9H, Si(CH3)3). 13C NMR (101 MHz, CDCl3) δ 154.1, 144.2, 136.7, 130.5, 128.8, 128.3, 127.5, 
121.8, 117.9, 106.3, 102.7, 70.9, 70.9, 66.2, 38.1, 17.9, 15.6, -1.3. HRMS calc. for C22H31N2O3Si [M+H]+, 
399.2104 found, 399.2104. IR ATR (cm-1): 2951, 2894, 1702, 1477, 1245, 1078, 833. 
 
8.4.8. Synthesis of 3-ethyl-4-hydroxy-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-
benzo[d]imidazol-2(3H)-one (38) 
A catalytic amount of Pd/C was added to 37 (250 mg, 627 µmol) in EtOH (5 mL). The 
reaction was then carried out for 18 hours under an atmosphere of hydrogen after which 
the reaction mixture was run through celite and concentrated in vacuo. The crude mixture 
was purified on silica gel by column chromatography (5% – 30% EtOAc/Hexane) to yield 
the product 38 as a pink solid (140 mg, 454 µmol, 73%). 
Rf, 0.44 (40% EtOAc/Hexane) 1H NMR (300 MHz, CDCl3) δ 6.99 (br s, 1H, OH), 6.96 – 6.89 (m, 1H, ArH), 
6.78 (dd, J = 7.9, 0.9 Hz, 1H, ArH), 6.66 (dd, J = 8.1, 0.9 Hz, 1H, ArH), 5.32 (s, 2H, CH2), 4.21 (q, J = 7.1 Hz, 
2H, CH2), 3.67 – 3.57 (m, 2H, CH2), 1.37 (t, J = 7.1 Hz, 3H, CH3), 0.98 – 0.87 (m, 2H, CH2), -0.05 (s, 9H, 
Si(CH3)3). 13C NMR (75 MHz, CDCl3) δ 154.4, 141.7, 130.8, 122.1, 116.8, 110.1, 101.8, 70.9, 66.3, 38.2, 18.0, 
15.7, -1.3. HRMS calc. for C15H25N2O3Si [M+H]+, 309.1634 found, 309.1631. IR ATR (cm-1): 3144, 2953, 
1673, 1075. IR ATR (cm-1): 3176, 2953, 1664, 1483, 1071, 777. Mp: 116 °C. 
 
8.4.9. Synthesis of 3-ethyl-4-phenoxy-1-((2-(trimethylsilyl)ethoxy)methyl)-1,3-dihydro-2H-
benzo[d]imidazol-2-one (39) 
DMSO (2 mL) was added to a Schlenk tube charged with 38 (200 mg, 648 µmol), K3PO4 
(275 mg, 1.30 mmol), 2-picolinic acid (16 mg, 0.13 mmol) and iodobenzene (24) (0.20 
mL, 1.8 mmol) and the reaction mixture was degassed under a positive flow of argon 
for approximately 15 minutes prior to the addition of CuI (12 mg, 63 µmol). The 
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reaction mixture was then heated to 90 °C and run for 18 hours after which the reaction was cooled to 
room temperature, diluted with EtOAc (50 mL) and quenched with H2O (100 mL). The aqueous layer was 
separated and extracted twice with EtOAc (2 × 100 mL). The organic phases were then combined, washed 
with brine (200 mL) and dried over MgSO4. The organic phase was then concentrated in vacuo and purified 
by silica gel column chromatography (5% – 30% EtOAc/Hexane) to give the product 39 as a clear oil (174 
mg, 453 µmol, 70%). 
Rf, 0.41 (20% EtOAc/Hexane) 1H NMR (500 MHz, CDCl3) δ 7.37 – 7.32 (m, 2H, ArH), 7.13 – 7.09 (m, 1H, 
ArH), 7.03 – 6.96 (m, 4H, ArH), 6.69 (dd, J = 8.0, 1.2 Hz, 1H, ArH), 5.33 (s, 2H, CH2), 4.03 (q, J = 7.1 Hz, 2H, 
CH2), 3.66 – 3.60 (m, 2H, CH2), 1.27 (t, J = 7.1 Hz, 3H, CH3), 0.98 – 0.90 (m, 2H, CH2), -0.02 (s, 9H, Si(CH3)3). 
13C NMR (126 MHz, CDCl3) δ 157.7, 154.2, 140.4, 131.3, 130.1, 123.4, 121.9, 120.6, 117.8, 113.8, 104.8, 
71.0, 66.3, 38.0, 18.0, 15.3, -1.3. HRMS calc. for C21H29O3N2Si [M+H]+, 385.19420 found, 385.19413. 
 
8.4.10. Synthesis of 4-(3,5-dimethylphenoxy)-3-ethyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,3-
dihydro-2H-benzo[d]imidazol-2-one (40) 
This reaction was carried out according to the procedure described for 39 using the 
following: 38 (200 mg, 648 µmol), K3PO4 (275 mg, 1.30 mmol), 2-picolinic acid (16 
mg, 0.13 mmol), 5-iodo-m-xylene (25) (0.30 mL, 2.1 mmol) and CuI (12 mg, 63 
µmol). The reaction yielded 40 as a clear oil (163 mg, 395 µmol, 61%). 
Rf, 0.46 (20% EtOAc/Hexane) 1H NMR (500 MHz, CDCl3) δ 7.02 – 6.99 (m, J = 8.0 
Hz, 1H, ArH), 6.96 (dd, J = 7.8, 1.1 Hz, 1H, ArH), 6.76 – 6.74 (m, 1H, ArH), 6.68 (dd, J = 8.1, 1.1 Hz, 1H, ArH), 
6.63 – 6.61 (m, 2H, ArH), 5.33 (s, 2H, CH2), 4.03 (q, J = 7.1 Hz, 2H, CH2), 3.67 – 3.61 (m, J = 10.9, 5.5 Hz, 2H, 
CH2), 2.29 (s, 6H, (CH3)2), 1.28 (t, J = 7.1 Hz, 3H, CH3), 0.97 – 0.91 (m, 2H, CH2), -0.02 (s, 9H, Si(CH3)3). 13C 
NMR (126 MHz, CDCl3) δ 157.6, 154.2, 140.6, 139.9, 131.2, 125.2, 121.9, 120.5, 115.5, 113.8, 104.6, 71.0, 
66.3, 38.0, 21.5, 18.0, 15.3, -1.3. HRMS calc. for C23H33O3N2Si [M+H]+, 413.22550 found, 413.22535. 
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8.4.11. Synthesis of 1-ethyl-7-phenoxy-1,3-dihydro-2H-benzo[d]imidazol-2-one (21) 
A solution of tetrabutylammonium fluoride (TBAF) (1.0 M in THF, 0.60 mL, 2.1 mmol) 
was added dropwise to a solution of 39 (68 mg, 0.18 mmol) in THF (0.5 mL) and the 
reaction was heated to 60 °C. After 18 hours the reaction was cooled to room 
temperature, diluted with EtOAc (50 mL) and washed with brine (50 mL). The organic 
phase was then dried over MgSO4, concentrated in vacuo and then purified by column chromatography 
(40% – 100% EtOAc/Hexane) to afford compound 21 as a white solid (8.0 mg, 0.021 mmol, 18%).  
Rf, 0.43 (100% EtOAc/Hexane) 1H NMR (500 MHz, CDCl3) δ 11.07 (s, 1H, NH), 7.37 – 7.32 (m, 2H, ArH), 
7.14 – 7.09 (m, 1H, ArH), 7.04 – 6.96 (m, 4H, ArH), 6.69 – 6.64 (m, 1H, ArH), 4.07 (q, J = 7.1 Hz, 2H, CH2), 
1.33 (t, J = 7.1 Hz, 3H, CH3). 13C NMR (126 MHz, CDCl3) δ 157.7, 155.9, 140.4, 130.6, 130.0, 123.3, 121.9, 
121.3, 117.7, 113.0, 105.9, 37.7, 15.4. HRMS calc. for C15H15O2N2 [M+H]+, 255.11280 found, 255.11283. IR 
ATR (cm-1): 3162, 2978, 1692, 1501, 1230, 744. Mp: 137 °C. 
 
8.4.12. Synthesis of 3-ethyl-1-(hydroxymethyl)-4-phenoxy-1,3-dihydro-2H-benzo[d]imidazol-
2-one (47)  
Boron trifluoride diethyl etherate (BF3OEt2) (0.60 mL, 4.9 mmol) was added dropwise 
to 39 (163 mg, 424 µmol) in DCM (2 mL) at 0 °C after which the reaction was allowed 
to warm to room temperature. After 4 hours TLC revealed that all 39 had been 
consumed, therefore the reaction was once more cooled to 0 °C, quenched with a 
saturated solution of NaHCO3 (40 mL) and subsequently extracted twice with DCM (2 
× 50 mL). The organic phases were then combined, dried over MgSO4 and concentrated in vacuo. The 
resulting crude product was then purified by column chromatography (40% – 100% EtOAc/Hexane) to 
afford the hemiaminal 47 as a white waxy solid (107 mg, 376 µmol, 88%).  
Rf, 0.43 (100% EtOAc/Hexane)1H NMR (500 MHz, CDCl3) δ 7.38 – 7.30 (m, 2H, ArH), 7.14 – 6.95 (m, 5H, 
ArH), 6.72 – 6.66 (m, 1H, ArH), 5.45 (s, 2H, CH2), 3.96 (q, J = 7.0 Hz, 2H, CH2), 1.21 (t, J = 7.0 Hz, 3H, CH3). 
13C NMR (126 MHz, CDCl3) δ 157.5, 153.8, 140.6, 130.9, 130.0, 123.4, 122.2, 120.3, 117.8, 113.7, 104.6, 
65.3, 37.9, 15.2. HRMS calc. for C16H17O3N2 [M+H]+, 285.12337 found, 285.12359.  IR ATR (cm-1): 3230, 
2982, 2947, 1679, 1477, 1035, 694. 
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8.4.13. Cleavage of the hemiaminal to afford 1-ethyl-7-phenoxy-1,3-dihydro-2H-
benzo[d]imidazol-2-one (21) 
For the cleavage of the hemiaminal 47, NaOH (30 mg, 0.75 mmol) was added to 47 
(107 mg, 0.376 mmol) in THF (7 mL) and H2O (1 mL). After 18 hours the reaction was 
quenched with a saturated solution of NH4Cl (50 mL) and extracted twice with DCM 
(2 × 50 mL). The organic phases were combined, dried over MgSO4 and concentrated 
in vacuo. The crude product was then purified by column chromatography to afford compound 21 as a 
white solid (48 mg, 0.19 mmol, 50%). 
*Spectral data described in 8.4.11. 
 
8.4.14. Synthesis of 7-(3,5-dimethylphenoxy)-1-ethyl-1,3-dihydro-2H-benzo[d]imidazol-2-one 
(22) 
BF3OEt2 (0.50 mL, 4.1 mmol) was added dropwise to 40 (154 mg, 0.373 mmol) in 
DCM (2 mL) at 0 °C after which the reaction was allowed to warm to room 
temperature. After 4 hours TLC revealed that all 40 had been consumed, therefore 
the reaction was once more cooled to 0 °C, quenched with a saturated solution of 
NaHCO3 (40 mL) and subsequently extracted twice with DCM (2 × 50 mL). The 
organic phases were then combined, dried over MgSO4 and concentrated in vacuo. The crude product was 
then taken up in THF (7 mL) and H2O (1 mL) and treated with NaOH (30 mg, 0.75 mmol). After 18 hours 
the reaction was quenched with a saturated solution of NH4Cl (40 mL) and extracted twice with DCM (2 × 
50 mL). The organic phases were combined, dried over MgSO4 and concentrated in vacuo. The crude 
product was then purified by column chromatography to afford compound 22 as a white solid (50 mg, 
0.18 mmol, 48% over two steps). 
Rf, 0.43 (100% EtOAc/Hexane) 1H NMR (500 MHz, CDCl3) δ 11.05 (s, 1H, NH), 7.01 – 6.95 (m, 2H, ArH), 
6.77 – 6.74 (m, 1H, ArH), 6.68 – 6.64 (m, 3H, ArH), 4.08 (q, J = 7.1 Hz, 2H, CH2), 2.30 (s, 6H, (CH3)3), 1.35 (t, 
J = 7.1 Hz, 3H, CH2). 13C NMR (126 MHz, CDCl3) δ 157.67, 155.9, 140.6, 139.9, 130.5, 125.1, 121.9, 121.3, 
115.4, 113.0, 105.7, 37.7, 21.4, 15.4. HRMS calc. for C17H19O2N2 [M+H]+, 283.14410 found, 283.14395. IR 
ATR (cm-1): 3150, 2915, 1703, 1591, 1229, 772. Mp: 173 °C. 
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8.4.15. Synthesis of 3-chloro-5-((3-ethyl-2-oxo-1-((2-(trimethylsilyl)ethoxy)methyl)-2,3-
dihydro-1H-benzo[d]imidazol-4-yl)oxy)benzonitrile (52) 
3-chloro-5-fluorobenzonitrile (51) (101 mg, 649 µmol) was added to 38 (100 mg, 
324 µmol) and Cs2CO3 (211 mg, 648 µmol) in DMF (2 mL) and the reaction was 
heated to 100 °C. After 2 hours TLC revealed that all of 38 had been consumed. 
As a result, the reaction was cooled to room temperature, diluted with EtOAc (50 
mL) and quenched with water (50 mL). The organic phase was subsequently 
washed with brine (50 mL), dried over MgSO4 and then concentrated in vacuo. Purification of the crude 
material by silica gel column chromatography (5% – 40% EtOAc/Hexane) yielded the desired product 52 
as a clear oil (107 mg, 241 µmol, 74%). 
Rf, 0.52 (40% EtOAc/Hexane) 1H NMR (500 MHz, CDCl3) δ 7.37 – 7.36 (m, 1H, ArH), 7.23 – 7.22 (m, 1H, 
ArH), 7.14 (dd, J = 2.4, 1.3 Hz, 1H, ArH), 7.11 – 7.07 (m, 2H, ArH), 6.72 (dd, J = 6.7, 2.5 Hz, 1H, ArH), 5.33 
(s, 2H, CH2), 3.93 (q, J = 7.1 Hz, 2H, CH2), 3.66 – 3.61 (m, 2H, CH2), 1.24 (t, J = 7.1 Hz, 3H, CH3), 0.97 – 0.92 
(m, 2H, CH2), -0.03 (s, 9H, Si(CH3)3). 13C NMR (126 MHz, CDCl3) δ 159.1, 154.0, 137.7, 136.9, 131.8, 126.6, 
122.4, 122.0, 120.9, 118.5, 117.0, 115.0, 114.4, 106.5, 71.0, 66.5, 37.9, 17.9, 15.2, -1.3. HRMS calc. for 
C22H26O3N3ClSi [M+]+, 444.15047 found, 444.15102.  IR ATR (cm-1): 3075, 2952, 2235, 1710, 1573, 1212, 
1079. 
 
8.4.16. Synthesis of 3-chloro-5-((3-ethyl-2-oxo-1-((2-trimethylsilyl)ethoxy)methyl)-2,3-
dihydro-1H-benzo[d]imidazol-4-yl)oxy)benzonitrile (50) 
This reaction was carried out according to the procedure described for 22 using 
the following: 52 (107 mg, 0.241 mmol), BF3OEt2 (0.30 mL, 2.4 mmol) and NaOH 
(20 mg, 0.48 mmol). The reaction yielded 50 as a white solid (38 mg, 0.12 mmol, 
50% over two steps). 
Rf, 0.15 (40% EtOAc/Hexane) 1H NMR (300 MHz, CDCl3) δ 10.04 (s, 1H, NH), 7.38 
– 7.36 (m, 1H, ArH), 7.25 – 7.23 (m, 1H, ArH), 7.17 – 7.14 (m, 1H, ArH), 7.10 – 7.00 (m, 2H, ArH), 6.69 (dd, 
J = 7.6, 1.7 Hz, 1H, ArH), 3.95 (q, J = 7.1 Hz, 2H, CH2), 1.28 (t, J = 7.1 Hz, 3H, CH3). 13C NMR (75 MHz, CDCl3) 
δ 159.2, 155.3, 137.8, 136.9, 130.9, 126.6, 122.5, 122.0, 121.7, 118.5, 117.0, 115.1, 113.8, 107.4, 37.7, 
15.3. HRMS calc. for C16H13ClO2N3 [M+H]+, 314.0696 found, 314.0711. IR ATR (cm-1): 3130, 2236, 1693, 
1573, 959, 848. Mp: 206 °C. 
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8.4.17. Synthesis of 2-(benzyloxy)-N-methyl-6-nitroaniline (55) 
This reaction was carried out according to the procedure (conditions A) described for 34 
using the following: 33 (300 mg, 1.23 mmol), methyl iodide (0.12 mL, 1.8 mmol) and NaH 
(114 mg, 4.75 mmol). This reaction yielded 55 as a red solid (307 mg, 1.19 mmol, 97%). 
Rf, 0.39 (20% EtOAc/Hexane) 1H NMR (300 MHz, CDCl3) δ 7.72 (dd, J = 8.7, 1.4 Hz, 1H, ArH), 7.56 (s, 1H, 
NH), 7.46 – 7.34 (m, 5H, ArH), 6.99 (dd, J = 7.8, 1.3 Hz, 1H, ArH), 6.63 – 6.54 (m, 1H, ArH), 5.07 (s, 2H, CH2), 
3.15 (d, J = 4.5 Hz, 3H, CH3). 13C NMR (75 MHz, CDCl3) δ 149.9, 139.9, 136.1, 128.9, 128.5, 127.9, 127.4, 
119.2, 117.8, 115.5, 72.1, 34.3. HRMS calc. for C14H15N2O3 [M+H]+, 259.1083 found, 259.1076. IR ATR (cm-
1): 3310, 2939, 1745, 1521, 1247, 1191. Mp: 74 °C. 
 
8.4.18. Synthesis of 2-(benzyloxy)-N-propyl-6-nitroaniline (56) 
This reaction was carried out according to the procedure (conditions C) described for 34 
using the following: 33 (500 mg, 2.05 mmol), propyl bromide (0.19 mL, 2.1 mmol) and NaH 
(82 mg, 3.4 mmol). This reaction yielded 56 as a red solid (399 mg, 1.39 mmol, 68%). 
Rf, 0.44 (20% EtOAc/Hexane) 1H NMR (400 MHz, CDCl3) δ 7.76 – 7.71 (m, 1H, ArH), 7.46 – 
7.32 (m, 5H, ArH), 7.00 – 6.95 (m, 1H, ArH), 6.64 – 6.58 (m, 1H, ArH), 5.06 (s, 2H, CH2), 3.49 (t, J = 7.1 Hz, 
2H, CH2), 1.62 – 1.51 (m, 2H, CH2), 0.85 (t, J = 7.4 Hz, 3H, CH3). 13C NMR (101 MHz, CDCl3) δ 150.0, 138.8, 
136.1, 128.8, 128.5, 127.9, 119.2, 117.7, 115.8, 72.0, 48.9, 24.4, 11.3. HRMS calc. for C16H19O3N2 [M+H]+, 
287.13902 found, 287.13884. IR ATR (cm-1): 3330, 2960, 2872, 1517, 1260, 1028. Mp: 50 °C. 
 
8.4.19. Synthesis of 4-(benzyloxy)-3-methyl-1H-benzo[d]imidazol-2-one (57) 
The reduction of 55 was carried out according to the procedure (conditions B) described for 
35 using the following: 55 (504 mg, 1.95 mmol) and SnCl2.2H2O (4.4g, 19 mmol). However, in 
this instance the reduced product was taken crude to the following ring-closing step with 
CDI. 
Rf, 0.30 (40% EtOAc/Hexane) 1H NMR (300 MHz, CDCl3) δ 7.48 – 7.32 (m, 5H, ArH), 6.90 – 6.80 (m, 1H, 
ArH), 6.46 – 6.39 (m, 2H, ArH), 5.07 (s, 2H, CH2), 4.51 (s, 3H, NH), 2.70 (s, 3H, CH3). 13C NMR (75 MHz, 
CDCl3) δ 152.5, 142.0, 137.3, 128.7, 128.1, 127.6, 125.4, 124.0, 109.4, 102.7, 70.6, 34.4. HRMS calc. for 
C14H17N2O [M+H]+, 229.1341 found, 229.1345. IR ATR (cm-1): 3433, 3352, 1613, 1486, 1431, 1144.  
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The subsequent ring-closing reaction was carried out according to the procedure 
(conditions B) described for 36 using the following: the crude N-methylated phenylene 
diamine and CDI (519 mg, 3.20 mmol). The reaction yielded 59 as a white solid (387 mg, 
1.52 mmol, 78% over two steps). 
Rf, 0.38 (40% EtOAc/Hexane) 1H NMR (300 MHz, DMSO-d) δ 10.83 (s, 1H, NH), 7.51 – 7.31 (m, 5H, ArH), 
6.93 – 6.86 (m, 1H, ArH), 6.81 – 6.76 (m, 1H, ArH), 6.63 (dd, J = 7.7, 0.7 Hz, 1H, ArH), 5.18 (s, 2H, CH2), 3.46 
(s, 3H, CH3). 13C NMR (75 MHz, DMSO-d) δ 154.3, 143.5, 137.0, 129.5, 128.5, 127.9, 127.6, 121.4, 119.1, 
105.9, 102.8, 70.2, 29.1. HRMS calc. for C15H15N2O2 [M+H]+, 255.1134 found, 255.1133. IR ATR (cm-1): 
3006, 1682, 1474, 1246, 1104. Mp: 238 °C. 
 
8.4.20. Synthesis of 4-(benzyloxy)-3-propyl-1H-benzo[d]imidazol-2-one (58) 
The reduction of 56 was carried out according to the procedure (conditions B) described for 
35 using the following: 56 (350 mg, 1.22 mmol) and SnCl2.2H2O (2.8 g, 12 mmol). However, 
in this instance the reduced product was taken crude to the following ring-closing step with 
CDI. 
Rf, 0.18 (40% EtOAc/Hexane) 1H NMR (500 MHz, CDCl3) δ 7.51 – 7.36 (m, 5H, ArH), 6.91 – 6.85 (m, 1H, 
ArH), 6.49 – 6.43 (m, 2H, ArH), 5.10 (s, 2H, CH2), 3.82 (s, 3H, NH), 2.95 (t, J = 7.1 Hz, 2H, CH2), 1.69 – 1.57 
(m, 2H, CH2), 1.01 (t, J = 7.4 Hz, 3H, CH3). 13C NMR (101 MHz, CDCl3) δ 146.9, 137.5, 128.7, 128.1, 127.6, 
126.5, 116.9, 106.1, 70.9, 35.7, 9.4, 0.2. IR ATR (cm-1): 3345, 2957, 1612, 1440, 1243, 694. 
*Unable to obtain HRMS of this compound due to degradation 
The subsequent ring-closing reaction was carried out according to the procedure 
(conditions B) described for 36 using the following: the crude N-propylated phenylene 
diamine and CDI (316 mg, 1.95 mmol).  The reaction yielded 60 as a white solid (306 mg, 
1.08 mmol, 89% over two steps). 
Rf, 0.11 (40% EtOAc/Hexane) 1H NMR (500 MHz, DMSO-d) δ 10.82 (s, 1H, NH), 7.51 – 7.47 (m, 2H, ArH), 
7.44 – 7.40 (m, 2H, ArH), 7.38 – 7.34 (m, 1H, ArH), 6.94 – 6.90 (m, 1H, ArH), 6.83 – 6.79 (m, 1H, ArH), 6.65 
– 6.62 (m, 1H, ArH), 5.16 (s, 2H, CH2), 3.84 – 3.77 (m, 2H, CH2), 1.60 – 1.51 (m, 2H, CH2), 0.67 (d, J = 7.4 Hz, 
3H, CH3). 13C NMR (126 MHz, DMSO-d) δ 154.1, 143.3, 136.8, 129.6, 128.5, 128.0, 127.8, 121.3, 105.4, 
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70.1, 43.2, 23.2, 10.6. HRMS calc. for C17H19O2N2 [M+H]+, 283.14410 found, 283.14380. IR ATR (cm-1): 
3110, 2955, 2872, 1677, 1375, 1124, 749. Mp: 236 °C. 
 
8.4.21. Synthesis of 4-(benzyloxy)-3-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-
benzo[d]imidazol-2(3H)-one (59) 
This reaction was carried out according to the procedure described for 37 using the 
following: 57 (380 mg, 1.49 mmol), SEM-Cl (0.40 mL, 2.3 mmol) and NaH (60 mg, 2.5 
mmol). The reaction yielded 59 as a clear oil (382 mg, 0.993 mmol, 67%). 
Rf, 0.75 (60% EtOAc/Hexane) 1H NMR (300 MHz, CDCl3) δ 7.47 – 7.31 (m, 5H, ArH), 7.00 (m, 1H, ArH), 6.84 
(dd, J = 7.9, 0.8 Hz, 1H, ArH), 6.75 (dd, J = 8.4, 0.7 Hz, 1H, ArH), 5.29 (s, 2H, CH2), 5.15 (s, 2H, CH2), 3.63 (s, 
3H, CH3), 3.62 – 3.57 (m, 2H, CH2), 0.97 – 0.87 (m, 2H, CH2), -0.03 (s, 9H, Si(CH3)3). 13C NMR (75 MHz, CDCl3) 
δ 154.6, 144.5, 136.7, 130.3, 128.8, 128.3, 127.6, 122.0, 118.8, 106.6, 102.8, 71.09, 71.05, 66.2, 30.2, 18.0, 
-1.3. HRMS calc. for C21H29N2O3Si [M+H]+, 385.1947 found, 385.1952. IR ATR (cm-1): 2951, 2894, 1704, 
1481, 1247, 833. 
 
8.4.22. Synthesis of 4-(benzyloxy)-3-propyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-
benzo[d]imidazol-2(3H)-one (60) 
This reaction was carried out according to the procedure described for 37 using the 
following: 57 (380 mg, 1.49 mmol), SEM-Cl (0.40 mL, 2.3 mmol) and NaH (60 mg, 2.5 
mmol). The reaction yielded 60 as a clear oil (306 mg, 0.742 mmol, 70%) 
Rf, 0.52 (40% EtOAc/Hexane) 1H NMR (500 MHz, CDCl3) δ 7.47 – 7.33 (m, 5H, ArH), 7.05 – 
6.98 (m, 1H, ArH), 6.85 (dd, J = 7.9, 0.7 Hz, 1H, ArH), 6.76 (d, J = 8.3 Hz, 1H, ArH), 5.30 (s, 2H, CH2), 5.14 (s, 
2H, CH2), 4.02 – 3.97 (m, 2H, CH2), 3.62 – 3.57 (m, 2H, CH2), 1.75 – 1.66 (m, 2H, CH2), 0.94 – 0.90 (m, 2H, 
CH2), 0.77 (t, J = 7.4 Hz, 3H, CH3), -0.04 (s, 9H, Si(CH3)3). 13C NMR (126 MHz, CDCl3) δ 154.4, 144.3, 143.8, 
136.6, 130.5, 128.8, 128.4, 127.8, 118.1, 106.2, 102.7, 70.98, 70.86, 66.1, 44.6, 23.7, 18.0, 10.9, -1.3. HRMS 
calc. for C23H33O3N2Si [M+H]+, 413.2250 found, 413.22563. 
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8.4.23. Synthesis of 4-hydroxy-3-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-
benzo[d]imidazol-2(3H)-one (61) 
This reaction was carried out according to the procedure described for 38 using the 
following: 59 (382 mg, 993 µmol) and catalytic palladium on carbon. The reaction yielded 
61 as a white solid (236 mg, 961 µmol, 81%). 
Rf, 0.47 (50% EtOAc/Hexane) 1H NMR (300 MHz, CDCl3) δ 7.17 (s, 1H, OH), 6.98 – 6.86 (m, 1H, ArH), 6.77 
(dd, J = 7.9, 0.8 Hz, 1H, ArH), 6.66 (dd, J = 8.1, 0.8 Hz, 1H, ArH), 5.31 (s, 2H, CH2), 3.71 (s, 3H, CH3), 3.67 – 
3.58 (m, 2H, CH2), 0.97 – 0.88 (m, 2H, CH2), -0.05 (s, 9H, Si(CH3)3). 13C NMR (75 MHz, CDCl3) δ 154.8, 142.1, 
130.6, 122.2, 117.5, 110.2, 101.8, 71.1, 66.4, 30.0, 18.0, -1.3. HRMS calc. for C14H23N2O3Si [M+H]+, 
295.1478 found, 295.1481. IR ATR (cm-1): 3244, 2952, 2926, 1674, 1266, 1092. Mp: 123 °C. 
 
8.4.24. Synthesis of 4-hydroxy-3-propyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-
benzo[d]imidazol-2(3H)-one (62) 
This reaction was carried out according to the procedure described for 38 using the 
following: 60 (296 mg, 717 µmol) and catalytic palladium on carbon. The reaction yielded 
62 as a white solid (183 mg, 568 µmol, 79%). 
Rf, 0.36 (20% EtOAc/Hexane) 1H NMR (500 MHz, CDCl3) δ 7.03 (s, 1H, OH), 6.95 – 6.90 (m, 
1H, ArH), 6.79 – 6.77 (m, 1H, ArH), 6.68 – 6.65 (m, 1H, ArH), 5.33 (s, 2H, CH2), 4.13 – 4.09 (m, 2H, CH2), 
3.64 – 3.59 (m, 2H, CH2), 1.87 – 1.78 (m, 2H, CH2), 0.93 (t, J = 7.5 Hz, 3H, CH3), -0.06 (s, 9H, Si(CH3)3). 13C 
NMR (126 MHz, CDCl3) δ 154.7, 141.7, 130.7, 122.1, 117.1, 110.1, 101.8, 70.9, 66.4, 44.6, 23.7, 18.0, 11.1, 
-1.3. HRMS calc. for C16H27O3N2Si [M+H]+, 323.17855 found, 323.17901. IR ATR (cm-1): 3219, 2951, 1672, 
1483, 1260, 1053, 745. Mp: 127 °C. 
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8.4.25. Synthesis of 3-chloro-5-((3-methyl-2-oxo-1-((2-(trimethylsilyl)ethoxy)methyl)-2,3-
dihydro-1H-benzo[d]imidazol-4-yl)oxy)benzonitrile (63) 
This reaction was carried out according to the procedure described for 52 using 
the following: 61 (200 mg, 679 µmol), Cs2CO3 (332 mg, 1.02 mmol) and 51 (159 
mg, 1.02 mmol). This reaction yielded 63 as a clear oil (181 mg, 421 µmol, 64%). 
Rf, 0.56 (30% EtOAc/Hexane) 1H NMR (400 MHz, CDCl3) δ 7.36 – 7.35 (m, 1H, 
ArH), 7.20 – 7.19 (m, 1H, ArH), 7.12 – 7.07 (m, 3H, ArH), 6.73 (dd, J = 6.1, 3.2 Hz, 
1H, ArH), 5.33 (s, 2H, CH2), 3.66 – 3.61 (m, 2H, CH2), 3.44 (s, 3H, CH3), 0.96 – 0.91 (m, 2H, CH2), -0.03 (s, 
9H, Si(CH3)3). 13C NMR (101 MHz, CDCl3) δ 159.4, 154.3, 137.6, 136.78, 131.5, 126.4, 122.5, 121.8, 118.3, 
117.0, 114.9, 114.8, 106.7, 71.1, 66.5, 29.4, 17.9, -1.3. HRMS calc. for C21H24ClO3N3Si [M+]+, 427.12700 




This reaction was carried out according to the procedure described for 52 using 
the following: 62 (172 mg, 533 µmol), Cs2CO3 (348 mg, 1.07 mmol) and 51 (166 
mg, 1.07 mmol). This reaction yielded 64 as a clear oil (181 mg, 395 µmol, 74%). 
Rf, 0.36 (20% EtOAc/Hexane) 1H NMR (500 MHz, CDCl3) δ 7.37 – 7.36 (m, 1H, 
ArH), 7.22 – 7.21 (m, 1H, ArH), 7.14 – 7.13 (m, 1H, ArH), 7.11 – 7.07 (m, 2H, ArH), 
6.74 – 6.69 (m, 1H, ArH), 5.34 (s, 2H, CH2), 3.85 – 3.80 (m, 2H, CH2), 3.65 – 3.61 (m, 2H, CH2), 1.72 – 1.64 
(m, 2H, CH2), 0.97 – 0.91 (m, 2H, CH2), 0.86 (t, J = 7.4 Hz, 3H, CH3), -0.03 (s, 9H, Si(CH3)3). 13C NMR (126 
MHz, CDCl3) δ 159.1, 154.3, 137.6, 136.9, 131.8, 126.5, 122.4, 121.9, 121.1, 118.4, 117.0, 115.0, 114.4, 
106.5, 71.0, 66.5, 44.4, 23.3, 17.9, 11.1, -1.30. HRMS calc. for C23H28O3N3ClSi [M+]+, 458.16612 found, 
458.16653. IR ATR (cm-1): 2952, 2235, 1710, 1572, 1078, 833. 
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8.4.27. Synthesis of 3-chloro-5-((3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-
yl)oxy)benzonitrile (53) 
This reaction was carried out according to the procedure described for 22 using 
the following: 63 (139 mg, 0.323 mmol), BF3OEt2 (0.50 mL, 4.1 mmol) and NaOH 
(30 mg, 0.75 mmol). The reaction yielded 53 as a white solid (60 mg, 0.20 mmol, 
62% over two steps).  
Rf, 0.15 (40% EtOAc/Hexane) 1H NMR (500 MHz, DMSO-d) δ 11.13 (s, 1H, NH), 
7.78 – 7.77 (m, 1H, ArH), 7.48 – 7.47 (m, 1H, ArH), 7.45 – 7.44 (m, 1H, ArH), 7.04 – 7.00 (m, 1H, ArH), 6.92 
(dd, J = 7.8, 0.8 Hz, 1H, ArH), 6.73 (dd, J = 8.2, 0.8 Hz, 1H, ArH), 3.26 (s, 3H, CH3). 13C NMR (126 MHz, 
DMSO-d) δ 159.2, 154.3, 137.2, 135.3, 131.0, 126.4, 122.4, 122.0, 121.8, 119.3, 117.0, 114.2, 113.3, 106.5, 
28.4. HRMS calc. for C15H11N3O2Cl [M+H]+, 300.05343 found, 300.05322. IR ATR (cm-1): 3065, 2215, 1686, 
1574, 1230, 1105, 665. Mp: 267 °C. 
 
8.4.28. Synthesis of 3-chloro-5-((2-oxo-3-propyl-2,3-dihydro-1H-benzo[d]imidazol-4-
yl)oxy)benzonitrile (54) 
This reaction was carried out according to the procedure described for 22 using 
the following: 64 (176 mg, 0.384 mmol), BF3OEt2 (0.50 mL, 4.1 mmol) and NaOH 
(30 mg, 0.75 mmol). The reaction yielded 54 as a white solid (35 mg, 0.11 mmol, 
29% over two steps). 
Rf, 0.08 (40% EtOAc/Hexane) 1H NMR (500 MHz, CDCl3) δ 10.48 (s, 1H, NH), 7.38 
– 7.36 (m, 1H, ArH), 7.23 – 7.22 (m, 1H, ArH), 7.15 – 7.14 (m, 1H, ArH), 7.08 – 7.04 (m, 2H, ArH), 6.68 (dd, 
J = 7.4, 1.8 Hz, 1H, ArH), 3.87 – 3.82 (m, 2H, CH2), 1.74 – 1.68 (m, 2H, CH2), 0.90 (t, J = 7.4 Hz, 3H, CH3). 13C 
NMR (126 MHz, CDCl3) δ 159.2, 155.8, 137.8, 136.9, 131.0, 126.5, 122.4, 121.90, 121.87, 118.5, 117.0, 
115.0, 113.8, 107.4, 44.3, 23.4, 11.2. HRMS calc. for C17H15ClO2N3 [M+H]+, 328.08473 found, 328.08450. 
IR ATR (cm-1): 3064, 2210, 1700, 1571, 1427, 750. Mp: 210 °C. 
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This reaction was carried out according to the procedure described for 52 using 
the following: 38 (100 mg, 324 µmol), Cs2CO3 (211 mg, 648 µmol) and 5-
fluoroisophthalonitrile (70) (95 mg, 0.65 mmol). This reaction yielded 71 as a 
clear oil (132 mg, 304 µmol, 94%). 
Rf, 0.53 (30% EtOAc/Hexane) 1H NMR (500 MHz, CDCl3) δ 7.64 (t, J = 1.3 Hz, 1H, 
ArH), 7.47 (d, J = 1.4 Hz, 2H, ArH), 7.10 (dd, J = 4.7, 0.6 Hz, 2H, ArH), 6.72 – 6.68 (m, 1H, ArH), 5.32 (s, 2H, 
CH2), 3.89 (q, J = 7.1 Hz, 2H, CH2), 3.64 – 3.60 (m, 2H, CH2), 1.21 (t, J = 7.1 Hz, 3H, CH3), 0.94 – 0.91 (m, 2H, 
CH2), -0.05 (s, 9H, Si(CH3)3). 13C NMR (126 MHz, CDCl3) δ 158.9, 153.8, 136.9, 132.0, 129.5, 124.0, 122.5, 
120.8, 116.1, 115.7, 114.2, 106.9, 70.9, 66.4, 37.8, 17.8, 15.1, -1.4. HRMS calc. for C23H26O3N4Si [M+]+, 
434.17738 found, 434.17734. 
 
8.4.30. Synthesis of 5-((3-ethyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-
yl)oxy)isophthalonitrile (65) 
This reaction was carried out according to the procedure described for 22 using 
the following: 71 (132 mg, 0.304 mmol), BF3OEt2 (0.50 mL, 4.1 mmol) and NaOH 
(30 mg, 0.75 mmol). The reaction yielded 65 as a white solid (50 mg, 0.16 mmol, 
54% over two steps). 
Rf, 0.11 (40% EtOAc/Hexane) 1H NMR (500 MHz, DMSO-d) δ 11.14 (s, 1H, NH), 
8.21 (t, J = 1.3 Hz, 1H, ArH), 7.92 (d, J = 1.3 Hz, 2H, ArH), 7.05 – 6.99 (m, 1H, ArH), 6.92 (dd, J = 7.7, 0.8 Hz, 
1H, ArH), 6.71 (dd, J = 8.3, 0.7 Hz, 1H, ArH), 3.74 (q, J = 7.1 Hz, 2H, CH2), 1.10 (t, J = 7.1 Hz, 3H, CH3). 13C 
NMR (126 MHz, DMSO-d) δ 158.1, 153.9, 137.1, 131.2, 130.7, 125.3, 121.8, 121.2, 116.6, 114.4, 112.8, 
106.5, 36.6, 15.0. HRMS calc. for C17H13N4O2 [M+H]+, 305.10330 found, 305.10302. IR ATR (cm-1): 3067, 
2244, 2237, 1690, 1583, 1223. Mp: 245 °C. 
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8.4.31. Synthesis of 3-ethyl-4-(naphthalen-1-yloxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,3-
dihydro-2H-benzo[d]imidazole-2-one (72) 
This reaction was carried out according to the procedure described for 39 using the 
following: 38 (15 mg, 48 µmol), K3PO4 (20 mg, 97µmol), 2-picolinic acid (12 mg, 9.7 
µmol), iodonaphthalene (37 mg, 0.15 mmol) and CuI (9.0 mg, 4.8 µmol). The reaction 
yielded 40 as a clear oil (19 mg, 43 µmol, 91%). 
Rf, 0.35 (20% EtOAc/Hexane) 1H NMR (500 MHz, CDCl3) δ 8.34 – 8.30 (m, 1H, ArH), 
7.92 – 7.88 (m, 1H, ArH), 7.63 – 7.60 (m, 1H, ArH), 7.59 – 7.53 (m, 2H, ArH), 7.37 – 7.33 (m, 1H, ArH), 7.05 
– 7.01 (m, 2H, ArH), 6.87 – 6.84 (m, 1H, ArH), 6.73 – 6.69 (m, 1H, ArH), 5.37 (s, 2H, CH2), 4.05 (q, J = 7.0 
Hz, 2H, CH2), 3.70 – 3.65 (m, 2H, CH2), 1.30 (t, J = 7.1 Hz, 3H, CH3), 1.00 – 0.95 (m, 2H, CH2), 0.00 (s, H, 
Si(CH3)3). 13C NMR (126 MHz, CDCl3) δ 154.1, 153.6, 140.5, 135.0, 131.4, 128.0, 126.9, 126.3, 126.2, 125.8, 
123.3, 122.0, 121.7, 120.5, 113.9, 111.3, 105.0, 71.0, 66.4, 38.1, 18.0, 15.4, -1.3. HRMS calc. for 
C25H31O3N2Si [M+H]+, 435.20985 found, 435.21036.  IR ATR (cm-1): 2950, 1707, 1478, 1237, 1078, 769. 
 
8.4.32. Synthesis of 1-ethyl-7-(naphthalen-1-yloxy)-1,3-dihydro-2H-benzo[d]imidazol-2-one 
(66) 
This reaction was carried out according to the procedure described for 22 using the 
following: 72 (71 mg, 0.16 mmol), BF3OEt2 (0.30 mL, 2.4 mmol) and NaOH (20 mg, 
0.50 mmol). The reaction yielded 65 as a white solid (8.0 mg, 0.026 mmol, 16% over 
two steps). 
Rf, 0.26 (50% EtOAc/Hexane) 1H NMR (500 MHz, CDCl3) δ 10.31 (s, 1H, NH), 8.35 – 
8.31 (m, 1H, ArH), 7.92 – 7.88 (m, 1H, ArH), 7.63 – 7.54 (m, 3H, ArH), 7.38 – 7.34 (m, 1H, ArH), 7.02 – 6.96 
(m, 2H, ArH), 6.87 – 6.83 (m, 1H, ArH), 6.68 (dd, J = 7.1, 2.1 Hz, 1H, ArH), 4.06 (q, J = 7.0 Hz, 2H, CH2), 1.34 
(t, J = 7.1 Hz, 3H, CH3). 13C NMR (126 MHz, CDCl3) δ 153.7, 140.6, 135.1, 130.5, 128.0, 127.0, 126.3, 126.2, 
125.9, 123.2, 122.1, 121.7, 121.4, 113.3, 111.3, 105.9, 37.9, 15.5. HRMS calc. for C19H17O2N2 [M+H]+, 
305.12845 found, 305.12813. IR ATR (cm-1): 3188, 1703, 1473, 1227, 728. Mp: 212 °C. 
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DMF (1 mL) was added to a Schlenk tube charged with 38 (200 mg, 648 µmol), 
K2CO3 (134 mg, 970 µmol) and 4-chloropicolinonitrile (73) (135 mg, 974 µmol) 
and the reaction was carried out for 18 hours at 90 °C under argon. The reaction 
mixture was subsequently cooled to room temperature, quenched with H2O (50 
mL) and extracted twice with EtOAc (2 × 100 mL). The organic phases were 
combined, washed with brine (200 mL) and dried over MgSO4 before the solvent was removed in vacuo. 
The crude material was loaded onto silica gel and subsequently purified by column chromatography (5% 
EtOAc/hexane – 50% EtOAc/hexane) to yield the product as a clear oil. (251 mg, 611 µmol, 94%). 
Rf, 0.61 (3% MeOH/DCM) 1H NMR (400 MHz, CDCl3) δ 8.57 (d, J = 6.0 Hz, 1H, ArH), 7.28 (d, J = 2.3 Hz, 1H, 
ArH), 7.16 – 7.05 (m, 3H, ArH), 6.80 – 6.76 (m, 1H, ArH), 5.33 (s, 2H, CH2), 3.86 (q, J = 7.1 Hz, 2H, CH2), 3.68 
– 3.58 (m, 2H, CH2), 1.20 (t, J = 7.1 Hz, 3H, CH3), 0.98 – 0.89 (m, 2H, CH2), -0.03 (s, 9H, Si(CH3)3). 13C NMR 
(101 MHz, CDCl3) δ 165.2, 153.8, 153.1, 135.9, 135.8, 132.0, 122.5, 121.0, 116.8, 116.6, 114.9, 114.5, 
107.2, 71.0, 66.5, 37.8, 17.9, 15.1, -1.3. HRMS calc. for C21H27O3N4Si [M+H]+, 411.18469 found, 411.18478.  
 
8.4.34. Synthesis of 4-((3-ethyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-
yl)oxy)picolinonitrile (67) 
This reaction was carried out according to the procedure described for 22 using 
the following: 76 (118 mg, 0.287 mmol), BF3OEt2 (0.40 mL, 3.2 mmol) and NaOH 
(23 mg, 0.57 mmol). The reaction yielded 67 as a white solid (59 mg, 0.21 mmol, 
74% over two steps).  
Rf, 0.51 (60% EtOAc/Hexane) 1H NMR (400 MHz, CDCl3) δ 10.76 (s, 1H, NH), 8.59 (d, J = 5.7 Hz, 1H, ArH), 
7.30 (d, J = 2.2 Hz, 1H, ArH), 7.12 – 7.08 (m, 3H, ArH), 6.81 – 6.74 (m, 1H, ArH), 3.88 (q, J = 7.0 Hz, 2H, CH2), 
1.24 (t, J = 7.1 Hz, 3H, CH3). 13C NMR (101 MHz, CDCl3) δ 165.3, 155.5, 153.1, 136.0, 135.8, 131.2, 122.6, 
121.7, 116.8, 116.6, 114.5, 114.3, 108.3, 37.6, 15.2. HRMS calc. for C15H13O2N4 [M+H]+, 281.10330 found, 
281.10297. IR ATR (cm-1): 3135, 2980, 2243, 1701, 1634, 1579, 749.  Mp: 198 °C. 
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8.4.35. Synthesis of 2-((3-ethyl-2-oxo-1-((2-(trimethylsilyl)ethoxy)methyl)-2,3-dihydro-1H-
benzo[d]imidazol-4-yl)oxy)isonicotinonitrile (77) 
 This reaction was carried out according to the procedure described for 76 using the 
following: 38 (100 mg, 324 µmol), K2CO3 (70 mg, 0.51 mmol) and 2-
chloropicolinonitrile (74) (71 mg, 0.51 mmol). The reaction yielded 77 as a clear oil 
(121 mg, 295 µmol, 90%). 
Rf, 0.51 (3% MeOH/DCM) 1H NMR (500 MHz, CDCl3) δ 8.34 (dd, J = 5.1, 0.6 Hz, 1H, 
ArH), 7.27 – 7.24 (m, 2H, ArH), 7.12 – 7.07 (m, 2H, ArH), 6.84 – 6.80 (m, 1H, ArH), 5.31 (s, 2H, CH2), 3.88 
(q, J = 7.1 Hz, 2H, CH2), 3.64 – 3.59 (m, 2H, CH2), 1.18 (t, J = 7.1 Hz, 3H, CH3), 0.95 – 0.90 (m, 2H, CH2), -0.03 
(s, 9H, Si(CH3)3). 13C NMR (126 MHz, CDCl3) δ 163.9, 153.9, 149.5, 136.2, 131.5, 123.8, 121.8, 121.3, 120.2, 
116.0, 115.9, 113.6, 106.5, 70.9, 66.3, 37.6, 17.8, 14.9, -1.4. HRMS calc. for C21H27O3N4Si [M+H]+, 
411.18469 found, 411.18521. IR ATR (cm-1): 2952, 2241, 1707, 1597, 1077. 
 
8.4.36. Synthesis of 2-((3-ethyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-
yl)oxy)isonicotinonitrile (68) 
This reaction was carried out according to the procedure described for 22 using the 
following: 77 (121 mg, 0.295 mmol), BF3OEt2 (0.40 mL, 3.2 mmol) and NaOH (24 mg, 
0.59 mmol). The reaction yielded 68 as a white solid (75 mg, 0.27 mmol, 90% over 
two steps). 
Rf, 0.15 (60% EtOAc/Hexane) 1H NMR (500 MHz, CDCl3) δ 10.74 (s, 1H, NH), 8.36 (d, 
J = 5.0 Hz, 1H, ArH), 7.28 – 7.24 (m, 2H, ArH), 7.09 – 7.03 (m, 2H, ArH), 6.80 (dd, J = 7.7, 1.4 Hz, 1H, ArH), 
3.91 (q, J = 7.1 Hz, 2H, CH2), 1.24 (t, J = 7.1 Hz, 3H, CH3). 13C NMR (126 MHz, CDCl3) δ 164.0, 155.6, 149.6, 
136.4, 130.8, 123.9, 122.1, 121.9, 120.2, 116.0, 115.4, 113.6, 107.6, 37.4, 15.1. HRMS calc. for C15H13O2N4 
[M+H]+, 281.10330 found, 281.10298. IR ATR (cm-1): 2969, 2241, 1697, 1636, 1596, 1117. Mp: 201 °C. 
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8.4.37. Synthesis of 4-((2-chloropyridin-4-yl)oxy)-3-ethyl-1-((2-(trimethylsilyl)ethoxy)methyl)-
1,3-dihydro-2H-benzo[d]imidazol-2-one (78) 
This reaction was carried out according to the procedure described for 76 using the 
following: 38 (150 mg, 486 µmol), K2CO3 (101 mg, 729 µmol) and 2,4-dichloropyridine 
(75) (86 mg, 0.58 mmol). The reaction yielded 77 as a yellow oil (126 mg, 300 µmol, 
62%). 
Rf, 0.62 (100% EtOAc) 1H NMR (400 MHz, CDCl3) δ 8.28 – 8.25 (m, 1H, ArH), 7.13 – 
7.08 (m, 2H, ArH), 6.89 – 6.77 (m, 3H, ArH), 5.32 (s, 2H, CH2), 3.87 (q, J = 7.1 Hz, 2H, CH2), 3.66 – 3.59 (m, 
2H, CH2), 1.21 (t, J = 7.1 Hz, 3H, CH3), 0.97 – 0.89 (m, 2H, CH2), -0.04 (s, 9H, Si(CH3)3). 13C NMR (101 MHz, 
CDCl3) δ 166.4, 153.9, 153.2, 151.2, 136.4, 131.8, 122.3, 121.0, 115.2, 111.6, 110.9, 106.9, 71.0, 66.5, 37.8, 
17.9, 15.1, -1.3. HRMS calc. for C20H27O3N3ClSi [M+H]+, 420.15047 found, 420.15115. 
 
8.4.38. Synthesis of 7-((2-chloropyridin-4-yl)oxy)-1-ethyl-1,3-dihydro-2H-benzo[d]imidazol-2-
one (69) 
 This reaction was carried out according to the procedure described for 22 using the 
following: 78 (120 mg, 0.286 mmol), BF3OEt2 (0.40 mL, 3.2 mmol) and NaOH (23 mg, 
0.57 mmol). The reaction yielded 69 as a white solid (55 mg, 0.19 mmol, 66% over 
two steps). 
Rf, 0.17 (100% EtOAc) 1H NMR (400 MHz, CDCl3) δ 10.90 (s, 1H, NH), 8.29 (d, J = 5.7 
Hz, 1H, ArH), 7.11 – 7.03 (m, 2H, ArH), 6.91 – 6.74 (m, 3H, ArH), 3.91 (q, J = 7.1 Hz, 2H, CH2), 1.26 (t, J = 7.1 
Hz, 3H, CH3). 13C NMR (101 MHz, CDCl3) δ 166.5, 155.7, 153.2, 151.2, 136.5, 131.1, 122.4, 121.7, 114.5, 
111.6, 110.9, 107.9, 37.6, 15.2. HRMS calc. for C14H13ClO2N3 [M+H]+, 290.06908 found, 290.06895. 
 
8.4.39. Synthesis of 2-aminoresorcinol (81) 
 A mixture of 2-nitroresorcinol (80) (537 mg, 3.46 mmol) and a catalytic amount of palladium 
on activated charcoal in ethanol (10 mL) was vigorously stirred for 4 hours under an 
atmosphere of hydrogen. When the reaction had reached completion, the palladium was 
removed by filtration through celite. The filtrate was then concentrated in vacuo to yield the reduced 
product as a brown solid (414 mg, 3.31 mmol, 96%). This was taken to the next step crude. 
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Rf, 0.37 (60% EtOAc/Hexane) 1H NMR (300 MHz, CDCl3, CD3OD) δ 6.46 (t, J = 7.9 Hz, 1H, ArH), 6.30 (d, J = 
7.9 Hz, 2H, ArH).13C NMR (75 MHz, CDCl3, CD3OD) δ 146.2, 122.2, 119.0, 107.4. HRMS calc. for C6H8NO2 
[M+H]+, 126.0555 found, 126.0552. Mp: 161 °C. 
 
8.4.40. Synthesis of N-(2,6-dihydroxyphenyl)acetamide (82) 
 Triethylamine (2.2 mL, 16 mmol) was added to 81 (400 mg, 3.20 mmol) in THF (15 mL) at 0°C. 
After approximately 15 minutes acetyl chloride (0.30 mL, 3.5 mmol) was added to the reaction 
mixture at 0°C. The reaction was then allowed to warm to room temperature. After 18 hours 
the reaction mixture was basified with a 1M solution of KOH (50 mL) and stirred for 2 hours before 1M 
HCl (100 mL) was then added to acidify the reaction mixture to a pH of 2. The aqueous layer was extracted 
3 times with EtOAc (3 × 100 mL), the combined organic layers where then washed with brine (300 mL), 
dried over MgSO4, concentrated in vacuo and purified by silica gel column chromatography (40% – 100% 
EtOAc/Hexane) to yield the product 82 as an off-white solid (430 mg, 2.57 mmol, 80%) 
Rf, 0.37 (60% EtOAc/Hexane) 1H NMR (300 MHz, DMSO-d) δ 9.33 (s, 3H, NH/OH), 6.87 (t, J = 8.1 Hz, 1H, 
ArH), 6.35 (d, J = 8.1 Hz, 2H, ArH), 2.11 (s, 3H, CH3). 13C NMR (75 MHz, DMSO-d) δ 171.3, 153.0, 127.6, 
115.0, 108.5, 23.7. HRMS calc. for C8H10NO3 [M+H]+, 168.0661 found, 168.0658. IR ATR (cm-1): 3399, 3380, 
3277, 1656, 1536, 1485, 1026. Mp: 175 °C. 
 
8.4.41. Synthesis of 2-(ethylamino)benzene-1,3-diol (83) 
Aluminium trichloride (957 mg, 7.18 mmol) was added portionwise to lithium aluminium 
hydride (272 mg, 7.18 mmol) in THF (15 mL) at 0°C. The reaction was taken to room 
temperature and stirred for approximately 10 minutes before being once again cooled to 0°C 
at which point 82 (384 mg, 2.30 mmol) was added. The reaction was subsequently heated under reflux 
for 18 hours. After cooling the reaction was quenched with HCl (50 mL) and the crude product was 
extracted twice into EtOAc (2 × 100 mL). The organic phase was dried over MgSO4, concentrated in vacuo 
and subsequently purified by column chromatography (20% – 80% EtOAc/Hexane) to afford the product 
83 as a brown solid (214 mg, 1.40 mmol, 61%).  
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Rf, 0.25 (60% EtOAc/Hexane) 1H NMR (300 MHz, DMSO-d) δ 6.42 (t, J = 7.8 Hz, 1H, ArH), 6.24 (d, J = 7.8 
Hz, 2H, ArH), 3.36 (s, 3H, OH/NH), 3.12 (q, J = 7.1 Hz, 2H, CH2), 1.02 (t, J = 7.1 Hz, 3H, CH3). 13C NMR (75 
MHz, DMSO-d) δ 149.7, 125.6, 120.3, 107.8, 41.6, 17.0. HRMS calc. for C8H12NO2 [M+H]+, 154.0868 found, 
154.0867. IR ATR (cm-1): 3128, 2962, 1564, 1447, 1340, 1013. Mp: 153 °C.  
 
8.4.42. Synthesis of 3-ethyl-4-hydroxybenzo[d]oxazol-2(3H)-one (84) 
This reaction was carried out according to the procedure (conditions B) described for 36 
using the following: CDI (159 mg, 9.79 mmol) and 83 (100 mg, 653 µmol). This reaction 
yielded 84 as a yellow solid (97 mg, 541 µmol, 83%). 
Rf, 0.53 (60% EtOAc/Hexane) 1H NMR (300 MHz, CDCl3, CD3OD) δ 6.86 – 6.78 (m, 1H, ArH), 6.65 (dd, J = 
8.0, 0.8 Hz, 1H, ArH), 6.57 (dd, J = 8.3, 0.8 Hz, 1H, ArH), 3.99 (q, J = 7.1 Hz, 2H, CH2), 1.30 (t, J = 7.1 Hz, 3H, 
CH3). 13C NMR (75 MHz, CDCl3, CD3OD) δ 155.1, 144.1, 142.7, 122.6, 118.2, 111.4, 101.8, 38.9, 14.7.  HRMS 
calc. for C9H10NO3 [M+H]+, 180.0661 found, 180.0654. Mp: 247 °C. 
 
8.4.43. Synthesis of 3-chloro-5-((3-ethyl-2-oxo-2,3-dihydrobenzo[d]oxazol-4-
yl)oxy)benzonitrile (79) 
This reaction was carried out according to the procedure described for 52 using 
the following: 51 (113 mg, 728 µmol), 84 (87 mg, 0.49 mmol) and Cs2CO3 (237 mg, 
728 µmol). This reaction yielded the desired product 79 as a yellow solid (67 mg, 
0.21 mmol, 42%). 
Rf, 0.51 (40% EtOAc/Hexane) 1H NMR (400 MHz, CDCl3) δ 7.43 – 7.41 (m, 1H, ArH), 7.27 – 7.24 (m, 1H, 
ArH), 7.19 – 7.18 (m, 1H, ArH), 7.15 – 7.09 (m, 2H, ArH), 6.82 – 6.76 (m, 1H, ArH), 3.90 (q, J = 7.2 Hz, 2H, 
CH2), 1.30 (t, J = 7.2 Hz, 3H, CH3). 13C NMR (101 MHz, CDCl3) δ 158.3, 144.7, 137.8, 136.9, 127.0, 122.9, 
122.5, 122.1, 118.6, 116.6, 115.8, 115.1, 110.6, 107.5, 39.0, 14.5. HRMS calc. for C16H12N2O3Cl [M+H]+, 
315.0536 found, 315.0536. IR ATR (cm-1): 3075, 2236, 1761, 1206, 857. Mp: 101 °C. 
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8.4.44. Synthesis of 3-ethyl-4-methoxy-1-((2-(trimethylsilyl)ethoxy)methyl)-1,3-dihydro-2H-
benzo[d]imidazol-2-one (87) 
 Methyl iodide (30 µL, 0.48) was added to a mixture of 38 (100 mg, 0.324 mmol) and NaH 
(60% in mineral oil, 20 mg, 0.83 mmol) in DMF (2 mL). After 2 hours at room temperature 
the reaction was quenched with a saturated solution of NH4Cl (20 mL) and extracted twice 
with EtOAc (2 × 50 mL). The organic phases were combined, dried over MgSO4 and 
concentrated in vacuo. Subsequent purification by column chromatography (5% – 30% EtOAc/Hexane) 
afforded 87 as a clear oil (96 mg, 0.30 mmol, 92%). 
Rf, 0.38 (20% EtOAc/Hexane) 1H NMR (400 MHz, CDCl3) δ 7.04 – 6.98 (m, 1H, ArH), 6.84 – 6.80 (m, 1H, 
ArH), 6.69 – 6.65 (m, 1H, ArH), 5.29 (s, 2H, CH2), 4.14 (q, J = 7.1 Hz, 2H, CH2), 3.91 (s, 3H, CH3), 3.62 – 3.55 
(m, 2H, CH2), 1.30 (t, J = 7.1 Hz, 3H, CH3), 0.94 – 0.88 (m, 2H, CH2), -0.05 (s, 9H, Si(CH3)3). 13C NMR (101 
MHz, CDCl3) δ 154.1, 145.1, 130.2, 121.8, 117.6, 105.1, 102.4, 70.8, 66.1, 55.9, 38.1, 17.9, 15.5, -1.3. HRMS 
calc. for C16H27O3N2Si [M+H]+, 323.17855 found, 323.17871. 
 
8.4.45. Synthesis of 3-ethyl-4-((3-methylbut-2-en-1-yl)oxy)-1-((2-
(trimethylsilyl)ethoxy)methyl)-1,3-dihydro-2H-benzo[d]imidazol-2-one (88) 
Prenylbromide (50 µL, 0.43 mmol) was added to a solution of 38 (100 mg, 0.324 
mmol) and K2CO3 (54 mg, 0.39 mmol) in DMF (2 mL). After 18 hours at room 
temperature, the reaction was quenched with a saturated solution of NH4Cl (20 mL) 
)and extracted twice with EtOAc (2 × 50 mL). The organic phases were combined, 
dried over MgSO4 and concentrated in vacuo. Subsequent purification by column 
chromatography (5% – 30% EtOAc/Hexane) afforded 88 as a clear oil (79 mg, 0.21 mmol, 65%). 
Rf, 0.36 (20% EtOAc/Hexane) 1H NMR (500 MHz, CDCl3) δ 7.01 – 6.97 (m, 1H, ArH), 6.81 (dd, J = 7.9, 0.7 
Hz, 1H, ArH), 6.69 – 6.66 (m, 1H, ArH), 5.51 – 5.47 (m, 1H, CH), 5.28 (s, 2H, CH2), 4.61 (d, J = 6.6 Hz, 2H, 
CH2), 4.15 (q, J = 7.1 Hz, 2H, CH2), 3.62 – 3.56 (m, 2H, CH2), 1.79 (s, 3H, CH3), 1.75 (s, 3H, CH3), 1.30 (t, J = 
7.1 Hz, 3H, CH3), 0.93 – 0.88 (m, 2H, CH2), -0.05 (s, 9H, Si(CH3)3). 13C NMR (126 MHz, CDCl3) δ 154.1, 144.3, 
138.1, 130.4, 121.7, 119.6, 117.9, 106.3, 102.3, 70.8, 66.1, 65.6, 38.0, 25.8, 18.3, 17.9, 15.5, -1.3. HRMS 
calc. for C20H33O3N2Si [M+H]+, 377.22550 found, 377.22587. 
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8.4.46. Synthesis of 3-ethyl-4-hydroxy-1H-benzimidazol-2-one (89) 
This reaction was carried out according to the procedure described for 38 using the 
following: 36 (116 mg, 0.651 mmol) and catalytic palladium on activated carbon. 
The reaction afforded 89 as a white solid (59 mg, 0.33 mmol, 77%). 
Rf, 0.29 (40% EtOAc/Hexane) 1H NMR (500 MHz, DMSO-d) δ 10.66 (s, 1H, NH or OH), 9.66 (s, 1H, NH or 
OH), 6.78 – 6.73 (m, 1H, ArH), 6.50 – 6.44 (m, 2H, ArH), 3.94 (q, J = 7.0 Hz, 2H, CH2), 1.20 (t, J = 7.0 Hz, 3H, 
CH3). 13C NMR (126 MHz, DMSO-d) δ 153.9, 141.9, 130.0, 121.2, 117.1, 108.3, 100.7, 36.4, 15.6. HRMS 
calc. for C9H11N2O2 [M+H]+, 179.0821 found, 179.0814. IR ATR (cm-1): 3154, 2975, 1650, 1614. Mp: 218 °C. 
 
8.4.47. Synthesis of 1-ethyl-7-methoxy-1,3-dihydro-2H-benzo[d]imidazol-2-one (85) 
This reaction was carried out according to the procedure described for 87 using the 
following: 89 (30 mg, 0.17 mmol), methyl iodide (10 µL, 0.17 mmol) and NaH (60% in 
mineral oil, 7.0 mg, 0.29 mmol). This reaction afforded 85 as a white solid (7.0 mg, 0.036 
mmol, 22%). 
Rf, 0.14 (30% EtOAc/Hexane) 1H NMR (500 MHz, CDCl3) δ 10.10 (s, 1H, NH), 7.01 – 6.96 (m, 1H, ArH), 6.80 
– 6.76 (m, 1H, ArH), 6.65 – 6.62 (m, 1H, ArH), 4.15 (q, J = 7.1 Hz, 2H, CH2), 3.91 (s, 3H, OCH3), 1.34 (t, J = 
7.1 Hz, 3H, CH3). 13C NMR (126 MHz, CDCl3) δ 155.5, 145.2, 129.4, 121.9, 118.6, 104.5, 103.4, 55.9, 37.9, 
15.7. HRMS calc. for C10H13N2O2 [M+H]+, 193.09715 found, 193.09701. IR ATR (cm-1): 3017, 2951, 1688, 
1469, 1238. Mp: 124 °C. 
 
8.4.48. Synthesis of 1-ethyl-7-((3-methylbut-2-en-1-yl)oxy)-1,3-2H-benzo[d]imidazole-2-one 
(86) 
This reaction was carried out according to the procedure described for 88 using the 
following: prenylbromide (15 µL, 0.15 mmol) 89 (26 mg, 0.15 mmol) and K2CO3 (20 
mg, 0.15 mmol). This reaction afforded the product 86 as a white solid (15 mg, 0.065 
mmol, 44%). 
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Rf, 0.17 (40% EtOAc/Hexane) 1H NMR (400 MHz, CDCl3) δ 10.41 (s, 1H, NH), 7.10 – 6.86 (m, 1H, ArH), 6.78 
(d, J = 7.8 Hz, 1H, ArH), 6.63 (d, J = 8.3 Hz, 1H, ArH), 5.50 (t, J = 5.6 Hz, 1H, C=CH), 4.61 (d, J = 6.6 Hz, 2H, 
CH2), 4.17 (q, J = 7.0 Hz, 2H, CH2), 1.80 (s, 3H, CH3), 1.75 (s, 3H, CH3), 1.34 (t, J = 7.1 Hz, 3H, CH3). 13C NMR 
(101 MHz, CDCl3) δ 155.6, 144.5, 138.1, 129.6, 121.8, 119.6, 118.7, 105.4, 103.3, 65.5, 37.8, 25.9, 18.4, 
15.7. HRMS calc. for C14H19N2O2 [M+H]+, 247.14410 found, 247.14393. IR ATR (cm-1): 2968, 2926, 1687, 
1627, 1237, 719. Mp: 135 °C. 
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8.5. Experimental pertaining to Chapter 4 
 
8.5.1. Synthesis of 3-(3-fluorophenyl)propiolamide (94) 
Conditions A: Toluene (3 mL) was added to an oven dried Schlenk tube and degassed 
under a positive pressure of argon for 15 minutes. To the toluene was added 3-
fluoroiodobenzene (92) (0.20 mL, 1.8 mmol) and propiolamide (124 mg, 1.80 mmol), 
followed by Pd(PPh3)4 (62 mg, 54 µmol), copper iodide (31 mg, 0.16 mmol) and finally 
trimethylamine (0.25 mL, 1.8 mmol). The reaction was carried out for 18 hours at room temperature after 
which the reaction mixture was diluted with EtOAc (50 mL) and quenched with H2O (50 mL). The organic 
phase was separated and washed with brine (50 mL). The organic phase was then dried over MgSO4, 
concentrated in vacuo and purified on silica gel by column chromatography (40% – 100% EtOAc/hexane) 
to yield the product as a yellow solid (37 mg, 0.23 mmol, 13%). 
Conditions B: To an oven dried Schlenk tube, DMF (3 mL) was added and degassed under a positive 
pressure of argon for 10 minutes. To the DMF was added 92 (0.11 mL, 0.90 mmol) and propiolamide (75 
mg, 1.1 mmol) followed by triethylamine (0.60 mL, 4.5 mmol), triphenylphosphine (9.0 mg, 36 µmol) and 
finally Pd(OAc)2 (4.0 mg, 18 µmol). Once all reagents had been added the reaction was heated to 70 °C. 
After 18 hours the reaction was cooled to room temperature and quenched with H2O (30 mL). The reaction 
mixture was then extracted twice with EtOAc (2 × 50 mL), the organic phases were combined and washed 
with brine (100 mL) and then dried over MgSO4 before being concentrated in vacuo. The crude product 
was then purified on silica gel by column chromatography (40% – 100% EtOAc/Hexane) to yield the 
product as a yellow solid (101 mg, 0.619 mmol, 69%). 
Rf, 0.28 (60% EtOAc/Hexane) 1H NMR (300 MHz, CDCl3) δ 7.39 – 7.29 (m, 2H, ArH), 7.25 – 7.20 (m, 1H, 
ArH), 7.18 – 7.09 (m, 1H, ArH), 5.98 (2 × s, 2H, NH2). 13C NMR (75 MHz, CDCl3) δ 162.4 (d, JCF = 248 Hz), 
154.7, 130.5 (d, JCF = 8.5 Hz), 128.7 (d, JCF = 3.3 Hz), 121.9 (d, JCF = 9.9 Hz), 119.5 (d, JCF = 24 Hz), 118.0 (d, 
JCF = 21 Hz), 84.5 (d, JCF = 3.3 Hz), 82.9. HRMS calc. for C9H7FNO [M+H]+, 164.0512 found, 164.0513. IR ATR 
(cm-1): 3378, 3164, 2212, 1674, 1606, 1578. Mp: 112 °C. 
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8.5.2. Synthesis of ethyl 3-(3-fluorophenyl)propiolate (98) 
Sonogashira conditions: This reaction was carried out according to the procedure 
(conditions A) described for 94 using the following: 3-fluoroiodobenzene (92) (0.20 
mL, 1.8 mmol), ethyl propiolate (0.18 mL, 1.80 mmol), Pd(PPh3)4 (62 mg, 54 µmol), 
copper iodide (31 mg, 0.16 mmol) and finally trimethylamine (0.25 mL, 1.8 mmol). 
This reaction yielded 98 as a yellow oil (15 mg, 0.078 mmol, 4%). 
Negishi conditions: THF (5 mL) was added to an oven dried Schlenk tube and degassed under a positive 
pressure of argon for 15 minutes. n-BuLi (1.3 M in THF, 1.7 mL, 2.2 mmol) was then added to the THF 
followed by diisopropylamine (0.30 mL, 2.2 mmol) at -78 °C. To the reaction mixture was then added 92 
(0.2 mL, 1.8 mmol), zinc (II) bromide (568 mg, 2.52 mmol), ethyl propiolate (0.26 mL, 2.5 mmol) and 
Pd(PPh3)4 (104 mg, 90.0 µmol). The reaction was allowed to warm to room temperature and after 18 hours 
the reaction mixture was quenched with a saturated NH4Cl (40 mL) solution and extracted twice with Et2O 
(2 × 50 mL). The organic phase was then washed with a saturated solution of NaHCO3 (100 mL) followed 
by brine (100 mL). The organic phase was dried over MgSO4, concentrated in vacuo and purified on silica 
by column chromatography (5% – 20% EtOAc/Hexane) to yield the product as a yellow oil (45 mg, 0.23 
mmol, 13%). 
Rf, 0.53 (20% EtOAc/Hexane) 1H NMR (400 MHz, CDCl3) δ 7.40 – 7.32 (m, 2H, ArH), 7.30 – 7.25 (m, 1H, 
ArH), 7.20 – 7.13 (m, 1H, ArH), 4.31 (q, J = 7.1 Hz, 2H, CH2), 1.36 (t, J = 7.1 Hz, 3H, CH3). 13C NMR (75 MHz, 
CDCl3) δ 162.6 (d, JCF = 248 Hz), 154.1, 130.7 (d, JCF = 9 Hz), 129.2 (d, JCF = 3 Hz), 121.8 (d, JCF = 10 Hz), 120.0 
(d, JCF = 23 Hz), 118.4 (d, JCF = 21 Hz), 84.6 (d, JCF = 4 Hz), 81.5, 62.6, 14.4. 
This spectroscopic data compares favourably with that in the literature.228 
 
8.5.3. Synthesis of diethyl (E)-hex-2-en-4-ynedioate (99) 
Compound 99 was formed under the Sonogashira conditions described for 
the synthesis of 98. This product was obtained as an orange solid. 
 1H NMR (400 MHz, CDCl3) δ 6.74 (d, J = 16 Hz, 1H, CH), 6.42 (d, J = 16 Hz, 
1H, CH), 4.27 – 4.18 (m, 4H, CH2), 1.32 – 1.26 (m, 6H, CH3). 13C NMR (101 MHz, CDCl3) δ 164.7, 153.2, 
135.5, 121.6, 87.1, 81.5, 62.5, 61.4, 14.2, 14.0. 
This spectroscopic data compares favourably with that in the literature.229 
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8.5.4. Synthesis of ethyl (E)-3-(diisopropylamino)acrylate (100) 
Compound 100 was formed under the Negishi conditions described for the 
synthesis of 98. This product was obtained as a yellow oil. 
1H NMR (300 MHz, CDCl3) δ 7.53 (d, J = 13.2 Hz, 1H, CH), 4.63 (d, J = 13.1 Hz, 1H, CH), 4.09 (q, J = 7.1 Hz, 
2H, CH2), 3.69 – 7.53 (m, 2H, CH), 1.22 (t, J = 7.1 Hz, 3H, CH3), 1.17 (d, J = 6.8 Hz, 12H). 
This spectroscopic data compares favourably with that in the literature.234 
 
8.5.5. Synthesis of ((3-fluorophenyl)ethynyl)trimethylsilane (101) 
This reaction was carried out according to the procedure (conditions A) described for 
94 using the following: 92 (0.11 mL, 0.90 mmol), ethynyltrimethysilane (0.13 mL, 0.90 
mmol), Pd(PPh3)4 (31 mg, 27 µmol), copper iodide (15 mg, 81 µmol) and trimethylamine 
(0.13 mL, 0.90 mmol). This reaction afforded 101 as a colourless oil (174 mg, 0.90 mmol, 
quant.). 
Rf, 0.59 (100% hexane) 1H NMR (300 MHz, CDCl3) δ 7.28 – 7.19 (m, 2H, ArH), 7.17 – 7.11 (m, 1H, ArH), 
7.04 – 6.96 (m, 1H, ArH), 0.24 (s, 9H, Si(CH3)). 13C NMR (75 MHz, CDCl3) δ 162.4 (d, JCF = 246 Hz), 129.9 (d, 
JCF = 8.6 Hz), 128.0 (d, JCF = 3.0 Hz), 125.1 (d, J = 9.1 Hz), 118.9 (d, JCF = 23 Hz), 116.0 (d, JCF = 21 Hz), 103.8 
(d, JCF = 3 Hz), 95.5, 0.0. 
This spectroscopic data compares favourably with that in the literature.228 
 
8.5.6. Synthesis of 3-(3-fluorophenyl)prop-2-yn-1-ol (107) 
This reaction was carried out according to the procedure (conditions A) described for 
94 using the following: 92 (0.22 mL, 1.8 mmol), propargyl alcohol (0.11 mL, 1.8 mmol), 
Pd(PPh3)4 (62 mg, 54 µmol), copper iodide (30 mg, 0.16 mmol) and trimethylamine 
(0.26 mL, 1.8 mmol). This reaction afforded 107 as a yellow oil (264 mg, 1.76 mmol, 97%).  
Rf, 0.4 (40% EtOAc/Hexane) 1H NMR (300 MHz, CDCl3) δ 7.30 – 7.18 (m, 2H, ArH), 7.15 – 7.09 (m, 1H, ArH), 
7.06 – 6.98 (m, 1H, ArH), 4.50 (d, J = 5.9 Hz, 2H, CH2), 2.43 (t, J = 5.9 Hz, 1H, OH). 13C NMR (75 MHz, CDCl3) 
δ 162.4 (d, JCF = 245 Hz), 130.0 (d, JCF = 9 Hz), 127.7 (d, JCF = 3 Hz), 124.5 (d, JCF = 9 Hz), 118.6 (d, JCF = 23 
Hz), 116.0 (d, JCF = 21 Hz), 88.3, 84.5 (d, JCF = 3 Hz), 51.5.  
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This spectroscopic data compares favourably with that in the literature.284 
 
8.5.7. Synthesis of 3-(3-fluorophenyl)propiolonitrile (96) 
DMSO (0.25 mL, 3.4 mmol) in DCM (1 mL) was added to oxalyl chloride (70 µL, 0.80 mmol) 
in DCM (1 mL) in a Schlenk tube at -78 °C. After 15 minutes 94 (94 mg, 0.57 mmol) in a 
mixture of DCM (1 mL) and DMSO (0.2 mL) was added dropwise to the reaction mixture 
at -78 °C and the reaction mixture was stirred for 20 minutes. Finally, triethylamine (0.20 mL, 1.6 mmol) 
was added at -78 °C to the reaction mixture, after which the reaction was allowed to warm to room 
temperature. The reaction was monitored by TLC and after 1 hour all the starting material had been 
consumed. The reaction was quenched with NH4Cl (40 mL) and extracted twice with DCM (2 × 50 mL). The 
organic layers were combined, washed with brine (100 mL), dried over MgSO4 and concentrated in vacuo. 
The crude material was purified on silica gel by column chromatography (10% EtOAc/Hexane) to yield the 
dehydrated product 96 as a yellow solid (57 mg, 0.054 mmol, 69%). 
Rf, 0.76 (60% EtOAc/Hexane) 1H NMR (300 MHz, CDCl3) δ 7.47 – 7.38 (m, 2H, ArH), 7.35 – 7.24 (m, 2H, 
ArH). 13C NMR (75 MHz, CDCl3) δ 162.29 (d, JCF = 249 Hz), 130.92 (d, JCF = 8.5 Hz), 129.64 (d, JCF = 3.7 Hz), 
120.32 (d, JCF = 24 Hz), 119.78 (d, JCF = 21 Hz), 119.44 (d, JCF = 9.0 Hz), 105.26, 81.36 (d, JCF = 3.3 Hz), 63.85. 
IR ATR (cm-1): 3076, 2259, 2146, 1577, 1289, 1173. Mp: 53 °C. 
 
8.5.8. Synthesis of (E)-3-((3-ethyl-2-oxo-1-((2-(trimethylsilyl)ethoxy)methyl)-2,3-dihydro-1H-
benzo[d]imidazol-4-yl)oxy)-3-(3-fluorophenyl)acrylonitrile (115) 
This reaction was carried out according to the procedure described for 52 using the 
following: 38 (50 mg, 0.16 mmol), 96 (35 mg, 0.24 mmol) and Cs2CO3 (87 mg, 0.24 
mmol). Only trace amounts of 115 were obtained. 
 Rf, 0.43 (20% EtOAc/Hexane) 1H NMR (300 MHz, CDCl3) δ 7.90 – 7.84 (m, 1H, ArH), 
7.73 – 7.67 (m, 1H, ArH), 7.57 – 7.49 (m, 1H, ArH), 7.33 – 7.28 (m, 1H, ArH), 7.17 – 
7.09 (m, 2H, ArH), 6.84 (dd, J = 6.7, 2.6 Hz, 1H, ArH), 5.33 (s, 2H, CH2), 4.72 (s, 1H, CH), 3.91 (q, J = 7.1 Hz, 
2H, CH2), 3.68 – 3.59 (m, 2H, CH2), 1.25 (t, J = 7.1 Hz, 3H, CH3), 0.99 – 0.90 (m, 2H, CH2), -0.03 (s, 9H, 
Si(CH3)3). 13C NMR (101 MHz, CDCl3) δ 166.6 (d, JCF = 2.9 Hz), 163.0 (d, JCF = 248.3 Hz), 154.1, 139.6, 134.2 
(d, JCF = 7.7 Hz), 131.3, 131.1 (d, JCF = 8.4 Hz), 122.3 (d, JCF = 3.1 Hz), 121.9, 119.6, 119.1 (d, JCF = 21.7 Hz), 
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114.0 (d, JCF = 23.6 Hz), 113.6, 111.5, 105.9, 82.6, 71.0, 66.4, 38.3, 17.9, 15.5, -1.3. HRMS calc. for 
C24H29FN3O3Si [M+H]+, 454.1962 found, 454.1948. IR ATR (cm-1): 3056, 2952, 2218, 1712, 1582, 1210, 
1078. 
 
8.5.9. Synthesis of (E)-3-(3-fluorophenyl)acrylamide (119) 
This reaction was carried out according to the procedure (conditions B) described for 
94 using the following: 92 (0.11 mL, 0.90 mmol), acrylamide (77 mg, 1.1 mmol), 
triethylamine (0.60 mL, 4.5 mmol), triphenylphosphine (9.0 mg, 36 µmol) and 
Pd(OAc)2 (4.0 mg, 18 µmol). This reaction afforded the product 119 as a brown solid 
(150 mg, 0.901 mmol, quant.). 
Rf, 0.32 (100% EtOAc) 1H NMR (300 MHz, CDCl3) δ 7.62 (d, J = 15.7 Hz, 1H, CH), 7.39 – 7.32 (m, 1H, ArH), 
7.31 – 7.26 (m, 1H, ArH), 7.24 – 7.18 (m, 1H, ArH), 7.11 – 7.04 (m, 1H, ArH), 6.49 (d, J = 15.7 Hz, 1H, CH), 
5.99 (2 × s, 2H, NH2). 13C NMR (75 MHz, CDCl3) δ 167.6, 164.5 (d, JCF = 246 Hz), 141.2 (d, JCF = 2.6 Hz), 136.8 
(d, JCF = 8.0 Hz), 130.4 (d, JCF = 8.4 Hz), 124.0 (d, JCF = 2.9 Hz), 120.9, 116.8 (d, JCF = 21 Hz), 114.1, (d, JCF = 22 
Hz). HRMS calc. for C9H9FNO [M+H]+, 166.0668 found, 166.0667. IR ATR (cm-1): 3374, 3172, 1666, 1609, 
1396, 1265. 
 
8.5.10. Synthesis of (E)-3-(3-fluorophenyl)acrylonitrile (120) 
This reaction was carried out according to the procedure described for 96 using the 
following: DMSO (0.40 mL, 5.5 mmol), oxalyl chloride (0.11 mL, 1.3 mmol), 119 (150 mg, 
0.908 mmol) and triethylamine (0.40 mL, 2.5 mmol) This reaction afforded 120 as a 
yellow solid (69 mg, 0.47 mmol, 45%). 
Rf, 0.69 (60% EtOAc/Hexane) 1H NMR (400 MHz, CDCl3) δ 7.42 – 7.33 (m, 2H, ArH + CH), 7.25 – 7.21 (m, 
1H, Ar), 7.18 – 7.07 (m, 2H, Ar), 5.89 (d, J = 16.6 Hz, 1H, CH). 13C NMR (101 MHz, CDCl3) δ 163.1 (d, JCF = 
248 Hz), 149.3 (d, JCF = 2.8 Hz), 135.7 (d, JCF = 7.7 Hz), 130.9 (d, JCF = 8.3 Hz), 123.6 (d, JCF = 3 Hz), 118.3 (d, 
JCF = 21 Hz), 117.7, 113.9 (d, JCF = 22 Hz), 98.1. HRMS calc. for C9H7FN [M+H]+, 148.0563 found, 148.0557. 
IR ATR (cm-1): 3062, 2211, 1620, 1581, 1445, 1269, 965. Mp: 54 °C. 
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8.5.11. Synthesis of (E)-3-(3-cyano-5-fluorophenyl)acrylamide (122) 
Copper-free conditions: This reaction was carried out according to the procedure 
(conditions B) described for 94 using the following: 3-bromo-5-fluorobenzonitrile 
(91) (100 mg, 0.50 mmol), acrylamide (42 mg, 0.60 mmol), triethylamine (0.40 
mL, 2.4 µmol), triphenylphosphine (6.0 mg, 22 µmol) and Pd(OAc)2 (2.0 mg, 9.0 
µmol). This reaction afforded the product 122 as a yellow solid (16 mg, 0.079 mmol, 16%) 
Phosphine-free conditions: DMF (2 mL) was added to a Schlenk tube charged with 91 (100 mg, 0.50 
mmol), acrylamide (53 mg, 0.75 mmol) and N-phenylurea (14 mg, 0.10 mmol). The reaction mixture was 
then degassed under a positive pressure of argon for approximately 10 minutes. Pd(OAc)2 (11 mg, 50 
µmol) was then added to the reaction mixture followed by K2CO3 (138 mg, 1.00 mmol). The Schlenk tube 
was then placed in an oil bath preheated to 130 °C. After 2 hours the reaction was cooled to room 
temperature, quenched with H2O (50 mL) and extracted with three times with EtOAc (3 × 50 mL). The 
organic phases were combined, washed with brine (150 mL), dried over MgSO4 and concentrated in vacuo. 
The crude material was then purified by column chromatography (70% EtOAc/hexane – 100% EtOAc) to 
yield the desired product as a yellow solid (72 mg, 0.38 mmol, 76%). 
Rf, 0.28 (100% EtOAc/Hexane) 1H NMR (400 MHz, DMSO-d) δ 7.96 – 7.92 (m, 1H, ArH), 7.88 – 7.79 (m, 
2H, ArH), 7.58 (s, 1H, NH), 7.43 (d, J = 15.9 Hz, 1H, CH), 7.29 (s, 1H, NH), 6.77 (d, J = 15.9 Hz, 1H, CH). 13C 
NMR (101 MHz, DMSO) δ 166.0, 161.9 (d, JCF = 247 Hz), 139.1 (d, JCF = 8.9 Hz), 136.0 (d, JCF = 3.0 Hz), 127.9 
(d, JCF = 3.3 Hz), 126.3, 119.6 (d, JCF = 25.0 Hz), 119.1 (d, JCF = 22.2 Hz), 117.5 (d, JCF = 3.6 Hz), 113.5 (d, JCF = 
10.9 Hz). HRMS calc. for C10H8FN2 [M+H]+, 191.06152 found, 191.06146. IR ATR (cm-1): 3367, 3172, 3078, 
2235, 1669, 579. Mp: 115 °C. 
 
8.5.12. Synthesis of (E)-3-(2-cyanovinyl)-5-fluorobenzonitrile (123) 
 Conditions A: This reaction was carried out according to the procedure described 
for 96 using the following: DMSO (0.20 mL, 2.3 mmol), oxalyl chloride (0.11 mL, 50 
µmol), 122 (66 mg, 0.35 mmol) and triethylamine (0.15 mL, 1.1 mmol) This reaction 
afforded 123 as a yellow solid (17 mg, 0.099 mmol, 29%).  
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Conditions B: 122 (193 mg, 1.02 mmol) was suspended in POCl3 (2.0 mL, 21 mmol) at 0 °C for 30 minutes. 
The suspension was then allowed to warm to room temperature over 18 hours. The reaction mixture was 
cooled to 0 °C, quenched with H2O (50 mL) and extracted twice with EtOAc (2 × 100 mL). The combined 
organic phases were washed with brine (200 mL), dried over MgSO4 and concentrated in vacuo. The crude 
material was purified by column chromatography (10% EtOAc/hexane – 60% EtOAc/hexane) to yield the 
product as a white solid (133 mg, 0.77 mmol, 76%). 
Rf, 0.81 (50% EtOAc/Hexane) 1H NMR (400 MHz, CDCl3) δ 7.56 – 7.51 (m, 1H, ArH), 7.44 – 7.37 (m, 2H, 
ArH), 7.34 (d, J = 16.7 Hz, 1H, CH), 5.98 (d, J = 16.6 Hz, 1H, CH). 13C NMR (101 MHz, CDCl3) δ 162.6 (d, JCF = 
253 Hz), 146.7 (dCF, J = 2.7 Hz), 137.1 (dCF, J = 8.2 Hz), 127.1 (dCF, J = 3.5 Hz), 121.2 (dCF, J = 25 Hz), 118.6 
(dCF, J = 22 Hz), 116.8, 116.7 (dCF, J = 3.2 Hz), 115.2 (dCF, J = 9.8 Hz), 101.1. HRMS calc. for C10H6FN2 [M+H]+, 
173.05095 found, 173.05092. IR ATR (cm-1): 3076, 2235, 2219, 1589, 1438, 970, 671. Mp: 141 °C. 
 
8.5.13. Synthesis of 3-bromo-5-((3-ethyl-2-oxo-1-((2-(trimethylsilyl)ethoxy)methyl)-2,3-
dihydro-1H-benzo[d]imidazol-4-yl)oxy)benzonitrile (125) 
This reaction was carried out according to the procedure described for 52 using 
the following: 38 (400 mg, 1.30 mmol), 91 (519 mg, 2.60 mmol) and Cs2CO3 (634 
mg, 1.95 mmol). This reaction afforded 125 as a clear oil. (609 mg, 1.25 mmol, 
96%). 
Rf, 0.56 (20% EtOAc/Hexane) 1H NMR (300 MHz, CDCl3) δ 7.52 – 7.51 (m, 1H, 
ArH), 7.40 – 7.38 (m, 1H, ArH), 7.19 – 7.18 (m, 1H, ArH), 7.13 – 7.06 (m, 2H, ArH), 6.75 – 6.67 (m, 1H, ArH), 
5.34 (s, 2H, CH2), 3.93 (q, J = 7.1 Hz, 2H, CH2), 3.69 – 3.59 (m, 2H, CH2), 1.24 (t, J = 7.1 Hz, 3H, CH3), 0.99 – 
0.90 (m, 2H, CH2), -0.02 (s, 9H, Si(CH3)3). 13C NMR (75 MHz, CDCl3) δ 158.9, 153.8, 131.7, 129.2, 124.7, 
124.0, 122.3, 120.7, 118.8, 116.7, 115.2, 114.2, 106.4, 70.9, 66.4, 37.8, 17.8, 15.1, -1.4. HRMS calc. for 
C22H27BrN3O3Si [M+H]+, 488.1005 found, 488.0998. IR ATR (cm-1): 3074, 2952, 2235, 1708, 1588, 1211. 
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8.5.14. Synthesis of (E)-3-(3-cyano-5-((3-ethyl-2-oxo-1-((2-(trimethylsilyl)ethoxy)methyl)-2,3-
dihydro-1H-benzo[d]imidazol-4-yl)oxy)phenyl)acrylamide (126) 
The reaction was carried out according to the procedure (phosphine-free 
conditions) described for 122 using the following: 125 (500 mg, 1.02 
mmol), acrylamide (109 mg, 1.53 mmol), N-phenylurea (28 mg, 0.12 
mmol), Pd(OAc)2 (23 mg, 0.10 mmol) and K2CO3 (283 mg, 2.05 mmol). 
This reaction afforded 126 as a yellow solid (437 mg, 0.913 mmol, 89%).  
Rf, 0.13 (60% EtOAc/Hexane) 1H NMR (400 MHz, CDCl3) δ 7.59 – 7.50 (m, 2H, ArH), 7.36 – 7.30 (m, 1H, 
ArH), 7.24 – 7.21 (m, 1H, ArH), 7.12 – 7.05 (m, 2H, ArH), 6.75 – 6.68 (m, 1H, ArH), 6.47 (d, J = 15.6 Hz, 1H, 
CH), 5.68 (s, 2H, CH2), 5.34 (s, 2H, CH2), 3.95 (q, J = 7.0 Hz, 2H, CH2), 3.68 – 3.61 (m, 2H, CH2), 1.24 (t, J = 
7.0 Hz, 3H, CH3), 0.98 – 0.93 (m, 2H, CH2), -0.02 (s, 9H, Si(CH3)3). 13C NMR (101 MHz, CDCl3) δ 166.7, 158.8, 
153.9, 139.4, 138.2, 138.0, 131.7, 125.6, 123.2, 122.4, 120.8, 120.7, 120.6, 117.7, 114.6, 114.3, 106.3, 
71.0, 66.5, 37.9, 17.9, 15.2, -1.3. HRMS calc. for C25H31O4N4Si [M+H]+, 479.21091 found, 479.21167. IR ATR 
(cm-1): 3324, 2925, 2231, 1674, 1581, 1214, 834. 
 
8.5.15. Synthesis of (E)-3-(3-cyano-5-((3-ethyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-
yl)oxy)phenyl)acrylamide (128) 
This reaction was carried out according to the procedure described for 
21 using the following: 126 (415 mg, 0.867 mmol) and TBAF (3.5 mL, 13 
mmol). The reaction yielded 128 as an off-white solid (97 mg, 0.28 
mmol, 32%). 
Rf, 0.33 (2% EtOAc/MeOH) 1H NMR (500 MHz, CD3OD) δ 7.70 – 7.67 (m, 
1H), 7.54 – 7.46 (m, J = 15.8 Hz, 2H), 7.35 – 7.32 (m, 1H), 7.09 – 7.05 (m, J = 8.5 Hz, 1H), 7.00 – 6.95 (m, J 
= 8.5 Hz, 1H), 6.73 – 6.63 (m, 2H), 3.92 (q, J = 7.0 Hz, 2H), 1.20 (t, J = 6.7 Hz, 3H). 13C NMR (126 MHz, 
CD3OD) δ 166.3, 158.6, 155.0, 138.5, 138.4, 137.9, 131.0, 125.8, 124.0, 122.1, 121.1, 120.6, 120.1, 117.2, 
114.2, 113.0, 106.3, 37.0, 14.0. HRMS calc. for C19H17O3N4 [M+H]+, 349.12952 found, 349.12955. IR ATR 
(cm-1): 3148, 3067, 2228, 1688, 1582, 1475, 1225. Mp: degrades at 256 °C. 
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8.5.16. Synthesis of (E)-3-(2-cyanovinyl)-5-((3-ethyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-
yl)oxy)benzonitrile (127) 
This reaction was carried out according to the procedure (conditions B) 
described for 123 using the following: 128 (135 mg, 0.388 mmol) and POCl3 
(0.80 mL, 8.6 mmol). The reaction afforded 127 as a white solid (52 mg, 0.16 
mmol, 41%). 
Rf, 0.33 (50% EtOAc/Hexane) 1H NMR (500 MHz, CDCl3) δ 10.01 (s, 1H, NH), 
7.47 – 7.45 (m, 1H, ArH), 7.35 – 7.29 (m, 3H, ArH), 7.09 – 7.02 (m, 2H, ArH), 6.70 – 6.66 (m, 1H, ArH), 5.94 
(d, J = 16.6 Hz, 1H, CH), 3.95 (q, J = 7.1 Hz, 2H, CH2), 1.28 (t, J = 7.1 Hz, 3H, CH3). 13C NMR (126 MHz, CDCl3) 
δ 159.1, 155.3, 147.3, 137.9, 136.9, 130.9, 125.2, 122.5, 122.0, 121.6, 119.7, 117.2, 116.9, 115.2, 113.6, 
107.4, 100.7, 37.7, 15.4. HRMS calc. for C19H15O2N4 [M+H]+, 331.11895 found, 331.11880. IR ATR (cm-1): 
3049, 2224, 1669, 1582, 1225, 749. Mp: 241 °C. 
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8.6. Experimental pertaining to Chapter 5 
8.6.1. Synthesis of 1-(benzyloxy)-2-iodo-3-nitrobenzene (131)  
33 (500 mg, 2.05 mmol) was added to a mixture of DMSO (9 mL) and a 30% solution of HsSO4 
(9 mL) and heated to 50 °C. After 2 hours, the reaction was cooled to 0 °C and NaNO2 (212 
mg, 3.07 mmol) in H2O (1 mL) was added dropwise to the reaction mixture. After an hour at 
0 °C potassium iodide (1.0 g, 6.0 mmol) in H2O (1 mL) was added to the reaction mixture and the notable 
evolution of gas was indicative that displacement of the diazonium salt was transpiring. Following another 
hour additional potassium iodide (1.0 g, 6.0 mmol) was introduced into the reaction mixture and the 
reaction was left to run for 18 hours. The resulting product was subsequently extracted twice from the 
reaction mixture with EtOAc (2 × 100 mL). The organic phases were then combined and washed with 
sodium thiosulfate (200 mL), H2O (200 mL) and brine (200 mL). The organic phase was then dried over 
MgSO4, concentrated in vacuo and purified on silica gel by column chromatography (5% – 20% 
EtOAc/Hexane) to afford the desired product 131 as a yellow solid (441 mg, 1.24 mmol, 60%). 
Rf, 0.36 (20% EtOAc/Hexane) 1H NMR (400 MHz, CDCl3) δ 7.50 – 7.22 (m, 7H, ArH), 6.99 (dd, J = 8.2, 1.0 
Hz, 1H, ArH), 5.21 (s, 2H, CH2). 13C NMR (101 MHz, CDCl3) δ 158.8, 135.5, 130.1, 128.9, 128.4, 127.1, 117.2, 
115.2, 80.9, 71.9. HRMS calc. for C13H11IO3N [M+H]+, 355.97781 found, 355.97812. IR ATR (cm-1): 2361, 
1521, 1337, 1260, 1015, 692, 566. Mp: 90 °C. 
 
8.6.2. Attempted synthesis of 1-(2-(benzyloxy)-6-nitrophenyl)ethan-1-one  (132) 
n-BuLi (0.90 M in THF, 1.1 mL, 1.0 mmol) was added dropwise to 131 (300 mg, 845 µmol) in THF (3 mL) at 
-78 °C. After approximately 1 hour at this temperature, N-Methoxy-N-methylacetamide 139 (0.11 mL, 1.0 
mmol) was added dropwise to the reaction mixture and the reaction was allowed to warm to room 
temperature. After 18 hours the reaction was quenched with a saturated solution of NH4Cl (50 ml) and 
extracted twice with EtOAc (2 × 100 mL). The organic phases were combined, washed with brine (200 mL), 
dried over MgSO4 and concentrated in vacuo. Purification by column chromatography (2% – 10% 
EtOAc/Hexane), however, afforded compounds 140 and 141 (or 142) and not the desired product 132. 
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1H NMR (400 MHz, CDCl3) δ 7.87 – 7.80 (m, 2H, ArH), 7.48 – 7.27 (m, 7H, ArH), 5.15 (s, 2H, 
CH2). 13C NMR (101 MHz, CDCl3) δ 159.3, 135.8, 130.1, 128.9, 128.6, 127.7, 122.1, 116.2, 
109.3, 70.7. 
This spectroscopic data compares favourably with that in the literature.285 
For 141 or 142: 
Rf, 0.78 (20% EtOAc/Hexane) 1H NMR (400 MHz, CDCl3) δ 7.79 (dd, J = 8.2, 
2.1 Hz, 1H, ArH), 7.75 (d, J = 2.1 Hz, 1H, ArH), 7.47 – 7.32 (m, 5H, ArH), 7.27 
(d, J = 8.2 Hz, 1H, ArH), 5.15 (s, 2H, CH2), 2.77 – 2.69 (m, 2H, CH2), 1.65 – 1.54 
(m, 2H, CH2), 1.41 – 1.31 (m, 2H, CH2), 0.92 (t, J = 7.3 Hz, 3H, CH3). 13C NMR (101 MHz, CDCl3) δ 196.4, 
156.7, 140.0, 136.2, 130.0, 128.8, 128.3, 127.3, 116.1, 106.4, 70.4, 31.6, 30.3, 22.7, 14.1. 
 
8.6.3. Attempted synthesis of 3-(benzyloxy)-2-iodoaniline (148) 
The reaction was carried out according to the procedure (conditions B) described for 35 using the 
following: 131 (500 mg, 1.41 mmol) and SnCl2.2H2O (2.7g, 9.0 mmol). However, in this instance the 
reduced product 149 was obtained and not the desired product 148. 
For 149: 
 1H NMR (500 MHz, CDCl3) δ 7.46 – 7.31 (m, 5H, ArH), 7.10 – 7.06 (m, 1H, ArH), 6.44 – 6.41 
(m, 1H, ArH), 6.35 – 6.31 (m, 2H, ArH), 5.04 (s, 2H, CH2), 3.61 (s, 2H, NH2). 13C NMR (126 MHz, 
CDCl3) δ 160.1, 147.9, 137.3, 130.2, 128.7, 128.0, 127.6, 108.3, 105.0, 102.1, 69.9. HRMS calc. 
for C13H14ON [M+H]+, 200.10699 found, 200.10708. IR ATR (cm-1): 3436, 3361, 1583, 1158, 1024. Mp: 57 
°C. 
 
8.6.4. Synthesis of tert-butyl (3-(benzyloxy)phenyl)carbamate  (150) 
 149 (526 mg, 2.64 mmol) was treated with Boc anhydride (576 mg, 2.64 mmol) and DMAP 
(32 mg, 0.26 mmol) in THF (10 mL). After 1 hour, TLC indicated that the reaction had 
reached completion. The reaction mixture was therefore concentrated in vacuo and 
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loaded onto silica gel. Subsequent purification by column chromatography (5% – 20% EtOAc/Hexane) 
afforded 150 as a clear oil (620 mg, 2.07 mmol, 90%). 
1H NMR (500 MHz, CDCl3) δ 10.96 (s, 1H, NH), 7.45 – 7.29 (m, 5H, ArH), 7.22 – 7.18 (m, 1H, ArH), 6.83 – 
6.80 (m, 2H, ArH), 6.73 – 6.70 (m, 1H, ArH), 5.04 (s, 2H, CH2), 1.36 (s, 9H, CH3). 13C NMR (126 MHz, CDCl3) 
δ 159.6, 152.0, 139.4, 129.7, 128.7, 128.0, 127.6, 121.5, 114.8, 112.4, 84.2, 70.1, 28.0. HRMS calc. for 
C18H22O3N [M+H]+, 300.15942 found, 300.15968. IR ATR (cm-1): 3283, 2922, 1722, 1287, 1151. 
 
8.6.5. Synthesis of 1-(benzyloxy)-2-methyl-3-nitrobenzene (165) 
The reaction was carried out according to the procedure described for 33 using the following: 
2-methyl-3-nitrophenol (153) (500 mg, 3.27 mmol), benzyl bromide (0.50 mL, 4.2 mmol) and 
K2CO3 (542 mg, 3.92 mmol). This reaction afforded 165 as a pale yellow solid (702 mg, 2.89 
mmol, 88%). 
Rf, 0.60 (20% EtOAc/Hexane) 1H NMR (400 MHz, CDCl3) δ 7.43 – 7.31 (m, 6H, ArH), 7.25 – 7.20 (m, 1H, 
ArH), 7.10 – 7.06 (m, 1H, ArH), 5.11 (s, 2H, CH2), 2.41 (s, 3H, CH3). 13C NMR (101 MHz, CDCl3) δ 157.5, 
151.2, 136.3, 128.8, 128.3, 127.2, 126.8, 122.5, 116.1, 115.4, 70.9, 11.9. HRMS calc. for C14H14O3N [M+H]+, 
244.09682 found, 244.09691. IR ATR (cm-1): 1606, 1523, 1262, 703. Mp: 64 °C. 
 
8.6.6. Synthesis of 2-(benzyloxy)-6-nitrobenzaldehyde (167) 
N,N-dimethylformamide dimethyl acetal (162) (0.35 mL, 2.5 mmol) was added to 165 (200 
mg, 822 µmol) in DMF (2 mL) and the reaction was heated to 135 °C. After 18 hours the 
reaction was cooled to 0 °C and subsequently added to a vigorously stirring solution of NaIO4 
(528 mg, 2.47 mmol) in DMF (1.5 mL) and H2O (3 mL) at 0 °C. The reaction was then allowed to warm to 
room temperature. After an additional 18 hours the reaction was filtered through a bed of celite and the 
resulting filtrate was subsequently washed with H2O (40 mL) and brine (40 mL), dried over MgSO4, 
concentrated in vacuo and then purified on silica gel by column chromatography to afford the 
benzaldehyde 167 as an orange solid (31 mg, 0.12 mmol, 15%). 
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Rf, 0.18 (20% EtOAc/Hexane) 1H NMR (500 MHz, CDCl3) δ 10.43 (s, 1H, CHO), 7.58 – 7.53 (m, 1H, ArH), 
7.44 – 7.34 (m, 6H, ArH), 7.30 – 7.27 (m, 1H, ArH), 5.22 (s, H, CH2). 13C NMR (126 MHz, CDCl3) δ 187.7, 
159.0, 148.9, 135.2, 133.6, 129.0, 128.7, 127.4, 117.8, 115.9, 110.1, 71.7. HRMS calc. for C14H12O4N 
[M+H]+, 258.07608 found, 258.07613. IR ATR (cm-1): 2910, 2864, 1705, 1276, 739. Mp: 67 °C. 
 
8.6.7. Synthesis of 1-methoxy-2-methyl-3-nitrobenzene (168) 
This reaction was carried out according to the procedure described for 87 using the 
following: 153 (500 mg, 2.99 mmol), methyl iodide (0.24 mL, 3.9 mmol) and NaH (154 mg, 
6.4 mmol). This reaction afforded 168 as a pale yellow solid (502 mg, 2.55 mmol, 92%). 
Rf, 0.37 (20% EtOAc/Hexane) 1H NMR (500 MHz, CDCl3) δ 7.41 – 7.38 (m, 1H, ArH), 7.28 – 7.24 (m, 1H, 
ArH), 7.05 – 7.02 (m, 1H, ArH), 3.89 (s, 3H, CH3), 2.36 (s, 3H, CH3). 13C NMR (126 MHz, CDCl3) δ 158.6, 
151.1, 126.8, 122.1, 115.9, 113.9, 56.4, 11.6. HRMS calc. for C8H10O3N [M+H]+, 168.06552 found, 
168.06555. IR ATR (cm-1): 3015, 2841, 1519, 1466, 1262, 1064. Mp: 53 °C. 
 
8.6.8. Synthesis of 2-methoxy-6-nitrobenzoic acid (169) 
KMnO4 (11 g, 70 mmol) was added to a suspension of 168 (1.98 g, 11.8 mmol) in t-BuOH 
(10 mL) and H2O (20 mL) and reaction mixture was heated under reflux for 18 hours. The 
reaction mixture was then cooled to room temperature and filtered through a bed of celite. 
Following extraction of 169 from the filtrate, the resulting aqueous phase was acidified with 3N HCl (100 
mL) and the product was extracted twice with EtOAc (2 × 100 mL). The organic phases containing the 
product were combined, dried over MgSO4 and concentrated in vacuo to afford the desired carboxylic 
acid 169 as a white solid (784 mg, 3.98 mmol, 34%). 
1H NMR (500 MHz, DMSO-d) δ 7.76 – 7.54 (m, 3H, ArH), 3.89 (s, 3H, CH3). 13C NMR (126 MHz, DMSO-d) δ 
165.1, 156.3, 145.4, 131.0, 120.4, 118.3, 115.6, 56.9. HRMS calc. for C8H8O5N [M+H]+, 198.03970 found, 
198.03974. IR ATR (cm-1): 2851, 1703, 1530, 1477, 1351, 1269. Mp: degrades at 144 °C. 
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8.6.9. Synthesis of methyl 2-hydroxy-6-nitrobenzoate (170) 
Methyl iodide (0.36 mL, 5.8 mmol) was added to a solution of 169 (750 mg, 3.80 mmol) 
and K2CO3 (789 mg, 5.71 mmol) in DMF (10 mL). After 2 hours the reaction was quenched 
with a saturated solution of NH4Cl (50 mL) and extracted twice with EtOAc (2 × 100 mL). 
The organic phases were combined, dried over MgSO4, concentrated in vacuo and purified by column 
chromatography to 170 as a yellow solid (773 mg, 3.66 mmol, 96%).  
Rf, 0.29 (40% EtOAc/Hexane) 1H NMR (500 MHz, CDCl3) δ 7.74 (dd, J = 8.3, 0.8 Hz, 1H, ArH), 7.53 – 7.49 
(m, 1H, ArH), 7.27 – 7.24 (m, 1H, ArH), 3.95 (s, 3H, CH3), 3.90 (s, 3H, CH3). 13C NMR (126 MHz, CDCl3) δ 
165.1, 157.3, 146.3, 131.0, 119.8, 117.1, 116.0, 56.9, 53.3. HRMS calc. for C9H10O5N [M+H]+, 212.05535 
found, 212.05542. IR ATR (cm-1): 1734, 1530, 1347, 1264, 1110, 1072, 1050. Mp: 67 °C. 
 
8.6.10. Synthesis of methyl 2-amino-6-methoxybenzoate (171) 
A catalytic amount of palladium on activated charcoal was added to a solution of 170 (773 
mg, 3.66 mmol) in EtOH (20 mL) under an atmosphere of hydrogen. After 18 hours the 
reaction was filtered through a bed of celite. The resulting filtrate was concentrated in 
vacuo, loaded onto silica gel and then purified by column chromatography to afford 171 as a white solid 
(613 mg, 3.38 mmol, 93%). 
Rf, 0.49 (40% EtOAc/Hexane) 1H NMR (500 MHz, CDCl3) δ 7.12 – 7.08 (m, 1H, ArH), 6.27 (dd, J = 8.2, 0.9 
Hz, 1H, ArH), 6.22 (dd, J = 8.3, 0.6 Hz, 1H, ArH), 4.93 (s, 2H, NH2), 3.87 (s, 3H, CH3), 3.79 (s, H, CH3). 13C 
NMR (126 MHz, CDCl3) δ 168.6, 160.3, 149.8, 132.8, 109.4, 104.6, 100.3, 56.1, 51.8. HRMS calc. for 
C9H12O3N [M+H]+, 182.08117 found, 182.08125. IR ATR (cm-1): 3465, 3354, 1668, 1236, 1113, 1077. Mp: 
59 °C. 
 
8.6.11. Synthesis of 2-(2-amino-6-methoxyphenyl)propan-2-ol (172) 
171 (511 mg, 2.82 mmol) was dissolved in THF (10 mL) and cooled to 0 °C. After 
methylmagnesium bromide (3.0 M in Et2O, 4.7 mL, 41 mmol) was added to the reaction at 
0 °C, the reaction mixture warmed to room temperature. After 4 hours, the reaction was 
taken back to 0 °C, slowly quenched with H2O (100 ml) and then extracted twice with DCM (2 × 200 mL). 
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The organic phases were combined, dried over MgSO4 and concentrated in vacuo to afford 172 as an 
orange solid (521 mg, 2.47 mmol, 91%). 
Rf, 0.26 (40% EtOAc/Hexane) 1H NMR (399 MHz, CDCl3) δ 6.97 – 6.92 (m, 1H, ArH), 6.31 – 6.25 (m, 2H, 
ArH), 4.00 (s, 2H, NH2), 3.75 (s, 3H, CH3), 1.71 (s, 6H, CH3). 13C NMR (100 MHz, CDCl3) δ 157.9, 146.8, 127.8, 
119.2, 111.9, 102.0, 76.3, 55.5, 30.9. HRMS calc. for C10H16O2N [M+H]+, 182.11756 found, 182.11766. 
 
8.6.12. Synthesis of 5-methoxy-4,4-dimethyl-1,4-dihydro-2H-benzo[d][1,3]oxazin-2-one (173) 
This reaction was carried out according to the procedure (conditions B) described for 36 
using the following: 172 (464 mg, 2.56 mmol) and CDI (623 mg, 3.84 mmol). The reaction 
yielded 173 as a white solid (360 mg, 1.74 mmol, 68%). 
Rf, 0.27 (40% EtOAc/Hexane) 1H NMR (500 MHz, CDCl3) δ 9.47 (s, 1H, NH), 7.16 – 7.12 (m, 1H, ArH), 6.58 
– 6.55 (m, 1H, ArH), 6.49 (dd, J = 7.9, 0.9 Hz, 1H, ArH), 3.82 (s, 3H, CH3), 1.78 (s, 6H, CH3). 13C NMR (126 
MHz, CDCl3) δ 155.6, 152.5, 135.0, 129.4, 113.6, 107.8, 106.3, 84.8, 55.6, 28.5. HRMS calc. for C11H14O3N 
[M+H]+, 208.09682 found, 208.09682. IR ATR (cm-1): 3106, 2968, 1704, 1597, 1368, 1247, 780. Mp: 147 
°C. 
 
8.6.13. Synthesis of 5-hydroxy-4,4-dimethyl-1,4-dihydro-2H-benzo[d][1,3]oxazin-2-one (174) 
Boron tribromide (1.0 M in DCM, 2.0 mL, 21 mmol) was added to a solution of 173 (232 
mg, 1.12 mmol) in DCM (6 mL) at 0 °C. After 4 hours the reaction was cooled to -10 °C 
(acetone/ice) and quenched slowly with H2O (100 mL). Subsequent extraction with EtOAc 
(2 × 200 mL)  and concentration in vacuo afforded 174 as a pale yellow solid (195 mg, 1.01 mmol, 90%).  
Rf, 0.26 (50% EtOAc/Hexane) 1H NMR (400 MHz, DMSO-d) δ 9.98 (s, 1H, NH or OH), 9.85 (s, 1H, NH or 
OH), 7.00 – 6.94 (m, 1H, ArH), 6.48 – 6.42 (m, 1H, ArH), 6.33 – 6.28 (m, 1H, ArH), 1.65 (s, 6H, CH3). 13C NMR 
(101 MHz, DMSO-d) δ 153.3, 149.9, 135.9, 128.9, 111.5, 110.3, 105.2, 82.4, 28.0. HRMS calc. for C10H12O3N 
[M+H]+, 194.08117 found, 194.08129. IR ATR (cm-1): 3185, 3099, 2978, 2935, 1688, 1392, 1056, 784. Mp: 
268 °C. 
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8.6.14. Synthesis of 3-chloro-5-((4,4-dimethyl-2-oxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-5-
yl)oxy)benzonitrile (130) 
This reaction was carried out according to the procedure described for 52 using 
the following: 174 (72 mg, 0.37 mmol), 51 (59 mg, 0.38 mmol) and Cs2CO3 (122 
mg, 0.374 mmol). However, in this instance the reaction was carried out at 70 °C. 
This reaction afforded 130 as a white solid (16 mg, 0.049 mmol, 13%) 
Rf, 0.42 (50% EtOAc/Hexane) 1H NMR (500 MHz, CDCl3) δ 9.41 (s, 1H, NH), 7.40 
– 7.38 (m, 1H, ArH), 7.25 – 7.21 (m, 2H, ArH), 7.15 (dd, J = 2.3, 1.3 Hz, 1H, ArH), 6.76 (dd, J = 8.0, 0.9 Hz, 
1H, ArH), 6.55 (dd, J = 8.2, 0.8 Hz, 1H, ArH), 1.77 (s, 6H, CH3). 13C NMR (126 MHz, CDCl3) δ 158.2, 152.1, 
150.8, 136.9, 136.4, 130.2, 126.9, 123.0, 119.5, 117.9, 116.9, 115.12, 115.02, 111.8, 83.6, 28.7. HRMS calc. 
for C17H14ClO3N2 [M+H]+, 329.06875 found, 329.06869. IR ATR (cm-1): 3090, 2992, 2940, 2228, 1709, 1572, 
1058 Mp: 211 °C. 
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Addendum I: X-ray Crystallographic Data for 130 
Crystal Data and Experimental 
 
 
Crystal data was obtained by John Bacsa at the Emory 
University X-ray Crystallography Center 
Experimental. Compound 130 was dissolved in hot ethanol 
and single colourless needle-shaped crystals formed on 
cooling the solution. A suitable crystal 
0.35×0.10×0.05  mm3 was selected and mounted on a loop 
with paratone oil on an XtaLAB Synergy, Dualflex, HyPix 
diffractometer. The crystal was cooled to T = 100(2) K 
during data collection. The structure was solved with the 
ShelXT structure solution program using the Intrinsic 
Phasing solution method and by using Olex2 as the 
graphical interface.286-287 The model was refined with 
version 2017/1 of ShelXL using Least Squares 
minimisation.288 
Crystal Data. C17H13ClN2O3, Mr = 328.74, monoclinic, P21/c 
(No. 14), a = 21.3495(13) Å, b = 5.2431(3) Å, c = 
14.3162(12) Å,  = 106.429(8)°, =  = 90°, V = 
1537.08(19) Å3, T = 100(2) K, Z = 4, Z' = 1, µ(MoKα) = 0.265, 
13778 reflections measured, 3225 unique (Rint = 0.0913) 
which were used in all calculations. The final wR2 was 
0.1830 (all data) and R1 was 0.0788 (I > 2σ(I)). 
Compound  130 
    
Formula  C17H13ClN2O3  
Dcalc./ g cm-3  1.421  
µ/mm-1  0.265  
Formula Weight  328.74  
Colour  colourless  
Shape  needle  
Size/mm3  0.35×0.10×0.05  
T/K  100(2)  
Crystal System  monoclinic  
Space Group  P21/c  
a/Å  21.3495(13)  
b/Å  5.2431(3)  
c/Å  14.3162(12)  
/° 90  
/° 106.429(8)  
/° 90  
V/Å3  1537.08(19)  
Z  4  
Z'  1  
Wavelength/Å  0.71073  
Radiation type  MoKα  
min/° 2.850  
max/° 26.732  
Measured Refl.  13778  
Independent Refl.  3225  
Reflections with I > 
2σ(I)  
2899  
Rint  0.0913  
Parameters  293  
Restraints  278  
Largest Peak  0.535  
Deepest Hole  -0.329  
GooF  1.204  
wR2 (all data)  0.1830  
wR2  0.1799  
R1 (all data)  0.0853  
R1  0.0788  









A colourless needle-shaped crystal with dimensions 0.35×0.10×0.05 mm3 was mounted on a loop with 
paratone oil. Data were collected using an XtaLAB Synergy, Dualflex, HyPix diffractometer equipped with an 
Oxford Cryosystems low-temperature device, operating at T = 100(2) K. 
Data were measured using ω scans of 1/2° per frame for 15s using MoK  radiation (micro-focus sealed X-ray 
tube, 50 kV, 1.0 mA). The total number of runs and images was based on the strategy calculation from the 
program CrysAlisPro (Rigaku, V1.171.39.35c, 2017). The maximum resolution that was achieved was  = 
26.732°. 
The diffraction patterns were indexed using CrysAlisPro (Rigaku, V1.171.39.35c, 2017) and the unit cells were 
refined using CrysAlisPro (Rigaku, V1.171.39.35c, 2017) on 6194 reflections, 45 % of the observed reflections. 
Data reduction, scaling and absorption corrections were performed using CrysAlisPro (Rigaku, V1.171.39.35c, 
2017). A numerical absorption correction based on Gaussian integration over a multifaceted crystal model 
was applied. An empirical absorption correction using spherical harmonics, implemented in SCALE3 ABSPACK 
scaling algorithm was also used. The final completeness is 99.20% out to 26.732° in . The absorption 
coefficient µ of this material is 0.265 mm-1 at this wavelength (λ = 0.71073Å) and the minimum and maximum 
transmissions are 0.672 and 1.000. 
The structure was solved and the space group P21/c (# 14) determined by the ShelXT structure solution 
program using Intrinsic Phasing and refined by Least Squares using version 2017/1 of ShelXL.287-288 All non-
hydrogen atoms were refined anisotropically. Hydrogen atom positions were calculated geometrically and 
refined using the riding model.  
The chlorobenzonitrile group is disordered but can be satisfactorily resolved using two disorder components. 
 
Images of the Crystal on the Diffractometer 
 
 





Figure 63: Plot of the asymmetric unit showing disorder component #1. 
 
 
Figure 2: Plot of the asymmetric unit showing disorder component #2. 
_exptl_absorpt_process_details: CrysAlisPro 1.171.39.35c (Rigaku Oxford Diffraction, 2017) Numerical absorption 
correction based on gaussian integration over a multifaceted crystal modelEmpirical absorption correction using spherical 
harmonics, implemented in SCALE3 ABSPACK scaling algorithm. 




There is a single molecule in the asymmetric unit, which is represented by the reported sum formula. In other words: Z is 
4 and Z' is 1. 
Data Plots: Diffraction Data 
    
    
  
 
Data Plots: Refinement and Data 
    






Total reflections (after filtering)  14649  Unique reflections  3225  
Completeness  0.988  Mean I/σ  11.29  
hklmax collected  (28, 6, 18)  hklmin collected  (-28, -6, -18)  
hklmax used  (25, 6, 18)  hklmin used  (-26, 0, 0)  
Lim dmax collected  20.0  Lim dmin collected  0.79  
dmax used  9.61  dmin used  0.79  
Friedel pairs  3050  Friedel pairs merged  1  
Inconsistent equivalents  10  Rint  0.0913  
Rsigma  0.072  Intensity transformed  0  
Omitted reflections  0  Omitted by user (OMIT hkl)  2  
Multiplicity  (5306, 3176, 924, 311, 47, 6, 2)  Maximum multiplicity  12  
Removed systematic absences  869  Filtered off (Shel/OMIT)  1310  
 
Table 7: Fractional Atomic Coordinates (×104) and Equivalent Isotropic Displacement Parameters (Å2×103) for 130. Ueq is 
defined as 1/3 of the trace of the orthogonalised Uij. 
 
Atom x y z Ueq 
C1 8011.3(15) 2740(6) 4616(2) 17.6(3) 
C2 8198.1(15) 1422(6) 3790(2) 17.1(4) 
C3 7802.1(15) -156(6) 3089(2) 17.7(4) 
C4 8032.0(16) -1443(6) 2406(2) 20.3(5) 
C5 8682.6(16) -1202(6) 2423(2) 20.7(6) 
C6 9095.4(16) 338(6) 3115(2) 21.2(6) 
C7 8851.5(15) 1622(6) 3789(2) 16.7(5) 
C8 9053.3(15) 4996(6) 4986(2) 17.2(5) 
C9 7319.7(15) 3777(6) 4378(2) 19.1(4) 
C10 8165.5(16) 1006(6) 5508(2) 19.2(4) 
N8 9270.2(13) 3151(5) 4497(2) 19.5(5) 
O1 8412.4(10) 5065(4) 4886.9(17) 18.7(4) 
O2 7166.5(11) -652(4) 3122.6(17) 20.3(4) 
O3 9407.9(11) 6628(4) 5483.3(18) 22.6(5) 
C11_2 6668(3) 450(20) 2343(7) 16.9(14) 
C12_2 6749(4) 2390(20) 1734(9) 19.1(16) 
C13_2 6213(3) 3313(19) 1054(7) 19.4(16) 
C14_2 5589(3) 2444(16) 949(6) 24.2(16) 
C15_2 5506(3) 489(17) 1561(7) 21.5(15) 
C16_2 6051(4) -550(20) 2276(9) 20.2(19) 
C17_2 4872(3) -419(17) 1506(6) 26.6(16) 
Cl1_2 6305.6(10) 5867(4) 305.0(17) 22.5(5) 
N2_2 4343(3) -1116(17) 1419(6) 39.6(19) 
C11_1 6645(3) 154(18) 2429(6) 18.4(12) 
C12_1 6048(4) -979(17) 2353(7) 18.0(13) 
C13_1 5510(3) -94(13) 1669(5) 19.5(11) 
C14_1 5527(2) 1856(11) 1035(4) 18(1) 
C15_1 6128(3) 3000(15) 1109(6) 18.9(12) 
C16_1 6704(3) 2149(19) 1814(7) 20.3(14) 
C17_1 6176(3) 5029(13) 479(5) 23.4(11) 
Cl1_1 4748.1(8) -1538(4) 1562.0(12) 29.5(5) 
N2_1 6239(3) 6641(12) -41(5) 31.2(14) 




Table 8: Anisotropic Displacement Parameters (×104) 130. The anisotropic displacement factor exponent takes the form: 
-2π2[h2a*2 × U11+ ... +2hka* × b* × U12] 
 
Atom U11 U22 U33 U23 U13 U12 
C1 18.0(6) 13.1(6) 20.9(6) -0.9(4) 4.0(5) 0.6(4) 
C2 18.4(5) 11.7(7) 19.9(6) 0.2(5) 3.3(4) 1.3(4) 
C3 19.3(4) 12.8(8) 19.8(6) 0.1(5) 3.3(4) 0.1(4) 
C4 22.4(6) 15.9(10) 21.9(8) -2.4(8) 5.0(6) -0.6(6) 
C5 22.8(7) 16.6(11) 22.5(9) -4.2(8) 5.9(6) -0.7(6) 
C6 21.5(7) 17.9(11) 23.9(8) -5.6(8) 6.3(5) -0.3(6) 
C7 18.5(5) 11.3(9) 19.3(7) -0.4(7) 3.5(4) 1.4(4) 
C8 18.0(5) 12.9(7) 20.4(10) -1.8(7) 4.7(5) 0.6(4) 
C9 18.2(6) 13.8(9) 24.4(10) -0.8(8) 4.5(6) 1.0(5) 
C10 22.2(10) 14.2(8) 20.9(7) -0.5(7) 5.6(7) 2.8(7) 
N8 17.9(5) 16.1(7) 23.4(8) -4.9(7) 4.2(4) 1.0(4) 
O1 18.2(5) 13.1(6) 24.6(8) -2.6(5) 5.6(5) 0.6(4) 
O2 19.2(4) 18.7(8) 21.2(7) 1.1(5) 3.2(4) -0.9(4) 
O3 19.5(6) 19.2(7) 29.4(10) -9.1(7) 7.2(6) -1.9(6) 
C11_2 19.0(5) 15(2) 16.8(18) -3.1(18) 4.8(7) 1.1(8) 
C12_2 20.1(7) 17(3) 20(2) 0(2) 5.1(10) 1(1) 
C13_2 20.0(7) 19(2) 20(2) 0(2) 5.5(10) 1.3(9) 
C14_2 20.1(7) 25(2) 27(2) 7(2) 4.4(10) 0.5(9) 
C15_2 19.1(5) 21(3) 23(2) 3(2) 4.0(7) 0.5(9) 
C16_2 19.1(5) 19(3) 21(3) 1(3) 3.9(8) 0.5(9) 
C17_2 19.1(5) 27(3) 31(3) 10(2) 3.4(8) 0.2(11) 
Cl1_2 23.1(9) 21.2(10) 24.3(10) 4.0(7) 8.2(7) 2.6(6) 
N2_2 21.5(8) 50(4) 45(5) 13(4) 5.1(16) -6.5(17) 
C11_1 18.8(5) 18(2) 18.2(15) -1.4(15) 4.4(6) 0.4(7) 
C12_1 19.0(5) 19(2) 16(2) -2.6(18) 4.5(7) -0.3(8) 
C13_1 18.5(5) 22.8(19) 17.1(17) -0.2(15) 4.9(6) -0.3(8) 
C14_1 17.7(7) 21.2(17) 15.9(16) -1.5(13) 6.0(8) 1.2(8) 
C15_1 17.4(7) 20.9(19) 18.8(17) 0.3(16) 5.7(8) 1.7(8) 
C16_1 18.0(7) 20(2) 21.5(19) 1.7(19) 4.4(9) 0.7(9) 
C17_1 16.7(11) 27.1(18) 26.0(18) 7.0(15) 5.3(13) 1.7(12) 
Cl1_1 20.0(5) 38.5(10) 27.4(8) 9.9(7) 2.6(5) -5.4(6) 
N2_1 32(3) 31.1(19) 30(2) 9.8(16) 9(2) -1.3(17) 
Table 9: Bond Lengths in Å for 130. 
 
Atom Atom Length/Å 
C1 C2 1.518(4) 
C1 C9 1.519(4) 
C1 C10 1.525(4) 
C1 O1 1.477(4) 
C2 C3 1.388(4) 
C2 C7 1.399(4) 
C3 C4 1.387(4) 
C3 O2 1.396(4) 
C4 C5 1.388(4) 
C5 C6 1.384(5) 
C6 C7 1.393(4) 
C7 N8 1.399(4) 
C8 N8 1.350(4) 
C8 O1 1.336(4) 
Atom Atom Length/Å 
C8 O3 1.228(4) 
O2 C11_2 1.429(5) 
O2 C11_1 1.334(5) 
C11_2 C12_2 1.381(9) 
C11_2 C16_2 1.396(9) 
C12_2 C13_2 1.363(9) 
C13_2 C14_2 1.374(7) 
C13_2 Cl1_2 1.761(6) 
C14_2 C15_2 1.392(7) 
C15_2 C16_2 1.424(9) 
C15_2 C17_2 1.417(9) 
C17_2 N2_2 1.158(8) 
C11_1 C12_1 1.381(9) 
C11_1 C16_1 1.396(9) 




Atom Atom Length/Å 
C12_1 C13_1 1.363(9) 
C13_1 C14_1 1.374(7) 
C13_1 Cl1_1 1.761(6) 
C14_1 C15_1 1.392(7) 
Atom Atom Length/Å 
C15_1 C16_1 1.424(9) 
C15_1 C17_1 1.417(9) 
C17_1 N2_1 1.159(8) 
 
Table 10: Bond Angles in ° for 130. 
 
Atom Atom Atom Angle/° 
C2 C1 C9 116.1(3) 
C2 C1 C10 109.8(2) 
C9 C1 C10 111.6(3) 
O1 C1 C2 108.6(2) 
O1 C1 C9 102.6(2) 
O1 C1 C10 107.5(2) 
C3 C2 C1 126.5(3) 
C3 C2 C7 116.6(3) 
C7 C2 C1 116.6(3) 
C2 C3 O2 119.0(3) 
C4 C3 C2 122.3(3) 
C4 C3 O2 118.4(3) 
C3 C4 C5 119.7(3) 
C6 C5 C4 119.8(3) 
C5 C6 C7 119.4(3) 
C6 C7 C2 122.2(3) 
C6 C7 N8 119.4(3) 
N8 C7 C2 118.4(3) 
O1 C8 N8 117.1(3) 
O3 C8 N8 123.7(3) 
O3 C8 O1 119.2(3) 
C8 N8 C7 122.9(3) 
C8 O1 C1 120.4(2) 
C3 O2 C11_2 114.4(4) 
C11_1 O2 C3 122.1(4) 
C12_2 C11_2 O2 126.4(6) 
Atom Atom Atom Angle/° 
C12_2 C11_2 C16_2 121.2(4) 
C16_2 C11_2 O2 112.3(6) 
C13_2 C12_2 C11_2 118.8(6) 
C12_2 C13_2 C14_2 123.5(5) 
C12_2 C13_2 Cl1_2 119.2(5) 
C14_2 C13_2 Cl1_2 117.3(5) 
C13_2 C14_2 C15_2 117.9(4) 
C14_2 C15_2 C16_2 120.7(5) 
C14_2 C15_2 C17_2 120.2(5) 
C17_2 C15_2 C16_2 119.1(5) 
C11_2 C16_2 C15_2 117.9(5) 
N2_2 C17_2 C15_2 177.0(8) 
O2 C11_1 C12_1 118.7(6) 
O2 C11_1 C16_1 120.1(6) 
C12_1 C11_1 C16_1 121.2(3) 
C13_1 C12_1 C11_1 118.8(5) 
C12_1 C13_1 C14_1 123.5(5) 
C12_1 C13_1 Cl1_1 119.1(4) 
C14_1 C13_1 Cl1_1 117.3(4) 
C13_1 C14_1 C15_1 117.8(4) 
C14_1 C15_1 C16_1 120.7(5) 
C14_1 C15_1 C17_1 120.4(5) 
C17_1 C15_1 C16_1 118.9(5) 
C11_1 C16_1 C15_1 117.9(5) 
N2_1 C17_1 C15_1 177.0(7) 
 
Table 11: Hydrogen Fractional Atomic Coordinates (×104) and Equivalent Isotropic Displacement Parameters (Å2×103) for 
130. Ueq is defined as 1/3 of the trace of the orthogonalised Uij. 
 
Atom x y z Ueq 
H4 7745.67 -2485.54 1929.26 24 
H5 8844.05 -2090.34 1960.92 25 
H6 9540.93 518.31 3129.71 25 
H9A 7215.94 4682.63 3753.8 29 
H9B 7284.2 4954.48 4891.71 29 
H9C 7012.8 2361.48 4333.33 29 
H10A 7879.52 -491.73 5369.3 29 
H10B 8093.81 1939.7 6061.92 29 
H10C 8622.26 456.43 5665.85 29 
H8 9693.89 2899.47 4629.99 23 
H12_2 7169.75 3073.35 1787.58 23 
H14_2 5226.97 3154.18 473.87 29 




Atom x y z Ueq 
H16_2 5997.5 -1888.7 2694.47 24 
H12_1 6013.77 -2350.47 2768.85 22 
H14_1 5142.06 2404.72 561.85 22 
H16_1 7115.3 2915.01 1863.81 24 
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